




- (51) **International Patent Classification:**
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2014/054114
- (22) **International Filing Date:**
4 September 2014 (04.09.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/874,310 5 September 2013 (05.09.2013) US
- (71) **Applicants:** GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). CONSTELLATION PHARMACEUTICALS, INC. [US/US]; 215 First Street, Suite 200, Cambridge, MA 02142 (US).
- (72) **Inventors:** ALBRECHT, Brian, K.; 179 Chestnut Street, #2, Cambridge, MA 02139 (US). BELLON, Steven, F.; 14 Greenlawn Avenue, Wellesley, MA 02481 (US). GEHLING, Victor, S.; 10 Ware Street, Rear Unit, Somerville, MA 02144 (US). HARMANGE, Jean-Christophe; 57 William Street, Andover, MA 01810 (US). LEBLANC, Yves; 8 Lafford, Kirkland, Québec H9J 3Y3 (CA). LIANG, Jun; 1 DNA Way, South San Francisco, CA 94080-4900 (US). MAGNUSON, Steven; 1 DNA Way, South San Francisco, CA 94080-4990 (US). TSUI, Vickie; 1 DNA Way, South San Francisco, CA 94080-4990 (US). ZHANG, Birong; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (74) **Agents:** HARRIS, Robert, J. et al.; Viksnins Harris & Padys PLLP, 7900 International Drive, Suite 670, Bloomington, MN 55425 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report (Art. 21(3))
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ANTIPROLIFERATIVE COMPOUNDS



(I)

(57) **Abstract:** The present invention relates to compounds formula (I) and to salts thereof, wherein R^1 - R^4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

ANTIPROLIFERATIVE COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATION

This patent application claims the benefit of priority of U.S. application serial No.
5 61/874,310, filed September 5, 2013, which application is herein incorporated by reference.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to compounds useful as inhibitors of histone demethylases, such as KDM5.

BACKGROUND OF THE INVENTION

10 Packaging the 3 billion nucleotides of the human genome into the nucleus of a cell requires tremendous compaction. To accomplish this feat, DNA in our chromosomes is wrapped around spools of proteins called histones to form dense repeating protein/DNA polymers known as chromatin. Far from serving as mere packaging modules, chromatin templates form the basis of a newly appreciated and fundamentally important set of gene control mechanisms termed epigenetic
15 regulation. By conferring a wide range of specific chemical modifications to histones and DNA, epigenetic regulators modulate the structure, function, and accessibility of our genome, thereby exerting a tremendous impact on gene expression. Hundreds of epigenetic effectors have recently been identified, many of which are chromatin-binding or chromatin-modifying enzymes. Significantly, an increasing number of these enzymes have been associated with a variety of
20 disorders such as cancer. Thus, therapeutic agents directed against this emerging class of gene regulatory enzymes promise new approaches to the treatment of human diseases.


Additionally, the relatively rapid acquisition of resistance to cancer drugs remains a key obstacle to successful cancer therapy. Substantial efforts to elucidate the molecular basis for such drug resistance have revealed a variety of mechanisms, including drug efflux, acquisition of drug
25 binding-deficient mutants of the target, engagement of alternative survival pathways and epigenetic alterations. Rare, stochastic, resistance-conferring genetic alterations have been found within a tumor cell population selected during drug treatment. *See* Sharma *et al.*, *Cell* 141(1):69-80 (2010). The KDM5/JARID1 family of histone demethylases was found to play a role in cancer resistance. The KDM5/JARID1 family of demethylases in humans contains four members, KDM5A, KDM5B,
30 KDM5C and KDM5D. KDM5 family members contain five conserved domains: JmjN, ARID, JmjC, PHD and a C₅HC₂ zinc finger. Amino acid sequences of KDM5A, KDM5B, KDM5C and KDM5D are known and are publicly available, *e.g.*, *see* UniProtKB/Swiss-Prot (*see e.g.*, KDM5A (*e.g.*, P29375-1 and P29375-2), KDM5B (*e.g.*, Q9UGL1-1 and Q9UGL1-2), KDM5C (*e.g.*,

P41229-1, P41229-2, P41229-3 and P41229-4) and KDM5D (e.g., Q9BY66-1, Q9BY66-2 and Q9BY66-3). There is currently a need for compounds that inhibit of KDM5 demethylases for treating hyperproliferative diseases, preventing drug resistance, and/or for improving the efficacy of other cancer treatments (e.g. targeted therapies, chemotherapies, and radiotherapies).

5

SUMMARY OF THE INVENTION

One aspect includes the use of a compound of formula (I):



I

10 or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each independently H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x ; and wherein R^1 and R^2 are not each H; or R^1 and R^2 taken together with the atoms to which they are attached form a 4, 5, 6, 7, or 8 membered carbocyclyl, which carbocyclyl is optionally substituted with one or more groups R^x ;

20

R^3 is H, C_{1-6} alkyl, trifluoromethyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, halo, $-OR^f$, $-SR^f$, $-N(R^f)_2$, $-CN$, or $-NO_2$, wherein said alkyl, carbocyclyl and heterocyclyl are optionally substituted with one or more groups independently selected from oxo, halo, C_{1-3} alkoxy and C_{1-3} alkyl;

25

R^4 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^g$, $-SR^g$, $-N(R^g)_2$, $-CN$, $-NO_2$, $-C(O)R^g$, $-CO_2R^g$, $-C(O)N(R^g)_2$, $-C(O)SR^g$, $-C(O)C(O)R^g$, $-C(O)CH_2C(O)R^g$, $-C(S)N(R^g)_2$, $-C(S)OR^g$, $-S(O)R^g$, $-SO_2R^g$, $-SO_2N(R^g)_2$, $-N(R^g)C(O)R^g$, $-N(R^g)C(O)N(R^g)_2$, $-N(R^g)SO_2R^g$, $-N(R^g)SO_2N(R^g)_2$, $-N(R^g)N(R^h)_2$, $-N(R^g)C(=N(R^g))N(R^g)_2$, $-C(=N)N(R^g)_2$, $-C=NOR^g$, $-C(=N(R^g))N(R^g)_2$, $-OC(O)R^g$, or $-OC(O)N(R^g)_2$, wherein each C_{1-12} alkyl,

30

C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R⁴ is optionally substituted with one or more groups R^x;

R⁵ is H, C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, C₁₋₁₂alkyl, C₁₋₁₂haloalkyl, carbocyclyl, heterocyclyl, halo, -CN, -NO₂, -NR^mR^m, -OR^m, -C(=O)OR^m, and -OC(=O)R^m; or R⁵ and R² taken together with the atoms to which they are attached form a heterocyclyl;

each R^a is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x;

each R^f is independently selected from H, C₁₋₃alkyl, trifluoromethyl, 3-6 membered carbocyclyl, and 3-6 membered heterocyclyl; or two R^f groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^g is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^g groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^m is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, and benzyl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, or benzyl is optionally substituted with one or more groups independently selected from halo, -CN, -NO₂, -NR^yR^z, and -OR^w; or two R^m groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

A is a monocyclic or bicyclic heteroaryl ring that is substituted with R⁴ and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl;

each R^t is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^t groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^v is independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halo, amino,

hydroxyl, and C₁-C₆ alkyl that is optionally substituted with one or more groups independently selected from oxo and halo; or two R^v are taken together with the nitrogen to which they are attached to form a heterocyclyl that is optionally substituted with one or more groups independently selected from oxo, halo and C₁₋₃alkyl that is optionally substituted with one or more groups independently selected from oxo and halo;

each R^w is independently selected from H, C₁₋₄alkyl, C₁₋₄alkanoyl, phenyl, benzyl, and phenethyl;

each R^x is independently selected from oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, -F, -Cl, -Br, -I, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -O-R^v, -S-R^v, -O-C(O)-R^v, -O-C(O)-O-R^v, -C(O)-R^v, -C(O)-O-R^v, -S(O)-R^v, -S(O)₂-R^v, -O-C(O)-N(R^v)₂, -N(R^v)-C(O)-OR^v, -N(R^v)-C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v, -N(R^v)-S(O)-R^v, -N(R^v)-S(O)₂-R^v, -N(R^v)-S(O)-N(R^v)₂, and -N(R^v)-S(O)₂-N(R^v)₂, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl and carbocyclyl is optionally substituted with one or more groups independently selected from oxo, halo, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -O-R^v, -S-R^v, -O-C(O)-R^v, -C(O)-R^v, -C(O)-O-R^v, -S(O)-R^v, -S(O)₂-R^v, -C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v, -N(R^v)-S(O)-R^v, -N(R^v)-S(O)₂-R^v and C₁₋₆alkyl that is optionally substituted with one or more groups independently selected from oxo and halo; and

each R^y and R^z is independently selected from H, C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl, phenyl, benzyl, and phenethyl, or R^y and R^z together with the nitrogen to which they are attached form a heterocyclyl;

for the prophylactic or therapeutic treatment of a proliferative disorder (e.g. cancer).

Another aspect includes a composition, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

Another aspect includes compounds and compositions for treating diseases, disorders or conditions associated with KDM5 activity. Such diseases, disorders, or conditions include those described herein.

Another aspect includes a compound of formula (I) and salts thereof.

Another aspect includes a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Another aspect includes a method of treating a disease associated with KDM5 activity, comprising administering an therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in therapy. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in therapy.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in treating a disease associated with KDM5 activity. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in treating a disease associated with KDM5 activity.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with KDM5 activity. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with KDM5 activity.

Another aspect includes a method of increasing the efficacy of a cancer treatment comprising a cancer therapy agent, comprising administering to a patient (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) an effective amount of the cancer therapy agent.

Another aspect includes a method of treating an individual with cancer who has an increased likelihood of developing resistance to a cancer therapy agent comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) an effective amount of the cancer therapy agent.

Another aspect includes compounds for the study of histone demethylases, such as KDM5, the study of intracellular signal transduction pathways mediated by such histone demethylases, and the comparative evaluation of modulators of these demethylases.

Another aspect includes a process for preparing a compound of formula I or a salt thereof.

DETAILED DESCRIPTION

Compounds and Definitions

Definitions and terms are described in more detail below. Chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, *Handbook of Chemistry and Physics*, 75th Ed.

Unless otherwise stated, compounds of formula I include enantiomeric, diastereomeric and geometric (or conformational) isomeric forms of a given structure. For example, the R and S configurations for each asymmetric center, Z and E double bond isomers, Z and E conformational isomers, , single stereochemical isomers, as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures are included. Unless otherwise stated, all tautomeric forms of structures

depicted herein are included. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds of formula I, wherein the independent replacement or enrichment of one or more: hydrogen by deuterium or tritium, carbon by ^{13}C - or ^{14}C carbon, nitrogen by a ^{15}N nitrogen, sulfur by a ^{33}S , ^{34}S or ^{36}S sulfur, or oxygen by a ^{17}O or ^{18}O oxygen. are included. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents.

Where a particular enantiomer is described, it may, in certain embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as “optically enriched.” “Optically-enriched,” as used herein, means that the mixture of enantiomers is made up of a significantly greater proportion of one enantiomer, and may be described by enantiomeric excess (ee %). In certain embodiments, the mixture of enantiomers is made up of at least about 90% by weight of a given enantiomer (about 90% ee). In other embodiments, the mixture of enantiomers is made up of at least about 95%, 98% or 99% by weight of a given enantiomer (about 95%, 98% or 99% ee). Enantiomers and diastereomers may be isolated from racemic mixtures by any method known to those skilled in the art, including recrystallization from solvents in which one stereoisomer is more soluble than the other, chiral high pressure liquid chromatography (HPLC), supercritical fluid chromatography (SFC), the formation and crystallization of chiral salts, which are then separated by any of the above methods, or prepared by asymmetric syntheses and optionally further enriched. See, for example, Jacques et al., *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen, et al., *Tetrahedron* 33:2725 (1977); Eliel, E.L. *Stereochemistry of Carbon Compounds* (McGraw-Hill, NY, 1962); Wilen, S.H. *Tables of Resolving Agents and Optical Resolutions* p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

The term “heteroatom” means any atom independently selected from an atom other than carbon or hydrogen, for example, one or more of oxygen, sulfur, nitrogen, phosphorus or silicon (including any oxidized form of nitrogen, sulfur, phosphorus or silicon; and the quaternized form of any nitrogen).

The terms “halo” and “halogen” as used herein refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) and iodine (iodo, -I).

The term “unsaturated”, as used herein, means that a moiety has one or more units of unsaturation.

The term “carbocyclyl” used alone or as part of a larger moiety, refers to a saturated, partially unsaturated, or aromatic ring system having 3 to 20 carbon atoms. In one embodiment,

carbocyclyl includes 3 to 12 carbon atoms (C₃-C₁₂). In another embodiment, carbocyclyl includes C₃-C₈, C₃-C₁₀ or C₅-C₁₀. In other embodiment, carbocyclyl, as a monocycle, includes C₃-C₈, C₃-C₆ or C₅-C₆. In another embodiment, carbocyclyl, as a bicycle, includes C₇-C₁₂. In another embodiment, carbocyclyl, as a spiro system, includes C₅-C₁₂. Examples of monocyclic carbocyclyls include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, phenyl, and cyclododecyl; bicyclic carbocyclyls having 7 to 12 ring atoms include [4,3], [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems, for example bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, naphthalene, and bicyclo[3.2.2]nonane; and spiro carbocyclyls include spiro[2.2]pentane, spiro[2.3]hexane, spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane, each of which are independently optionally substituted with one or more groups described herein. The term carbocyclyl includes aryl ring systems as defined herein.

The term "alkyl," as used herein, refers to a saturated linear or branched-chain monovalent hydrocarbon radical. In one embodiment, the alkyl radical is one to eighteen carbon atoms (C₁-C₁₈). In other embodiments, the alkyl radical is C₀-C₆, C₀-C₅, C₀-C₃, C₁-C₁₂, C₁-C₁₀, C₁-C₈, C₁-C₆, C₁-C₅, C₁-C₄ or C₁-C₃. C₀ alkyl refers to a bond. Examples of alkyl groups include methyl (Me, -CH₃), ethyl (Et, -CH₂CH₃), 1-propyl (n-Pr, n-propyl, -CH₂CH₂CH₃), 2-propyl (i-Pr, i-propyl, -CH(CH₃)₂), 1-butyl (n-Bu, n-butyl, -CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (i-Bu, i-butyl, -CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl, -CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH₃)₃), 1-pentyl (n-pentyl, -CH₂CH₂CH₂CH₂CH₃), 2-pentyl (-CH(CH₃)CH₂CH₂CH₃), 3-pentyl (-CH(CH₂CH₃)₂), 2-methyl-2-butyl (-C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl (-CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (-CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl (-CH₂CH(CH₃)CH₂CH₃), 1-hexyl (-CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl (-CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (-CH(CH₂CH₃)(CH₂CH₂CH₃)), 2-methyl-2-pentyl (-C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl (-CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (-CH(CH₃)CH₂CH(CH₃)₂), 3-methyl-3-pentyl (-C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl (-CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (-C(CH₃)₂CH(CH₃)₂), 3,3-dimethyl-2-butyl (-CH(CH₃)C(CH₃)₃), heptyl, octyl, nonyl, decyl, undecyl and dodecyl.

The term "alkenyl," as used herein, denotes a linear or branched-chain monovalent hydrocarbon radical with at least one carbon-carbon double bond. An alkenyl includes radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. In one example, the alkenyl radical is two to eighteen carbon atoms (C₂-C₁₈). In other examples, the alkenyl radical is C₂-C₁₂, C₂-C₁₀, C₂-C₈, C₂-C₆ or C₂-C₃. Examples include, but are not limited to, ethenyl or vinyl

(-CH=CH₂), prop-1-enyl (-CH=CHCH₃), prop-2-enyl (-CH₂CH=CH₂), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hexa-1,3-dienyl.

The term “alkynyl,” as used herein, refers to a linear or branched monovalent hydrocarbon radical with at least one carbon-carbon, triple bond. In one example, the alkynyl radical is two to
 5 eighteen carbon atoms (C₂-C₁₈). In other examples, the alkynyl radical is C₂-C₁₂, C₂-C₁₀, C₂-C₈, C₂-C₆ or C₂-C₃. Examples include, but are not limited to, ethynyl (-C≡CH), prop-1-ynyl (-C≡CCH₃), prop-2-ynyl (propargyl, -CH₂C≡CH), but-1-ynyl, but-2-ynyl and but-3-ynyl.

The term “alkoxy” refers to a linear or branched monovalent radical represented by the
 10 formula -OR in which R is alkyl, alkenyl, alkynyl or carbocyclyl. Alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, mono-, di- and tri-fluoromethoxy and cyclopropoxy.

The term “haloalkyl,” as used herein, refers to an alkyl as defined herein that is substituted with one or more (e.g. 1, 2, 3, or 4) halo groups.

The term “aryl” used alone or as part of a larger moiety as in “arylalkyl”, “arylalkoxy”, or
 15 “aryloxyalkyl”, refers to a monocyclic, bicyclic or tricyclic, carbon ring system, that includes fused rings, wherein at least one ring in the system is aromatic. The term “aryl” may be used interchangeably with the term “aryl ring”. In one embodiment, aryl includes groups having 6-18 carbon atoms. In another embodiment, aryl includes groups having 6-10 carbon atoms. Examples of aryl groups include phenyl, naphthyl, anthracyl, biphenyl, phenanthrenyl, naphthacenyl, 1,2,3,4-
 20 tetrahydronaphthalenyl, 1H-indenyl, 2,3-dihydro-1H-indenyl, and the like, which may be substituted or independently substituted by one or more substituents described herein. A particular aryl is phenyl. In another embodiment aryl includes an aryl ring fused to one or more carbocyclic rings, such as indanyl, phthalimidyl, naphthimidyl, phenantriidiny, or tetrahydronaphthyl, and the like, where the radical or point of attachment is on an aromatic ring.

The term “heteroaryl” used alone or as part of a larger moiety, e.g., “heteroarylalkyl”, or
 25 “heteroarylalkoxy”, refers to a monocyclic, bicyclic or tricyclic ring system having 5 to 14 ring atoms, wherein at least one ring is aromatic and contains at least one heteroatom. In one embodiment, heteroaryl includes 4-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen that is independently optionally substituted. In another
 30 embodiment, heteroaryl includes 5-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen that is independently optionally substituted. Example heteroaryl groups include thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, tetrazolo[1,5-b]pyridazinyl, imidazol[1,2-

a]pyrimidinyl, purinyl, benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoimidazolyl, indolyl, 1,3-thiazol-2-yl, 1,3,4-triazol-5-yl, 1,3-oxazol-2-yl, 1,3,4-oxadiazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 1H-tetrazol-5-yl, 1,2,3-triazol-5-yl, and pyrid-2-yl N-oxide. The terms “heteroaryl” also includes groups in which a heteroaryl is fused to one or more aryl, carbocyclyl, or heterocyclyl rings, where the radical or point of attachment is on the heteroaryl ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4*H*-quinoliziny, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and pyrido[2,3-*b*]-1,4-oxazin-3(4*H*)-one. A heteroaryl group may be mono-, bi- or tri-cyclic.

As used herein, the term “heterocyclyl” refers to a “carbocyclyl” as defined herein, wherein one or more (*e.g.* 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (*e.g.* O, N, or S). A heterocyclyl can optionally be substituted with one or more substituents independently selected from those defined herein.

In one example, heterocyclyl includes 3-12 ring atoms and includes monocycles, bicycles, tricycles and spiro ring systems, wherein the ring atoms are carbon, and one to five ring atoms is a heteroatom selected from nitrogen, sulfur or oxygen, which is independently optionally substituted by one or more groups. In one example, heterocyclyl includes 1 to 4 heteroatoms. In another example, heterocyclyl includes 3- to 7-membered monocycles having one or more heteroatoms selected from nitrogen, sulfur or oxygen. In another example, heterocyclyl includes 4- to 6-membered monocycles having one or more heteroatoms selected from nitrogen, sulfur or oxygen. In another example, heterocyclyl includes 3-membered monocycles. In another example, heterocyclyl includes 4-membered monocycles. In another example, heterocyclyl includes 5-6 membered monocycles. In one example, the heterocyclyl group includes 0 to 3 double bonds. Any nitrogen or sulfur heteroatom may optionally be oxidized (*e.g.* NO, SO, SO₂), and any nitrogen heteroatom may optionally be quaternized (*e.g.* [NR₄]⁺Cl⁻, [NR₄]⁺OH⁻). Example heterocyclyls include oxiranyl, aziridinyl, thiiranyl, azetidiny, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl, dihydro-1*H*-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl, morpholiny, thiomorpholiny, 1,1-dioxo-thiomorpholiny, dihydropyranyl, tetrahydropyranyl, hexahydrothiopyranyl, hexahydropyrimidinyl, oxazinanyl, thiazinanyl, thioxanyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, oxazepiny, oxazepanyl, diazepanyl, 1,4-diazepanyl, diazepiny, thiazepiny, thiazepanyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,1-dioxoisothiazolidinonyl, oxazolidinonyl, imidazolidinonyl, 4,5,6,7-tetrahydro[2*H*]indazolyl,

tetrahydrobenzoimidazolyl, 4,5,6,7-tetrahydrobenzo[d]imidazolyl, 1,6-dihydroimidazol[4,5-
 d]pyrrolo[2,3-b]pyridinyl, thiazinyl, oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl,
 oxathiazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazoliny, dihydropyrimidyl,
 tetrahydropyrimidyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, thiapyranyl, 2H-pyranyl,
 5 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl,
 pyrimidinonyl, pyrimidindionyl, pyrimidin-2,4-dionyl, piperazinonyl, piperazindionyl,
 pyrazolidinylimidazoliny, 3-azabicyclo[3.1.0]hexanyl, 3,6-diazabicyclo[3.1.1]heptanyl,
 6-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl,
 azabicyclo[2.2.2]hexanyl, 2-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl,
 10 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[2.2.2]octanyl, 7-oxabicyclo[2.2.1]heptane,
 azaspiro[3.5]nonanyl, azaspiro[2.5]octanyl, azaspiro[4.5]decanyl, 1-azaspiro[4.5]decan-2-yl,
 azaspiro[5.5]undecanyl, tetrahydroindolyl, octahydroindolyl, tetrahydroisindolyl,
 tetrahydroindazolyl, 1,1-dioxohexahydrothiopyranyl. Examples of 5-membered heterocyclyls
 containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl, including thiazol-
 15 2-yl and thiazol-2-yl N-oxide, thiadiazolyl, including 1,3,4-thiadiazol-5-yl and 1,2,4-thiadiazol-5-
 yl, oxazolyl, for example oxazol-2-yl, and oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and 1,2,4-
 oxadiazol-5-yl. Example 5-membered ring heterocyclyls containing 2 to 4 nitrogen atoms include
 imidazolyl, such as imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl; 1,2,3-triazol-5-yl, 1,2,4-
 triazol-5-yl, and tetrazolyl, such as 1H-tetrazol-5-yl. Example benzo-fused 5-membered
 20 heterocyclyls are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl. Example 6-membered
 heterocyclyls contain one to three nitrogen atoms and optionally a sulfur or oxygen atom, for
 example pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as pyrimid-2-yl and
 pyrimid-4-yl; triazinyl, such as 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in particular
 pyridazin-3-yl, and pyrazinyl. The pyridine N-oxides and pyridazine N-oxides and the pyridyl,
 25 pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1,3,4-triazin-2-yl groups, are other example
 heterocyclyl groups.

As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond between ring atoms but the ring moiety is not aromatic.

As used herein, the term “inhibitor” refers to a compound that binds to and inhibits a KDM5
 30 enzyme with measurable affinity and activity. In certain embodiments, an inhibitor has an IC₅₀
 and/or binding constant of less than about 50 μM, less than about 1 μM, less than about 500 nM, less
 than about 100 nM, or less than about 10 nM.

The terms “measurable affinity” and “measurably inhibit,” as used herein, refer to a measurable reduction in activity of a KDM5 enzyme between: (i) a sample comprising a compound

of formula I or composition thereof and such KDM5 enzyme, and (ii) an equivalent sample comprising such KDM5 enzyme, in the absence of said compound, or composition thereof.

“Pharmaceutically acceptable salts” include both acid and base addition salts.

5 “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid and the like, and organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic
10 acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

15 “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly base addition salts are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as
20 isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly organic non-toxic bases are isopropylamine, diethylamine, ethanolamine,
25 tromethamine, dicyclohexylamine, choline, and caffeine.

The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of
30 some of the bonding electrons.

A “solvate” refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid and ethanolamine. The term “hydrate” refers to the complex where the solvent molecule is water.

“Therapeutically effective amount” refers to an amount of a compound of the present invention that (i) treats the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. For cancer therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR). In the case of immunological disorders, the therapeutic effective amount is an amount sufficient to decrease or alleviate an allergic disorder, the symptoms of an autoimmune and/or inflammatory disease, or the symptoms of an acute inflammatory reaction (e.g. asthma). In some embodiments, a therapeutically effective amount is an amount of a chemical entity described herein sufficient to significantly decrease the activity or number of drug tolerant or drug tolerant persisting cancer cells.

“Treatment” (and variations such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include one or more of preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, stabilized (*i.e.*, not worsening) state of disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, prolonging survival as compared to expected survival if not receiving treatment and remission or improved prognosis. In certain embodiments, a compound of formula I is used to delay development of a disease or disorder or to slow the progression of a disease or disorder. Those individuals in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder, (for example, through a genetic mutation or aberrant expression of a gene or protein) or those in which the condition or disorder is to be prevented.

Exemplary Values

In one embodiment a compound of formula (I) or a salt thereof is provided, provided that: when -A-R⁴ is 2-pyridyl, 3-pyridyl, 4-piperidino-3-pyridyl, 4-hydroxy-3-pyridyl, 4-methoxy-3-pyridyl, 4-morpholino-3-pyridyl, 4-pyrrolidino-3-pyridyl, 6-fluoro-2-pyridyl, and R³ is hydrogen, methyl, ethyl, or methoxy, then R¹ is not H;

when $-A-R^4$ is 2-thienyl and R^3 is trifluoromethyl, then R^1 is not H;

when R^1 and R^2 taken together with the atoms to which they are attached form a 5 membered carbocyclyl and $-A-R^4$ is 1-naphthyl, then R^3 is not methyl; a

when R^1 is 2-hydroxyethyl, R^2 is methyl, and R^3 is methyl, then $-A-R^4$ is not 6-(N,N-dimethylamino)-4-methyl-3-pyridyl;

when R^1 is 3-thienyl, R^2 is hydrogen, R^3 is hydrogen, then $-A-R^4$ is not 2-pyridyl or 3-pyridyl;

when R^1 is hydrogen, R^2 is 3-nitrophenyl or 2, 3, 4, 5-tetrafluorophenyl, and R^3 is trifluoromethyl, then $-A-R^4$ is not 2-thienyl;

when R^3 is methylthio then $-A-R^4$ is not 1,2,4-oxadiazol-5-yl substituted with 4-methylphenyl, 4-chlorophenyl, phenyl, 3,4-methylenedioxyphenyl, or 2-thienyl; and

when R^2 is H, R^3 is H, and $-A-R^4$ is 3-thienyl, then R^1 is not phenyl, 3-thienyl, 2-thienyl, 1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-5-yl, 1-ethyl-1H-pyrazol-3-yl, or 1-ethyl-1H-pyrazol-5-yl.

In certain embodiments R^1 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C(=N)N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more

In certain embodiments R^1 is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C(=N)N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .

In certain embodiments R^1 and R^2 taken together with the atoms to which they are attached form an optionally substituted 4, 5, 6, 7, or 8 membered carbocyclyl.

In certain embodiments R^1 is H, C_{1-6} alkyl, carbocyclyl, halo, or $-CN$, wherein any C_{1-6} alkyl or carbocyclyl is independently optionally substituted with one or more groups independently selected from carbocyclyl, halo, $-CN$, and $-O-R^v$.

In certain embodiments R^1 is H, methyl, ethyl, isopropyl, cyclopropyl, methoxy, fluoro, chloro, or cyano; or R^1 and R^2 taken together with the atoms to which they are attached form an optionally substituted 5 membered carbocyclyl.

In certain embodiments R^2 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C(=N)N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .

In certain embodiments R^2 is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C(=N)N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .

In certain embodiments R^2 is H, C_{1-6} alkyl, or aryl, wherein each C_{1-6} alkyl is optionally substituted with one or more groups independently selected from $-O-R^v$.

In certain embodiments R^2 is H, methyl, ethyl, isopropyl, hydroxymethyl, or phenyl; or R^1 and R^2 taken together with the atoms to which they are attached form an optionally substituted 5 membered carbocyclyl.

In certain embodiments, one of R^1 and R^2 are other than H.

In certain embodiments R^3 is H.

In certain embodiments R^3 is C_{1-3} alkyl, trifluoromethyl, 3-6 (e.g. 3, 4, 5, or 6) membered carbocyclyl, 3-6 (e.g. 3, 4, 5, or 6) membered heterocyclyl, halo, hydroxyl, $-OR^f$, $-SH$, $-SR^f$, $-N(R^f)_2$, $-CN$, or $-NO_2$.

In certain embodiments A is a 5 or 6 membered monocyclic heteroaryl ring that is substituted with R^4 and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

In certain embodiments A is a 9 or 10 membered bicyclic heteroaryl ring that is substituted with R^4 and that is also optionally substituted with one or more groups independently selected from

halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a 5-membered heteroaryl ring comprising 1, 2, 3, or 4 heteroatoms that is substituted with R⁴ and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a 5-membered heteroaryl ring comprising 1, 2, 3, or 4 nitrogen atoms, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a 5-membered heteroaryl ring comprising one heteroatom, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a 5-membered heteroaryl ring comprising two heteroatoms, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a 5-membered heteroaryl ring comprising three heteroatoms, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.

In certain embodiments A is a pyrazole, imidazole, oxadiazole, or isoxazole ring, which pyrazole, imidazole, oxadiazole, or isoxazole ring is substituted with R⁴ and which pyrazole, imidazole, oxadiazole, or isoxazole ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, carbocyclyl, and -N(R^t)₂.

In certain embodiments A is a pyrazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.

In certain embodiments A is an imidazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano,

C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.

In certain embodiments A is an oxadiazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.

In certain embodiments A is an isoxazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.

In certain embodiments R⁴ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, heterocyclyl, -C(O)R^g, -CO₂R^g, or -C(O)N(R^g)₂, wherein each C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, carbocyclyl, and heterocyclyl of R⁴ is independently optionally substituted with one or more groups R^x.


In certain embodiments R⁴ is heteroaryl that is optionally substituted with one or more groups independently selected from R^x.






In certain embodiments R⁴ is heteroaryl that is optionally substituted with one or more groups independently selected from C₁₋₆alkyl, C₁₋₆haloalkyl, carbocyclyl, -F, -Cl, -Br, -I, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -O-R^v,

-O-C(O)-R^v, -C(O)-R^v, -C(O)-O-R^v, -C(O)-N(R^v)₂, and -N(R^v)-C(O)-R^v.


In certain embodiments R⁴ is a pyrimidine, thiazole, pyridine, isoquinoline, or pyridazine ring, which ring is optionally substituted with one or more groups independently selected from C₁₋₆alkyl, carbocyclyl, -F, -Cl, -Br, -I, -N(R^v)₂, -O-R^v, and -C(O)-O-R^v.


In certain embodiments -A-R⁴ taken together is selected from:










5








Another aspect includes a compound selected from:












and salts thereof.

One embodiment provides the use of a compound of formula (I):



or a salt thereof, wherein:

- 5 R^1 and R^2 are each independently H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C(=N)N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x ; and wherein R^1 and R^2 are not each H; or R^1 and R^2 taken together with the atoms to which they are attached form a 4, 5, 6, 7, or 8 membered carbocyclyl, which carbocyclyl is optionally substituted with one or more groups R^x ;
- 10 R^3 is H, C_{1-6} alkyl, trifluoromethyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, halo, $-OR^f$, $-SR^f$, $-N(R^f)_2$, $-CN$, or $-NO_2$, wherein said alkyl, carbocyclyl and heterocyclyl are optionally substituted with one or more groups independently selected from oxo, halo, C_{1-3} alkoxy and C_{1-3} alkyl;
- 15 R^4 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^g$, $-SR^g$, $-N(R^g)_2$, $-CN$, $-NO_2$, $-C(O)R^g$, $-CO_2R^g$, $-C(O)N(R^g)_2$, $-C(O)SR^g$, $-C(O)C(O)R^g$, $-C(O)CH_2C(O)R^g$, $-C(S)N(R^g)_2$, $-C(S)OR^g$, $-S(O)R^g$, $-SO_2R^g$, $-SO_2N(R^g)_2$, $-N(R^g)C(O)R^g$, $-N(R^g)C(O)N(R^g)_2$, $-N(R^g)SO_2R^g$, $-N(R^g)SO_2N(R^g)_2$, $-N(R^g)N(R^h)_2$, $-N(R^g)C(=N(R^g))N(R^g)_2$, $-C(=N)N(R^g)_2$, $-C=NOR^g$, $-C(=N(R^g))N(R^g)_2$, $-OC(O)R^g$, or $-OC(O)N(R^g)_2$, wherein each C_{1-12} alkyl, C_{3-12} alkenyl, C_{3-12} alkynyl, carbocyclyl, and heterocyclyl of R^4 is optionally substituted with one or more groups R^x ;
- 20 R^5 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, C_{1-12} alkyl, C_{1-12} haloalkyl, carbocyclyl, heterocyclyl, halo, $-CN$, $-NO_2$, $-NR^mR^m$, $-OR^m$, $-C(=O)OR^m$, and $-OC(=O)R^m$; or R^5 and R^2 taken together with the atoms to which they are attached form a heterocyclyl;
- 25 R^5 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, C_{1-12} alkyl, C_{1-12} haloalkyl, carbocyclyl, heterocyclyl, halo, $-CN$, $-NO_2$, $-NR^mR^m$, $-OR^m$, $-C(=O)OR^m$, and $-OC(=O)R^m$; or R^5 and R^2 taken together with the atoms to which they are attached form a heterocyclyl;
- 30 R^5 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, C_{1-12} alkyl, C_{1-12} haloalkyl, carbocyclyl, heterocyclyl, halo, $-CN$, $-NO_2$, $-NR^mR^m$, $-OR^m$, $-C(=O)OR^m$, and $-OC(=O)R^m$; or R^5 and R^2 taken together with the atoms to which they are attached form a heterocyclyl;

each R^a is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x;

each R^f is independently selected from H, C₁₋₃ alkyl, trifluoromethyl, 3-6 membered carbocyclyl, and 3-6 membered heterocyclyl; or two R^f groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^g is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^g groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^m is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, and benzyl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, or benzyl is optionally substituted with one or more groups independently selected from halo, -CN, -NO₂, -NR^yR^z, and -OR^w; or two R^m groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

A is a monocyclic or bicyclic heteroaryl ring that is substituted with R⁴ and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl;

each R^t is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^t groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^v is independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halo, amino, hydroxyl, and C₁₋₆alkyl that is optionally substituted with one or more groups independently selected from oxo and halo; or two R^v are taken together with the nitrogen to which they are attached to form a heterocyclyl that is optionally substituted with one or more groups independently selected from oxo, halo and C₁₋₃alkyl that is optionally substituted with one or more groups independently selected from oxo and halo;

each R^w is independently selected from H, C₁₋₄alkyl, C₁₋₄alkanoyl, phenyl, benzyl, and phenethyl;

each R^x is independently selected from oxo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, carbocyclyl, -F, -Cl, -Br, -I, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -O-R^v, -S-R^v, -O-C(O)-R^v, -O-C(O)-O-R^v, -C(O)-R^v, -C(O)-O-R^v, -S(O)-R^v, -S(O)₂-R^v, -O-C(O)-N(R^v)₂, -N(R^v)-C(O)-OR^v, -N(R^v)-C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v, -N(R^v)-S(O)-R^v, -N(R^v)-S(O)₂-R^v, -N(R^v)-S(O)-N(R^v)₂, and -N(R^v)-S(O)₂-N(R^v)₂, wherein any C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl and carbocyclyl is optionally substituted with one or more groups independently selected from oxo, halo, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -O-R^v, -S-R^v, -O-C(O)-R^v, -C(O)-R^v, -C(O)-O-R^v, -S(O)-R^v, -S(O)₂-R^v, -C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v, -N(R^v)-S(O)-R^v, -N(R^v)-S(O)₂-R^v and C_{1-6} alkyl that is optionally substituted with one or more groups independently selected from oxo and halo; and

each R^y and R^z is independently selected from H, C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkoxycarbonyl, phenyl, benzyl, and phenethyl, or R^y and R^z together with the nitrogen to which they are attached form a heterocyclyl;

for the prophylactic or therapeutic treatment of a proliferative disorder.

In certain embodiments R^1 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂, -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂, -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .

In certain embodiments R^1 is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂, -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂, -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .

In certain embodiments R^2 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂, -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂, -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each

C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is independently optionally substituted with one or more groups R^x.

In certain embodiments R² is C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂, -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂, -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂, -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is independently optionally substituted with one or more groups R^x.

In certain embodiments R⁴ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, heterocyclyl, -C(O)R^g, -CO₂R^g, or -C(O)N(R^g)₂, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl of R⁴ is optionally substituted with one or more groups R^x.

Uses, Formulation and Administration

Pharmaceutically acceptable compositions

Another aspect includes a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier, adjuvant, or vehicle. In another embodiment, the composition further comprises an amount of the compound effective to measurably inhibit KDM5. In certain embodiments, the composition is formulated for administration to a patient in need thereof.

The term “patient” or “individual” as used herein, refers to an animal, such as a mammal, such as a human. In one embodiment, patient or individual refers to a human.

The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

Compositions comprising a compound of formula I or salt thereof may be administered orally, parenterally, by inhalation spray, topically, transdermally, rectally, nasally, buccally, sublingually, vaginally, intraperitoneal, intrapulmonary, intradermal, epidural or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

In one embodiment, the composition comprising a compound of formula I or salt thereof is formulated as a solid dosage form for oral administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In certain embodiments, the solid oral dosage form comprising a compound of formula (I) or a salt thereof further comprises one or more of (i) an inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and (ii) filler or extender such as starches, lactose, sucrose, glucose, mannitol, or silicic acid, (iii) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose or acacia, (iv) humectants such as glycerol, (v) disintegrating agent such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates or sodium carbonate, (vi) solution retarding agents such as paraffin, (vii) absorption accelerators such as quaternary ammonium salts, (viii) a wetting agent such as cetyl alcohol or glycerol monostearate, (ix) absorbent such as kaolin or bentonite clay, and (x) lubricant such as talc, calcium stearate, magnesium stearate, polyethylene glycols or sodium lauryl sulfate. In certain embodiments, the solid oral dosage form is formulated as capsules, tablets or pills. In certain embodiments, the solid oral dosage form further comprises buffering agents. In certain embodiments, such compositions for solid oral dosage forms may be formulated as fillers in soft and hard-filled gelatin capsules comprising one or more excipients such as lactose or milk sugar, polyethylene glycols and the like.

In certain embodiments, tablets, dragees, capsules, pills and granules of the compositions comprising a compound of formula I or salt thereof optionally comprise coatings or shells such as enteric coatings. They may optionally comprise opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions include polymeric substances and waxes, which may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

In another embodiment, a composition comprises micro-encapsulated compound of formula (I) or salt thereof, and optionally, further comprises one or more excipients.

In another embodiment, compositions comprise liquid dosage formulations comprising a compound of formula I or salt thereof for oral administration, and optionally further comprise one or more of pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In certain embodiments, the liquid dosage form optionally, further comprise one or
5 more of an inert diluent such as water or other solvent, a solubilizing agent, and an emulsifier such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols or fatty acid esters of sorbitan, and mixtures thereof. In certain embodiments,
10 liquid oral compositions optionally further comprise one or more adjuvant, such as a wetting agent, a suspending agent, a sweetening agent, a flavoring agent and a perfuming agent.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution,
15 suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic
20 acid are used in the preparation of injectables.

Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a compound of formula (I), it is often desirable to slow the
25 absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the
30 compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include

poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

In certain embodiments, the composition for rectal or vaginal administration are formulated as suppositories which can be prepared by mixing a compound of formula (I) or a salt thereof with
5 suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, for example those which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the compound of formula (I).

Example dosage forms for topical or transdermal administration of a compound of formula
10 (I) include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The compound of formula (I) or a salt thereof is admixed under sterile conditions with a pharmaceutically acceptable carrier, and optionally preservatives or buffers. Additional formulation examples include an ophthalmic formulation, ear drops, eye drops, transdermal patches. Transdermal dosage forms can be made by dissolving or dispensing the compound of
15 formula (I) or a salt thereof in medium, for example ethanol or dimethylsulfoxide. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

Nasal aerosol or inhalation formulations of a compound of formula (I) or a salt thereof may
20 be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

In certain embodiments, pharmaceutical compositions may be administered with or without food. In certain embodiments, pharmaceutically acceptable compositions are administered without
25 food. In certain embodiments, pharmaceutically acceptable compositions of this invention are administered with food.

Specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the
30 particular disease being treated. The amount of a provided compound of formula I or salt thereof in the composition will also depend upon the particular compound in the composition.

In one embodiment, the therapeutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01-100 mg/kg, alternatively about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used

being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, contain from about 5 to about 100 mg of the compound of the invention.

An example tablet oral dosage form comprises about 2 mg, 5 mg, 25mg, 50mg, 100mg, 250mg or 500mg of a compound of formula (I) or salt thereof, and further comprises about 95-30 mg anhydrous lactose, about 5-40 mg sodium croscarmellose, about 5-30mg polyvinylpyrrolidone (PVP) K30 and about 1-10 mg magnesium stearate. The process of formulating the tablet comprises mixing the powdered ingredients together and further mixing with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving about 2-500 mg of a compound of formula I or salt thereof, in a suitable buffer solution, e.g. a phosphate buffer, and adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g. using a 0.2 micron filter, to remove impurities and contaminants.

Uses of Compounds and Pharmaceutically Acceptable Compositions

Another aspect includes the use of a compound of formula (I) or a salt thereof for the inhibition of KDM5. Compounds of formula (I) may also be used to inhibit the removal of methyl marks on histone lysine residues, including inhibiting the removal of methyl marks from mono-, di- or tri-methylation of histones H1, H2A, H2B, H3 and H4, such as H3K4 (including for example the KDM5 substrate H3K4me3), thereby altering interactions of these histone proteins with DNA and/or other proteins, and altering certain subsequent genetic or protein expression. Compounds of formula (I) may also be used to inhibit KDM5 and reduce drug-tolerant cells, thereby treating or preventing drug-resistant diseases, such as drug-resistant cancer. In certain embodiments, the disease can be treated using compounds of formula (I) to prevent resistance from forming, for example before targets of chemotherapies become mutated to confer resistance to such chemotherapies.

In certain embodiments, the binding or inhibition activity of a compound of formula (I) may be determined by running a competition experiment where a compound of formula (I) is incubated with the KDM5 enzyme bound to known radioligands. Detailed conditions for assaying a compound of formula (I) as an inhibitor of KDM5 or a mutant thereof are set forth in the Examples below.

In certain embodiments, detection of KDM5 activity is achieved with *in vitro* assays, which can be either direct binding (non-catalytic) or enzymatic (catalytic) assays. Types of substrates that are used in such assays may include: short synthetic peptides corresponding to a number of residues from the N-terminus of histone sequences comprising the target lysine residue, single recombinant

histone polypeptides, histone octamers reconstituted with recombinant histone proteins, and reconstituted nucleosomes (using reconstituted octamers and specific recombinant DNA fragments). The reconstituted nucleosomes may be mononucleosomes or oligonucleosomes.

Another aspect includes a method of treating or preventing a disease responsive to the inhibition of KDM5 activity in a patient. The method includes administering a therapeutically effective amount of a compound of formula (I) or a salt thereof to a patient in need thereof.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in therapy. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in therapy.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in treating a disease associated with KDM5 activity. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in treating a disease associated with KDM5 activity.

Another aspect includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with KDM5 activity. Another aspect includes the use of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with KDM5 activity.

In certain embodiments, the disease or condition is a hyperproliferative disease, cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, multiple sclerosis, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, asthma, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, CNS disorders or a myeloproliferative disorder.

In certain embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

Another aspect includes a method for treating, ameliorating or preventing cancer, drug-resistant cancer or another proliferative disorder by administration of an effective amount of a compound of formula (I) or salt thereof to a mammal, for example a human, in need of such treatment. In certain embodiments, the disease to be treated is cancer or drug resistant cancer.

5 Examples of cancers that may be treated using the compounds and methods described herein include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid
10 odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, androgen dependent cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell
15 chronic lymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer,
20 Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell
25 fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney
30 cancer, laryngeal cancer, lentigo maligna, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocyoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell

lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preprimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor and Wilms' tumor.

Another embodiment includes a method for the treatment of benign proliferative disorders. Examples of benign proliferative disorders include, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma and juvenile polyposis syndrome.

Another embodiment includes a therapeutic method useful for modulating protein methylation, gene expression, cell proliferation, cell differentiation and/or apoptosis *in vivo* in diseases mentioned above, in particular cancer, comprising administering to a patient in need of such therapy a pharmacologically active and therapeutically effective amount of one or more of the compounds of formula (I).

Another embodiment includes a method for regulating endogenous or heterologous promoter activity by contacting a cell with a compound of formula (I).

Another embodiment includes the use of a compound of formula I or salt thereof for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis and/or amelioration of the diseases, disorders, illnesses and/or conditions as mentioned herein.

5 Another embodiment includes the use of a compound of formula I or salt thereof for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis of diseases and/or disorders responsive or sensitive to the inhibition of histone demethylases, particularly those diseases mentioned above, such as e.g. cancer.

10 Compounds of formula (I) or salts thereof may be administered using any amount and any route of administration effective for treating or lessening the severity of the disorder. The exact amount required will vary from patient to patient, depending on the species, age, and general condition of the patient, for example the severity of the disorder, the particular compound, its mode of administration, and the like. The total daily usage of a compound of formula (I) by a given patient will be decided by the attending physician within the scope of sound medical judgment.

15 The specific effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or

20 coincidental with the specific compound employed, and like factors well known in the medical arts.

Another embodiment includes a method of inhibiting KDM5 activity in a biological sample comprising contacting said biological sample with a compound of formula I or salt thereof.

25 The term "biological sample", as used herein, includes, without limitation, a cell, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

Co-Administration of Compounds and Other Agents

The compounds of formula (I) or salts thereof may be employed alone or in combination with other agents for treatment. For example, the second agent of the pharmaceutical combination

30 formulation or dosing regimen may have complementary activities to the compound of formula (I) such that they do not adversely affect each other. The compounds may be administered together in a unitary pharmaceutical composition or separately. In one embodiment a compound or a pharmaceutically acceptable salt can be co-administered with a cytotoxic agent to treat proliferative diseases and cancer.

The term "co-administering" refers to either simultaneous administration, or any manner of separate sequential administration, of a compound of formula (I) or a salt thereof, and a further active pharmaceutical ingredient or ingredients, including cytotoxic agents and radiation treatment. If the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.

Typically, any agent that has activity against a disease or condition being treated may be co-administered. Examples of such agents can be found in Cancer Principles and Practice of Oncology by V.T. Devita and S. Hellman (editors), 6th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the disease involved.

In one embodiment, the treatment method includes the co-administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one cytotoxic agent. The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu); chemotherapeutic agents; growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.

Exemplary cytotoxic agents can be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A; inhibitors of fatty acid biosynthesis; cell cycle signaling inhibitors; HDAC inhibitors, proteasome inhibitors; and inhibitors of cancer metabolism.

"Chemotherapeutic agent" includes chemical compounds useful in the treatment of cancer. Examples of chemotherapeutic agents include erlotinib (TARCEVA[®], Genentech/OSI Pharm.), bortezomib (VELCADE[®], Millennium Pharm.), disulfiram, epigallocatechin gallate, salinosporamide A, carfilzomib, 17-AAG(geldanamycin), radicicol, lactate dehydrogenase A (LDH-A), fulvestrant (FASLODEX[®], AstraZeneca), sunitib (SUTENT[®], Pfizer/Sugen), letrozole (FEMARA[®], Novartis), imatinib mesylate (GLEEVEC[®], Novartis), finasunate (VATALANIB[®], Novartis), oxaliplatin (ELOXATIN[®], Sanofi), 5-FU (5-fluorouracil), leucovorin, Rapamycin

(Sirolimus, RAPAMUNE[®], Wyeth), Lapatinib (TYKERB[®], GSK572016, Glaxo Smith Kline), Lonafamib (SCH 66336), sorafenib (NEXAVAR[®], Bayer Labs), gefitinib (IRESSA[®], AstraZeneca), AG1478, alkylating agents such as thiotepa and CYTOXAN[®] cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including topotecan and irinotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); adrenocorticosteroids (including prednisone and prednisolone); cyproterone acetate; 5 α -reductases including finasteride and dutasteride); vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat dolastatin; aldesleukin, talc duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin γ II and calicheamicin ω II (*Angew Chem. Intl. Ed. Engl.* **1994** 33:183-186); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabycin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN[®] (doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiothane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;

amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamnlol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK[®] polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE[®] (Cremophor-free), albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumburg, Ill.), and TAXOTERE[®] (docetaxel, doxetaxel; Sanofi-Aventis); chloranmbucil; GEMZAR[®] (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE[®] (vinorelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA[®]); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above.

Chemotherapeutic agent also includes (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX[®]; tamoxifen citrate), raloxifene, droloxifene, iodoxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON[®] (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE[®] (megestrol acetate), AROMASIN[®] (exemestane; Pfizer), formestane, fadrozole, RIVISOR[®] (vorozole), FEMARA[®] (letrozole; Novartis), and ARIMIDEX[®] (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; buserelin, triptorelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all transretinoic acid, fenretinide, as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC- α , Ralf and H-Ras; (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME[®]) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example,

ALLOVECTIN[®], LEUVECTIN[®], and VAXID[®]; PROLEUKIN[®], rIL-2; a topoisomerase 1 inhibitor such as LURTOTECAN[®]; ABARELIX[®] rmRH; and (ix) pharmaceutically acceptable salts, acids and derivatives of any of the above.

Chemotherapeutic agent also includes antibodies such as alemtuzumab (Campath),
 5 bevacizumab (AVASTIN[®], Genentech); cetuximab (ERBITUX[®], Imclone); panitumumab (VECTIBIX[®], Amgen), rituximab (RITUXAN[®], Genentech/Biogen Idec), pertuzumab (OMNITARG[®], 2C4, Genentech), trastuzumab (HERCEPTIN[®], Genentech), tositumomab (Bexxar, Corixa), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG[®], Wyeth). Additional humanized monoclonal antibodies with therapeutic potential as agents in
 10 combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatumzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab,
 15 nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucosituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab, and the anti-
 20 interleukin-12 (ABT-874/J695, Wyeth Research and Abbott Laboratories) which is a recombinant exclusively human-sequence, full-length IgG₁ λ antibody genetically modified to recognize interleukin-12 p40 protein.

Chemotherapeutic agent also includes “EGFR inhibitors,” which refers to compounds that bind to or otherwise interact directly with EGFR and prevent or reduce its signaling activity, and is
 25 alternatively referred to as an “EGFR antagonist.” Examples of such agents include antibodies and small molecules that bind to EGFR. Examples of antibodies which bind to EGFR include MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509) (see, US Patent No. 4,943, 533, Mendelsohn *et al.*) and variants thereof, such as chimerized 225 (C225 or Cetuximab; ERBUTIX[®]) and reshaped human 225 (H225) (see,
 30 WO 96/40210, Imclone Systems Inc.); IMC-11F8, a fully human, EGFR-targeted antibody (Imclone); antibodies that bind type II mutant EGFR (US Patent No. 5,212,290); humanized and chimeric antibodies that bind EGFR as described in US Patent No. 5,891,996; and human antibodies that bind EGFR, such as ABX-EGF or Panitumumab (see WO98/50433, Abgenix/Amgen); EMD 55900 (Stragliotto *et al. Eur. J. Cancer* 32A:636-640 (1996)); EMD7200

(matuzumab) a humanized EGFR antibody directed against EGFR that competes with both EGF and TGF- α for EGFR binding (EMD/Merck); human EGFR antibody, HuMax-EGFR (GenMab); fully human antibodies known as E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 and E7.6.3 and described in US 6,235,883; MDX-447 (Medarex Inc); and mAb 806 or humanized mAb 806 (Johns *et al.*, *J. Biol. Chem.* 279(29):30375-30384 (2004)). The anti-EGFR antibody may be conjugated with a cytotoxic agent, thus generating an immunoconjugate (see, *e.g.*, EP659,439A2, Merck Patent GmbH). EGFR antagonists include small molecules such as compounds described in US Patent Nos: 5,616,582, 5,457,105, 5,475,001, 5,654,307, 5,679,683, 6,084,095, 6,265,410, 6,455,534, 6,521,620, 6,596,726, 6,713,484, 5,770,599, 6,140,332, 5,866,572, 6,399,602, 6,344,459, 6,602,863, 6,391,874, 6,344,455, 5,760,041, 6,002,008, and 5,747,498, as well as the following PCT publications: WO98/14451, WO98/50038, WO99/09016, and WO99/24037. Particular small molecule EGFR antagonists include OSI-774 (CP-358774, erlotinib, TARCEVA[®] Genentech/OSI Pharmaceuticals); PD 183805 (CI 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA[®]) 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166 ((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol); (R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine); CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butyramide); EKB-569 (N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); AG1571 (SU 5271; Pfizer); dual EGFR/HER2 tyrosine kinase inhibitors such as lapatinib (TYKERB[®], GSK572016 or N-[3-chloro-4-[(3 fluorophenyl)methoxy]phenyl]-6[5[[[2methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine).

Chemotherapeutic agents also include "tyrosine kinase inhibitors" including the EGFR-targeted drugs noted in the preceding paragraph; small molecule HER2 tyrosine kinase inhibitor such as TAK165 available from Takeda; CP-724,714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as antisense agent ISIS-5132 available from ISIS Pharmaceuticals which inhibit Raf-1 signaling; non-HER targeted TK inhibitors such as imatinib

mesylate (GLEEVEC®, available from Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors such as sunitinib (SUTENT®, available from Pfizer); VEGF receptor tyrosine kinase inhibitors such as vatalanib (PTK787/ZK222584, available from Novartis/Schering AG); MAPK extracellular regulated kinase I inhibitor CI-1040 (available from Pharmacia); quinazolines, such as PD 153035, 4-(3-chloroanilino) quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706; pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidines; curcumin (diferuloyl methane, 4,5-bis (4-fluoroanilino)phthalimide); tyrphostines containing nitrothiophene moieties; PD-0183805 (Warner-Lambert); antisense molecules (*e.g.* those that bind to HER-encoding nucleic acid); quinoxalines (US Patent No. 5,804,396); tryphostins (US Patent No. 5,804,396); ZD6474 (AstraZeneca); PTK-787 (Novartis/Schering AG); pan-HER inhibitors such as CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis/Lilly); imatinib mesylate (GLEEVEC®); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474 (AstraZeneca); PTK-787 (Novartis/Schering AG); INC-1C11 (Imclone), rapamycin (sirolimus, RAPAMUNE®); or as described in any of the following patent publications: US Patent No. 5,804,396; WO 1999/09016 (American Cyanamid); WO 1998/43960 (American Cyanamid); WO 1997/38983 (Warner Lambert); WO 1999/06378 (Warner Lambert); WO 1999/06396 (Warner Lambert); WO 1996/30347 (Pfizer, Inc); WO 1996/33978 (Zeneca); WO 1996/3397 (Zeneca) and WO 1996/33980 (Zeneca).

Chemotherapeutic agents also include dexamethasone, interferons, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, oprelvekin, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, plicamycin, porfimer sodium, quinacrine, rasburicase, sargramostim, temozolomide, VM-26, 6-TG, toremifene, tretinoin, ATRA, valrubicin, zoledronate, and zoledronic acid, and pharmaceutically acceptable salts thereof.

Chemotherapeutic agents also include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate,

clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene acetate; immune selective anti-inflammatory peptides (ImSAIDs) such as phenylalanine-glutamine-glycine (FEG) and its D-isomeric form (feG) (IMULAN BioTherapeutics, LLC); anti-rheumatic drugs such as azathioprine, ciclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, minocycline, sulfasalazine, tumor necrosis factor alpha (TNF α) blockers such as etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi), Interleukin 1 (IL-1) blockers such as anakinra (Kineret), T cell costimulation blockers such as abatacept (Orencia), Interleukin 6 (IL-6) blockers such as tocilizumab (ACTEMERA®); Interleukin 13 (IL-13) blockers such as lebrikizumab; Interferon alpha (IFN) blockers such as Rontalizumab; Beta 7 integrin blockers such as rhuMAb Beta7; IgE pathway blockers such as Anti-M1 prime; Secreted homotrimeric LTA3 and membrane bound heterotrimer LTA1/ β 2 blockers such as Anti-lymphotoxin alpha (LTA); radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu); miscellaneous investigational agents such as thioplatin, PS-341, phenylbutyrate, ET-18-OCH₃, or farnesyl transferase inhibitors (L-739749, L-744832); polyphenols such as quercetin, resveratrol, piceatannol, epigallocatechin gallate, theaflavins, flavanols, procyanidins, betulinic acid and derivatives thereof; autophagy inhibitors such as chloroquine; delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; acetylcamptothecin, scopoletin, and 9-aminocamptothecin); podophyllotoxin; tegafur (UFTORAL®); bexarotene (TARGRETIN®); bisphosphonates such as clodronate (for example, BONEFOS® or OSTAC®), etidronate (DIDROCAL®), NE-58095, zoledronic acid/zoledronate (ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), or risedronate (ACTONEL®); and epidermal growth factor receptor (EGF-R); vaccines such as THERATOPE® vaccine; perifosine, COX-2 inhibitor (e.g. celecoxib or etoricoxib), proteasome inhibitor (e.g. PS341); CCI-779; tipifarnib (R11577); orafenib, ABT510; Bcl-2 inhibitor such as oblimersen sodium (GENASENSE®); pixantrone; farnesyltransferase inhibitors such as lonafarnib (SCH 6636, SARASARTM); and pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone; and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin (ELOXATINTM) combined with 5-FU and leucovorin.

Chemotherapeutic agents also include non-steroidal anti-inflammatory drugs with analgesic, antipyretic and anti-inflammatory effects. NSAIDs include non-selective inhibitors of the enzyme cyclooxygenase. Specific examples of NSAIDs include aspirin, propionic acid derivatives such as

ibuprofen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and naproxen, acetic acid derivatives such as indomethacin, sulindac, etodolac, diclofenac, enolic acid derivatives such as piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, and COX-2 inhibitors such as celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, rofecoxib, and valdecoxib. NSAIDs can be indicated for the symptomatic relief of conditions such as rheumatoid arthritis, osteoarthritis, inflammatory arthropathies, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhoea, metastatic bone pain, headache and migraine, postoperative pain, mild-to-moderate pain due to inflammation and tissue injury, pyrexia, ileus, and renal colic.

Chemotherapeutic agents also include treatments for Alzheimer's Disease such as donepezil hydrochloride and rivastigmine; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex[®] and Rebif[®]), glatiramer acetate, and mitoxantrone; treatments for asthma such as albuterol and montelukast sodium; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.

Additionally, chemotherapeutic agents include pharmaceutically acceptable salts, acids or derivatives of any of chemotherapeutic agents, described herein, as well as combinations of two or more of them.

The amount of both the compound of formula (I) or salt thereof and additional agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. In certain embodiments, compositions of this invention are formulated such that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive can be administered.

The additional therapeutic agent and the compound of formula (I) may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent, or there may be fewer side effects for the patient given that a lower dose is used. In certain embodiments, in such compositions a dosage of between 0.01 – 1,000 µg/kg body weight/day of the additional therapeutic agent can be administered.

Another aspect includes treating or preventing drug resistance in a patient using a compound of formula (I) or a pharmaceutically acceptable salt thereof. For example, a method of treating or preventing drug resistant cancer in a patient comprises administering a therapeutically effective amount of a compound of formula (I) to the patient alone or in combination with a cytotoxic agent. In certain embodiments, the individual is selected for treatment with a cytotoxic agent (*e.g.*, targeted therapies, chemotherapies, and/or radiotherapies). In certain embodiments, the individual starts treatment comprising administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof prior to treatment with the cytotoxic agent. In certain embodiments, the individual concurrently receives treatment comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof and the cytotoxic agent. In certain embodiments, the compound of formula (I) or the pharmaceutically acceptable salt thereof increases the period of cancer sensitivity and/or delays development of cancer resistance.

In particular, provided herein are methods of treating cancer in an individual comprising administering to the individual (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) a cytotoxic agent (*e.g.*, targeted therapy, chemotherapy, and/or radiotherapy). In certain embodiments, the respective amounts of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the cytotoxic agent are effective to increase the period of cancer sensitivity and/or delay the development of cancer cell resistance to the cancer therapy agent. In certain embodiments, the respective amounts of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the cytotoxic agent are effective to increase efficacy of a cancer treatment comprising the cancer therapy agent. For example, in certain embodiments, the respective amounts of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the cytotoxic agent are effective to increase efficacy compared to a treatment (*e.g.*, standard of care treatment) (*e.g.*, standard of care treatment) comprising administering an effective amount of the cancer therapy agent without (in the absence of) the compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the respective amounts of the compound of formula (I) or a pharmaceutically acceptable salt thereof and cytotoxic agent are effective to increase response (*e.g.*, complete response) compared to a treatment (*e.g.*, standard of care

treatment) comprising administering an effective amount of cytotoxic agent without (in the absence of) the compound of formula (I) or a pharmaceutically acceptable salt thereof.

Also provided herein are methods of increasing efficacy of a cancer treatment comprising a cytotoxic agent in an individual comprising administering to the individual (a) an effective amount
5 of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of the cytotoxic agent.

Provided herein are methods of treating cancer in an individual wherein cancer treatment comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of a cytotoxic agent, wherein
10 the cancer treatment has increased efficacy compared to a treatment (e.g., standard of care treatment) comprising administering an effective amount of cytotoxic agent without (in the absence of) the compound of formula (I) or a pharmaceutically acceptable salt thereof.

In addition, provided herein are methods of delaying and/or preventing development of cancer resistant to a cancer therapy agent in an individual, comprising administering to the
15 individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of the cytotoxic agent.

Provided herein are methods of treating an individual with cancer who has an increased likelihood of developing resistance to a cancer therapy agent comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable
20 salt thereof and (b) an effective amount of the cytotoxic agent.

Further provided herein are methods of increasing sensitivity to a cancer therapy agent in an individual with cancer comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of the cytotoxic agent.

Provided herein are also methods of extending the period of a cancer therapy agent sensitivity in an individual with cancer comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of the cytotoxic agent.

Provided herein are methods of extending the duration of response to a cytotoxic agent in an individual with cancer comprising administering to the individual (a) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) an effective amount of the cytotoxic agent.

In certain embodiments of any of the methods, the cytotoxic agent is a targeted therapy. In certain embodiments, the targeted therapy is one or more of an EGFR antagonist, RAF inhibitor, and/or PI3K inhibitor.

In certain embodiments of any of the methods, the targeted therapy is an EGFR antagonist.

5 In certain embodiments of any of the methods, the EGFR antagonist is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine and/or a pharmaceutical acceptable salt thereof. In certain embodiments, the EGFR antagonist is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. In certain embodiments, the EGFR antagonist is N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine, di4-
10 methylbenzenesulfonate or a pharmaceutically acceptable salt thereof (*e.g.*, lapatinib).

In certain embodiments of any of the methods, targeted therapy is a RAF inhibitor. In certain embodiments, the RAF inhibitor is a BRAF inhibitor. In certain embodiments, the RAF inhibitor is a CRAF inhibitor. In certain embodiments, the BRAF inhibitor is vemurafenib. In certain embodiments, the RAF inhibitor is 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-
15 oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide or a pharmaceutically acceptable salt thereof (*e.g.*, AZ628 (CAS# 878739-06-1)).

In certain embodiments of any of the methods, the targeted therapy is a PI3K inhibitor.

In certain embodiments of any of the methods, the cytotoxic agent is chemotherapy. In certain embodiments of any of the methods, the chemotherapy is a taxane. In certain embodiments,
20 the taxane is paclitaxel. In certain embodiments, the taxane is docetaxel.

In certain embodiments of any of the methods, the cytotoxic agent is a platinum agent. In certain embodiments, the platinum agent is carboplatin. In certain embodiments, the platinum agent is cisplatin. In certain embodiments of any of the methods, the cytotoxic agent is a taxane and a platinum agent. In certain embodiments, the taxane is paclitaxel. In certain embodiments, the
25 taxane is docetaxel. In certain embodiments, the platinum agent is carboplatin. In certain embodiments, the platinum agent is cisplatin.

In certain embodiments of any of the methods, the cytotoxic agent is a vinca alkylid. In certain embodiments, the vinca alkylid is vinorelbine. In certain embodiments of any of the methods, the chemotherapy is a nucleoside analog. In certain embodiments, the nucleoside analog
30 is gemcitabine.

In certain embodiments of any of the methods, the cytotoxic agent is radiotherapy.

In certain embodiments of any of the methods, the compound of formula (I) or a pharmaceutically acceptable salt thereof is concomitantly administered with the cytotoxic agent


(*e.g.*, targeted therapy, chemotherapy, and/or radiotherapy). In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered prior to and/or concurrently with the cytotoxic agent (*e.g.*, targeted therapy, chemotherapy, and/or radiotherapy).

In certain embodiments of any of the methods, the cancer is lung cancer, breast cancer, pancreatic cancer, colorectal cancer, and/or melanoma. In certain embodiments, the cancer is lung. In certain embodiments, the lung cancer is NSCLC. In certain embodiments, the cancer is breast cancer. In certain embodiments, the cancer is melanoma.

EXEMPLIFICATION


As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures, wherein R^1 , R^2 , R^3 , and R^4 are as defined for formula I and its alternative embodiments; X is halogen; A, B and D are independently selected from carbon and heteroatom, in one example carbon or nitrogen; R is C_{1-6} alkyl; and M is $-C(O)H$, $-CN$, $-C(O)OH$ or $-C(O)O(C_{1-6} \text{ alkyl})$. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.

Scheme 1 (method A)




The general synthesis of targets **9** and **10** are illustrated in Scheme 1. 4-bromo-1H-pyrazol-5-amine (**1**) is condensed with β -ketoester **2** in refluxing acetic acid to give intermediate **3**. This is followed by reaction with phosphorus oxychloride that leads to intermediate **4**, which when treated with sodium methoxide in methanol forms bromide **5**. Suzuki coupling of bromide **5** with a SEM-protected-pyrazole boronate ester (**6**) provides intermediate **7**. After deprotection of SEM-group, the resulting pyrazole **8** is further coupled with a heteroaryl halide to give target **9**. Intermediate **8** can also react with an acid chloride or anhydride to give target **10**.

Scheme 2 (alternative synthesis of **4**)




An alternative synthesis of intermediate **4** is outlined in Scheme 2. Condensation of 1H-pyrazol-5-amine (**11**) gives pyrazolo[1,5-a]pyrimidin-7(4H)-one (**12**). This is followed by reaction with phosphorus oxychloride that leads to intermediate **13**, which upon bromination with NBS also provides bromide **4**.

Scheme 3 (alternative synthesis of **9**, method B)




An alternative synthesis (method B) of target **9** is outlined in Scheme 3. 1H-pyrazole-4-carboxylate is coupled to an heteroaryl halide either under basic, or Cu-catalyzed, conditions. Then ethyl ester **15** is reduced with DIBAL-H to give primary alcohol **16**, which is transformed to chloride **16** with thionyl chloride. Displacement of chloride with potassium cyanide gives **18**. When treated with N,N-dimethylformamide dimethylacetal (DMF-DMA), intermediate **19** is formed. Reaction with hydrazine gives amino-pyrazole **20**, which can be transformed to target **9** upon condensation with β -ketoester **2**.


10 Scheme 4 (Method C)




Synthesis of target **29** is shown in Scheme 4 (method C). An aldehyde (**21**) is condensed with 3,3-dibromo-1,1,1-trifluoropropan-2-one to give imidazole **22**, which upon treatment with ammonium hydroxide leads to compound nitrile **23**. Protection with SEM group, followed by reduction of nitrile with DIBAL-H provides aldehyde **25**. When the aldehyde is treated with TosMIC in the presence of potassium *tert*-butoxide, nitrile **26** is formed. Reaction of **26** with DMF-DMA, followed condensation with hydrazine, results in amino-pyrazole **28**. Subsequent reaction of compound **28** with β -ketoester **2** then provides target **29**.

Scheme 5 (Method D)

Synthesis of target **34** is shown in Scheme 5 (Method D). An imidazole (**30**) is alkylated with 2-bromoacetonitrile to give compound **31**. Reaction of **31** with DMF-DMA, followed condensation with hydrazine, provides amino-pyrazole **33**. Subsequent reaction of compound **33** with β -ketoester **2** then furnishes target **34**.

Scheme 6 (Method E)


Similarly, an amino-pyrazole **35**, in which the R group is an aldehyde or nitrile or ethyl, can also be condensed with β -ketoester **2** to give compound **36**. The R group can then be further transformed into a variety of other 5-membered heterocycls.

Scheme 7 (Method F)

A general synthetic scheme for target **41** with a 6-membered heterocycl is described in Scheme 7. Reaction of nitrile **38** with DMF-DMA, followed by condensation with hydrazine, provides aminopyrazole **40**. Subsequent reaction of aminopyrazole **40** with a β -ketoester **2** then furnishes target **41**.


In one embodiment the invention provides a method for preparing a compound of formula (I) comprising:

- a) coupling a compound of formula **100** or a salt thereof:




with a compound of formula R^4-X , wherein X is a halogen;


- b) acylating a compound of formula **100** or a salt thereof with a compound of formula R^4-X , wherein X is suitable leaving group;
- c) treating a compound of formula **101** or a salt thereof with a compound of formula **102** in the presence of a suitable acid to provide a compound of formula (I):




- d) treating a compound of formula **103** or a salt thereof with a compound of formula **102** in the presence of a suitable acid to provide a compound of formula (I):



- e) treating a compound of formula **104** or a salt thereof with a compound of formula **102** in the presence of a suitable acid to provide a compound of formula (I):



- f) treating a compound of formula **105** or a salt thereof wherein M is $-C(O)H$, $-CN$, $-C(O)OH$ or $-C(O)O(C_{1-6} \text{ alkyl})$, with a compound of formula **102** in the presence of a suitable acid to provide a compound of formula (I):




Another aspect includes compounds of formulae **101-105** and salts thereof that are useful for preparing compounds of formula (I).

Embodiments are illustrated by the following examples.

Examples


Example 1:

Step 1




3-bromo-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

A mixture of 4-bromo-1H-pyrazol-5-amine (16.1 g, 100.0 mmol) and ethyl 2-ethyl-3-oxobutanoate (19.0 g, 120.0 mmol) in AcOH (300 mL) was heated at reflux for 4 h. After evaporation of the solvent, the residue was washed with MTBE (200 mL x 3). The resulting solid was collected by filtration and dried to give the crude title compound (17.0 g, 67% yield). It was used directly for next step without further purification. LCMS (ESI) m/z : 255.9 $[M+H]^+$.


Step 2**3-bromo-7-chloro-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidine**

POCl₃ (60.8 g, 400.0 mmol) was added dropwise to a stirred and cooled (0 °C) mixture of 3-bromo-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (25.6 g, 100.0 mmol) and DIPEA (51.6 g, 400.0 mmol) in toluene (500 mL). After addition, the mixture was allowed to warm to 90 °C and stirring continued for 4 h, at which time LC-MS showed completion of the conversion. The solvent was removed under reduced pressure and the residue was adjusted to pH = 9 by adding aqueous NaHCO₃. The resulting mixture was extracted with EtOAc (300 ml x 3). The combined organic layers were dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (PE/EtOAc = 10:1) to give the title compound (15.0 g, 55% yield) as yellow solid. LCMS (ESI) m/z: 273.9 [M+H⁺].

Step 3**3-bromo-6-ethyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine**

NaOMe (2.70 g, 50.0 mmol) was added portionwise to a stirred solution of 3-bromo-7-chloro-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidine (2.74 g, 10.0 mmol) in methanol (50 mL). After addition, the reaction mixture was stirred at room temperature for 4 h, at which time LC-MS showed completion of the reaction. The solvent was evaporated under reduced pressure, and the residue was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were dried and concentrated to give the crude title compound (2.40 g, 89% yield). This crude was used in the next step without further purification. LCMS (ESI) m/z: 269.9 [M+H⁺].

Step 4




6-ethyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine

5

A mixture of 3-bromo-6-ethyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine (2.70 g, 10.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (4.86 g, 15.0 mmol), Pd(PPh₃)₂Cl₂ (0.50 g, 0.7 mmol) and Cs₂CO₃ (6.50 g, 20.0 mmol) in dioxane/H₂O (50 mL/10 mL) was heated at reflux for 10 h under nitrogen protection. The organic solvent was removed under reduced pressure, and the residue was extracted with EtOAc (50 mL x 3). The combined organic layers were dried and evaporated. The residue was purified by flash column (PE/EtOAc = 10:1) to give the title compound (1.30 g, 34% yield) as yellow oil. LCMS (ESI) m/z: 388.0 [M+H⁺].


15 Step 5



6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one


A mixture of 6-ethyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine (3.87 g, 10.0 mmol) in MeOH (50 mL) and HCl (2 N, 10 mL, 20.0 mmol) was heated at reflux for 2 h. The solvent was removed under reduced pressure, and the residue was diluted by addition of saturated aqueous NaHCO₃. The resulting mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were dried and evaporated. The residue was purified by flash column (DCM/MeOH = 10:1) to give the title compound (1.90 g, 78% yield) as a yellow solid. LCMS (ESI) m/z: 243.9 [M+H⁺].

Step 6

**6-ethyl-5-methyl-3-(1-(4-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)[1,5-a]pyrimidin-7(4H)-one**

- 5 NaH (60%, 40 mg, 1.0 mmol) was added to a stirred and cooled (0 °C) solution of 6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (122 mg, 0.5 mmol) in DMF (5 ml). Stirring was continued for 1 h at room temperature before 2-chloro-4-methylpyrimidine (128 mg, 1.0 mmol) was added. The reaction mixture was then stirred at room temperature for 12 h and quenched by addition of saturated aqueous NH₄Cl (0.1 mL). The solvent was evaporated, and the residue was purified by preparative HPLC to afford the title compound (22 mg, 13% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.50 (d, *J* = 2.0 Hz, 1 H), 9.06 (d, *J* = 0.8 Hz, 1 H), 8.70 (d, *J* = 4.8 Hz, 1 H), 8.22 (d, *J* = 0.8 Hz, 1 H), 8.19 (s, 1 H), 7.35 (d, *J* = 4.8 Hz, 1 H), 2.54 (s, 3 H), 2.46-2.48 (m, 2 H), 2.41 (s, 3 H), 1.02 (t, *J* = 7.6 Hz, 3 H). LCMS (Method C): Rt = 0.711 min, m/z: 335.9 [M+H⁺].

15


Example 2:**6-ethyl-5-methyl-3-(1-(5-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

20

In a similar procedure as shown in Example 1, the title compound was prepared in 15% yield from 2-chloro-5-methylpyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.43 (s, 1 H), 9.06 (s, 1 H), 8.70

(s, 2 H), 8.19 (s, 2 H), 2.45-2.47 (m, 2 H), 2.40 (s, 3 H), 2.29 (s, 3 H), 1.02-0.98 (m, 3 H). LCMS (Method C): RT = 0.721 min, m/z: 335.9 [M+H⁺].


Example 3:



6-ethyl-5-methyl-3-(1-(pyrimidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one


In a similar procedure as shown in Example 1, the title compound was prepared in 19% yield from 4-chloropyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.18 (s, 1 H), 9.11 (s, 1 H), 8.87 (d, *J* = 5.2 Hz, 1 H), 8.37 (s, 1H), 8.22 (s, 1 H), 7.95 (d, *J* = 5.2 Hz, 1 H), 2.48-2.45 (m, 2 H), 2.42 (s, 3 H), 1.03 (t, *J* = 6.8 Hz, 3 H). LCMS (Method C): RT = 0.713 min, m/z: 321.8, 665.1 [M+H⁺, 2M+1].

Example 4:




3-(1-(4-(dimethylamino)pyrimidin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 22% yield from 2-chloro-4-dimethylaminopyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.44-11.48 (m, 1 H), 8.96 (s, 1 H), 8.08-8.19 (m, 3 H), 6.60 (d, *J* = 6.0 Hz, 1 H), 3.06 (s, 6 H), 2.47-2.45 (m, 2 H), 2.39 (s, 3 H), 1.02 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.671 min, m/z: 364.9 [M+H⁺].

Example 5:


3-(1-(5-(dimethylamino)pyrimidin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 15% yield from 2-chloro-5-dimethylaminopyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.43 (s, 1 H), 8.90 (d, *J* = 0.4 Hz, 1 H), 8.32 (s, 2 H), 8.14 (s, 1 H), 8.09 (d, *J* = 0.8 Hz, 1 H), 2.98 (s, 6 H), 2.47-2.45 (m, 2 H), 2.40 (s, 3 H), 1.01 (t, *J* = 7.6 Hz, 3 H). LCMS (Method C): RT = 0.729 min, *m/z*: 364.9 [M+H⁺].

Example 6:

6-ethyl-5-methyl-3-(1-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 10 % yield from 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.50 (s, 1 H), 8.94 (s, 1 H), 8.13-8.12 (m, 3 H), 6.43 (s, 1 H), 3.63-3.59 (m, 4 H), 2.47-2.45 (m, 2 H), 2.40 (s, 3 H), 1.99-1.93 (m, 4 H), 1.01-1.00 (m, 3 H). LCMS (Method C): RT = 0.709 min, *m/z*: 390.9 [M+H⁺].


Example 7:

6-ethyl-3-(1-(4-methoxypyrimidin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

5

In a similar procedure as shown in Example 1, the title compound was prepared in 38% yield from 2-chloro-4-methoxypyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.05 (d, *J* = 0.4 Hz, 1 H), 8.55 (d, *J* = 5.6 Hz, 1 H), 8.22 (s, 1 H), 8.17 (s, 1 H), 6.88 (d, *J* = 5.6 Hz, 1 H), 4.03 (s, 3 H), 2.45 (q, *J* = 1.6 Hz, 2 H), 2.41 (s, 3 H), 1.02 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.724 min, *m/z*: 351.8 [M+H⁺].

10


Example 8:

6-ethyl-5-methyl-3-(1-(thiazol-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

15

In a similar procedure as shown in Example 1, the title compound was prepared in 10% yield from 2-bromothiazole. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.44 (s, 1 H), 9.02 (d, *J* = 0.4 Hz, 1 H), 8.24 (d, *J* = 0.4 Hz, 1 H), 8.20 (s, 1 H), 7.66 (d, *J* = 3.6 Hz, 1 H), 7.54 (d, *J* = 3.6 Hz, 1 H), 2.49-2.48 (m, 2 H), 2.48 (s, 3 H), 1.03 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.756 min, *m/z*: 326.9 [M+H⁺].


20

Example 9:**Step 1****4-cyclopropyl-2-fluoropyridine**

5

A mixture of 4-bromo-2-fluoropyridine (500 mg, 2.81 mmol), cyclopropylboronic acid (295 mg, 3.47 mmol), Pd(dppf)Cl₂ (223 mg, 0.30 mmol) and Cs₂CO₃ (1.86 g, 5.72 mmol) in dioxane/H₂O (16 mL/4 mL) was heated at 120 °C for 30 min under microwave conditions (with nitrogen protection). After being cooled, the mixture was filtered. The filtrate was evaporated and the residue was purified by flash chromatography on silica gel to give the title compound (100 mg, 26% yield) as an oil, which was used in the next step without purification.

10


Step 2

3-(1-(4-cyclopropylpyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

15

In a similar procedure as shown in Example 1, the title compound was prepared in 6.5% yield from 4-cyclopropyl-2-fluoropyridine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.06 (d, *J* = 0.8 Hz, 1 H), 8.31 (d, *J* = 5.6 Hz, 1 H), 8.19-8.18 (m, 2 H), 7.70 (d, *J* = 1.2 Hz, 1 H), 7.04 (dd, *J* = 1.6, 5.2 Hz, 1 H), 2.52-2.51 (m, 2 H), 2.43 (s, 3 H), 2.14-2.07 (m, 1 H), 1.15-1.13 (m, 2 H), 1.05 (t, *J* = 7.2 Hz, 3 H), 0.90-0.89 (m, 2 H). LCMS (Method C): RT = 0.816 min, *m/z*: 360.9 [M+H⁺].

20


Example 10:

2-(4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-1-yl)isonicotinic acid

5

In a similar procedure as shown in Example 1, the title compound was prepared in 6.6% yield from 2-fluoroisonicotinic acid. ¹H NMR (400MHz, DMSO-*d*₆): δ 11.50 (br. s, 1 H), 9.15 (s, 1 H) 8.68 (d, *J* = 5.2 Hz, 1 H), 8.36 (s, 1 H), 8.28-8.22 (m, 3 H), 7.77 (d, *J* = 4.8 Hz, 1 H), 2.51-2.50 (m, 2 H), 2.44 (s, 3 H), 1.05 (m, 3 H). LCMS (Method C): RT = 0.736 min, m/z: 364.9 [M+H⁺].

10

Example 11:

6-ethyl-3-(1-(4-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

15


Borane (1 M in THF, 0.2 mL, 0.2 mmol) was added dropwise to a stirred and cooled (0 °C) solution of 2-(4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-1-yl)isonicotinic acid (40 mg, 0.11 mmol) in THF (5 mL). After addition, the reaction mixture was warmed to room temperature and stirring continued for 48 h, at which time LC-MS showed the completion of reaction. The reaction was quenched by addition of MeOH (5 mL) and then evaporated. The residue was purified by preparative HPLC to give the title compound (7 mg, 18.2% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.52 (br. s, 1 H), 9.10 (s, 1 H),

20

8.43 (d, $J = 4.8$ Hz, 1 H), 8.21 (d, $J = 8.8$ Hz, 2 H), 7.97 (s, 1 H), 7.28 (d, $J = 4.8$ Hz, 1 H), 5.61 (t, $J = 6.0$ Hz, 1 H), 4.65 (d, $J = 5.6$ Hz, 2 H), 2.52-2.50 (m, 2 H), 2.44 (s, 3 H), 1.05 (t, $J = 7.2$ Hz, 3 H). LCMS (Method C): RT = 0.716 min, m/z : 350.9 $[M+H]^+$.

5 Example 12:

Step 1




6-(4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-1-yl)nicotinic acid

10

In a similar procedure as shown in Example 1, the crude title compound was prepared in 34% yield from 6-fluoronicotinic acid. The crude material was applied to next step without further purification.

15 Step 2




6-ethyl-3-(1-(5-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

20 In a similar procedure as shown in Example 11, the title compound was prepared in 8% yield from 6-(4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-1-yl)

nicotinic acid. ^1H NMR (400 MHz, DMSO- d_6): δ 9.06 (s, 1 H), 8.41 (s, 1 H), 8.18 (s, 1 H), 8.15 (s, 1 H), 7.92 (d, J = 1.2 Hz, 2 H), 5.37 (d, J = 5.6 Hz, 1 H), 4.55 (d, J = 5.2 Hz, 1 H), 2.48-2.45 (m, 2 H), 2.40 (s, 3 H), 1.02 (t, J = 7.6 Hz, 3 H). LCMS (Method C): RT = 0.709 min, m/z : 350.8 $[\text{M}+\text{H}^+]$.

5

Example 13:


3-(1-(4-chloropyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

10

A mixture of 6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (100 mg, 0.41 mmol), 2-bromo-4-chloropyridine (117 mg, 0.62 mmol), $\text{Pd}_2(\text{dba})_3$ (38 mg, 0.04 mmol), Xantphos (47 mg, 0.08 mmol) and Cs_2CO_3 (268 mg, 0.82 mmol) in dioxane (4 mL) was sealed in a microwave vial, purged with nitrogen and irradiated at 140 °C for 1 h under microwave conditions.


15 After cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over Na_2SO_4 and evaporated. The residue was purified by preparative HPLC to give the title compound (40 mg, 28% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6): δ 11.49 (br. s, 1 H), 9.09 (s, 1 H), 8.49 (d, J = 5.2 Hz, 1 H), 8.27 (s, 1 H), 8.22 (s, 1 H), 7.98 (s, 1 H), 7.50 (d, J = 4.4 Hz, 1 H), 2.50-2.48 (m, 2 H), 2.44 (s, 3 H), 1.05 (t, J = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.805 min, m/z : 354.8, 709.1 $[\text{M}+\text{H}^+, 2\text{M}+1]$.

20

Example 14:**6-ethyl-5-methyl-3-(1-(pyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

- 5 A mixture of 6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (120 mg, 0.49 mmol), 2-chloropyrimidine (84 mg, 0.74 mmol), CuI (47 mg, 0.25 mmol), N,N-dimethylethylenediamine (22 mg, 0.25 mmol) and Cs₂CO₃ (241 mg, 0.74 mmol) in dioxane (6 mL) was stirred at 110 °C for 12 h under nitrogen atmosphere. After cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with ammonia (5%,
- 10 5mL x 2), brine (10mL x 2), dried (Na₂SO₄) and evaporated. The residue was purified by preparative HPLC to afford the title compound (31 mg, 20% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.47-11.44 (m, 1 H), 9.12 (s, 1 H), 8.89 (d, *J* = 4.8 Hz, 2 H), 8.26 (s, 1 H), 8.20 (s, 1 H), 7.48 (t, *J* = 4.8 Hz, 1 H), 2.48-2.47 (m, 2 H), 2.42 (s, 3 H), 1.03 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.690 min, *m/z*: 321.8, 665.1 [*M*+H⁺, 2*M*+1].

15


Example 15:**Step 1****3-(1-(4-bromopyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one**

20

A solution of 6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (400 mg, 1.65 mmol) in DMF (5 mL) was added dropwise to a cooled (0 °C) suspension of NaH (60%, 99


mg, 2.47 mmol) in DMF (3 mL). Stirring was continued for 30 min, and then 4-bromo-2-fluoropyridine (432 mg, 2.47 mmol) was added in portions. After addition, the resultant mixture was stirred at room temperature for 8 h, and then poured in water (20 mL). After filtration, the solid cake was dried to give the title compound (480 mg, 73% yield) as a white solid. This was used directly into the next step with further purification.

Step 2



6-ethyl-3-(1-(4-methoxypyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one


NaOMe (33 mg, 0.61 mmol) was added to a stirred solution of 3-(1-(4-bromopyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (80 mg, 0.20 mmol) in DMF (3 mL). The mixture was heated at 135 °C for 12 h and then quenched by addition of saturated aqueous NH₄Cl (1 mL). The mixture was filtered and the filtrate was evaporated. The residue was purified by preparative HPLC to give the title compound (10 mg, 14% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD): δ 8.89 (s, 1 H), 8.28 (s, 1 H), 8.06 (s, 1 H), 8.37 (s, 2 H), 7.54 (s, 1 H), 6.92 (s, 1 H), 3.98 (s, 3 H), 2.70-2.60 (m, 2 H), 2.51 (s, 3 H), 1.17 (t, *J* = 6.8 Hz, 3 H). LCMS (Method C): RT = 0.757 min, *m/z*: 350.9, 701.1 [*M*+H⁺, 2*M*+1].

Example 16:

3-(1-(4-(dimethylamino)pyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

5


A mixture of 3-(1-(4-bromopyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (300 mg, 0.75 mmol) and dimethylamine hydrochloride (916 mg, 11.30 mmol) in DMF (10.0 mL) was treated with DIPEA (1.46 g, 11.31 mmol) and then heated at 150 °C for 30 min under microwave conditions. The resulting mixture was filtered and the filtrate was evaporated. The residue was purified by preparative HPLC to give the title compound (22.8 mg, 8.4% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.97 (s, 1 H), 8.27 (s, 1 H), 6.59 (dd, *J* = 2.4, 6.0 Hz, 1 H), 3.03 (s, 6 H), 2.48 (t, *J* = 1.6 Hz, 2 H), 2.38 (s, 3 H), 1.02 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.668 min, *m/z*: 364.1 [M+H⁺].

15 **Example 17:**

6-ethyl-3-(1-(4-(2-hydroxyethoxy)pyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one


20 NaH (60% dispersion in mineral oil, 24 mg, 0.6 mmol) was added to a stirred solution of ethane-1,2-diol (25 mg, 0.4 mmol) in DMF (2 ml). The mixture was stirred for 30 min at room temperature, then 3-(1-(4-bromopyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (80 mg, 0.2 mmol) was added. The reaction mixture was then heated at 100

°C for 1 h. After cooling, the mixture was quenched by addition of saturated aqueous NH₄Cl (0.2 mL). The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (13 mg, 17.0 % yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.59 (s, 1 H), 9.16 (s, 1 H), 8.31 (d, *J* = 6.0 Hz, 1 H), 8.24 (s, 1H), 8.21 (s, 1H), 7.51 (d, *J* = 2.0 Hz, 1 H), 7.00-6.98 (m, 1H), 4.22 (t, *J* = 4.8 Hz, 2 H), 3.77 (t, *J* = 4.8 Hz, 2 H), 2.51-2.50 (m, 2 H), 2.45 (s, 3 H), 1.04 (t, *J* = 7.4 Hz, 3 H). LCMS (Method C): RT = 0.719 min, *m/z*: 380.9 [M+H⁺].

Example 18:

3-(1-(4-(2-aminoethoxy)pyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one


NaH (60%, 24 mg, 0.60 mmol) was added to a stirred solution of tert-butyl (2-hydroxyethyl) carbamate (80 mg, 0.50 mmol) in DMF (2 ml). The mixture was stirred for 30 min at room temperature, then 3-(1-(4-bromopyridin-2-yl)-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (100 mg, 0.25 mmol) was added. The reaction mixture was then heated at 100 °C for 1 h. After evaporation of the solvent, the residue was diluted with HCl (2 M in EtOAc, 2 mL) and stirred for 2 h. The mixture was concentrated and the residue was purified by preparative HPLC to give the title compound (18 mg, 18.7% yield) as oil. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.52 (br. s, 1 H), 9.10 (s, 1 H), 8.37 (d, *J* = 5.6 Hz, 1 H), 8.23-8.21 (m, 5 H), 7.51 (d, *J* = 3.2 Hz, 1 H), 7.02-7.00 (m, 1 H), 4.40 (d, *J* = 5.2 Hz, 1 H), 3.27 (q, *J* = 5.2 Hz, 1 H), 2.50-2.48 (m, 2 H), 2.45 (s, 3 H), 1.05 (t, *J* = 7.6 Hz, 3 H). LCMS (Method C): RT = 0.668 min, *m/z*: 379.9 [M+H⁺].

Example 19:**Step 1****6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one**


5

A mixture of 1*H*-pyrazol-5-amine (5.0 g, 60.2 mmol) and 2-acetyl-3-methylbutanoate (9.1 g, 52.8 mmol) in AcOH (50 mL) was heated at 140 °C for 5 h. After evaporation of the solvent, the residue was washed with a mixture of PE and EtOAc (200 mL, 5:1) to give the crude title compound (4.1 g, 36% yield) as a white solid. LCMS (ESI) *m/z*: 192.0 [*M*+*H*⁺].

10


Step 2**7-chloro-6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidine**

15 POCl₃ (3.2 g, 21.3 mmol) was added dropwise to a stirred and cooled (0 °C) mixture of 6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (1.0 g, 5.2 mmol) and DIPEA (2.7, 21.3 mmol) in toluene (15 mL). After addition, the mixture was allowed to warm to 120 °C and stirring continued for 12 h, at which time LC-MS showed complete conversion. The solvent was removed under reduced pressure and the residue was adjusted to pH = 9 by adding aqueous NaHCO₃. The
20 resulting mixture was extracted with EtOAc (30 ml × 3). The combined organic layers were dried over Na₂SO₄ and evaporated. The residue was purified by flash chromatography (PE/EtOAc = 15:1) to give the title compound (0.9 g, 82% yield) as a yellow oil. LCMS (ESI) *m/z*: 210.0 [*M*+*H*⁺].

25 **Step 3****3-bromo-7-chloro-6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidine**

NBS (710 mg, 4.0 mmol) in CH₃CN (10 mL) was added in portions to a stirred solution of 7-chloro-6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidine (800 mg, 3.8 mmol) in DCM (10 mL) over a period of 30 min at room temperature. After addition, the mixture was stirred for another 1 h at room temperature, at which time TLC showed the complete conversion. The solvent was evaporated and the residue was purified by silica gel chromatography eluted with PE/EtOAc (20:1) to give the title compound (900 mg, 82% yield) as a yellow oil. LCMS (ESI) m/z: 287.9, 289.9 [M+H⁺].


Step 4



3-bromo-6-isopropyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine

NaOMe (810 mg, 15.0 mmol) was added portionwise to a stirred solution of 3-bromo-7-chloro-6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidine (900 mg, 3.1 mmol) in methanol (10 mL). After addition, the reaction mixture was stirred at room temperature for 4 h, at which time LCMS showed completion of the reaction. The solvent was evaporated under reduced pressure, and the residue was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were dried and concentrated to give the title compound (800 mg, 90% yield) as a yellow oil. This crude was used in the next step without further purification. LCMS (ESI) m/z: 284.0, 286.0 [M+H⁺].


Step 5



6-isopropyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine

A mixture of 3-bromo-6-isopropyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine (800 mg, 2.8 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.40 g, 4.2 mmol), Pd(PPh₃)₂Cl₂ (50 mg, 0.1 mmol) and Cs₂CO₃ (2.00 g, 6.2 mmol) in dioxane/H₂O (20 mL/40 mL) was heated at reflux for 12 h under nitrogen protection. The organic solvent was removed under reduced pressure, and the residue was extracted with EtOAc (20 mL x 3). The combined organic layers were dried and evaporated. The residue was purified by flash column (PE/EtOAc = 10:1) over silica gel to give the title compound (300 mg, 27% yield) as yellow oil. LCMS (ESI) m/z: 402.0 [M+H⁺].


Step 6



6-isopropyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

A mixture of 6-isopropyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine (300 mg, 0.8 mmol) in MeOH (20 mL) and HCl (2 N, 2 mL, 4.0 mmol) was heated at reflux for 2 h. The solvent was removed under reduced pressure, and the residue was diluted with addition of saturated aqueous NaHCO₃. The resulting mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were dried and evaporated. The residue was purified by flash column (DCM/MeOH = 10:1) to the title compound (120 mg, 65% yield) as a yellow solid. LCMS (ESI) m/z: 258.0 [M+H⁺].

Step 7




6-isopropyl-5-methyl-3-(1-(pyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-

one

68

In a similar procedure as shown in Example 1, the title compound was prepared in 13% yield from 2-chloropyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.40 (br. s, 1 H), 9.13 (s, 1 H), 8.90 (d, *J* = 4.4 Hz, 2 H), 8.27 (s, 1 H), 8.21 (s, 1 H), 7.49 (d, *J* = 4.0 Hz, 1 H), 3.06-3.03 (m, 1 H), 2.46 (s, 3 H), 1.31 (d, *J* = 6.8 Hz, 6 H). LCMS (Method C): RT = 0.746 min, *m/z*: 335.9 [M+H⁺].


Example 20:



6-isopropyl-5-methyl-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 80% yield from 2-fluoropyridine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.33 (s, 1 H), 9.07 (s, 1 H), 8.49 (d, *J* = 4.0 Hz, 1 H), 8.16 (d, *J* = 10.4 Hz, 2 H), 8.01-7.93 (m, 2 H), 7.37-7.34 (m, 1 H), 3.08-3.01 (m, 1 H), 2.43 (s, 3 H), 1.28 (d, *J* = 6.8 Hz, 6 H). LCMS (Method C): RT = 0.806 min, *m/z*: 334.9 [M+H⁺].

Example 21:




6-isopropyl-5-methyl-3-(1-(5-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 3% yield from 2-fluoro-5-methylpyridine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.35 (br. s, 1 H), 9.05 (s, 1 H),

8.34 (s, 1 H), 8.17-8.16 (m, 2 H), 7.89-7.82 (m, 2 H), 3.08-3.01 (m, 1 H), 2.45 (s, 3 H), 2.35 (s, 3 H), 1.31 (d, $J = 6.8$ Hz, 6 H). LCMS (Method C): RT = 0.824 min, m/z : 348.9 $[M+H]^+$.


Example 22:



6-isopropyl-5-methyl-3-(1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 6% yield from 2-fluoro-4-methylpyridine. ^1H NMR (400 MHz, DMSO- d_6): δ 11.41 (br. s, 1 H), 9.08 (s, 1 H), 8.36 (d, $J = 5.2$ Hz, 1 H), 8.20 (d, $J = 8.0$ Hz, 2 H), 7.83 (s, 1 H), 7.64-7.53 (m, 1 H), 7.21 (d, $J = 5.2$ Hz, 1 H), 3.08-3.01 (m, 1 H), 2.51 (s, 3 H), 2.44 (s, 3 H), 1.31 (d, $J = 6.8$ Hz, 6 H). LCMS (Method C): RT = 0.825 min, m/z : 348.9 $[M+H]^+$.

Example 23:




6-isopropyl-5-methyl-3-(1-(4-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 8% yield from 2-chloro-4-methylpyrimidine. ^1H NMR (400 MHz, DMSO- d_6): δ 11.41 (br. s, 1 H), 9.07 (d, $J = 0.8$ Hz, 1 H), 8.72 (d, $J = 5.2$ Hz, 1 H), 8.24 (d, $J = 0.8$ Hz, 1 H), 8.20 (s, 1 H), 7.37 (d, $J = 5.2$ Hz,

1 H), 3.08-3.00 (m, 1 H), 2.57 (s, 3 H), 2.46 (s, 3 H), 1.31 (d, $J = 7.2$ Hz, 6 H). LCMS (Method C): RT = 0.753 min, m/z: 349.8 $[M+H]^+$.


Example 24:



6-isopropyl-5-methyl-3-(1-(5-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 1, the title compound was prepared in 4% yield from 2-chloro-5-methylpyrimidine. ^1H NMR (400 MHz, DMSO- d_6): δ 11.38 (br. s, 1 H), 9.09 (s, 1 H), 8.74 (s, 2 H), 8.23-8.20 (m, 2 H), 3.06-3.03 (m, 1 H), 2.46 (s, 3 H), 2.33 (s, 3 H), 1.31 (d, $J = 6.8$ Hz, 6 H). LCMS (Method C): RT = 0.760 min, m/z: 349.9 $[M+H]^+$.

Example 25:




3-(1-(5-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-6-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

In a similar procedure as shown in Example 12, the title compound was prepared in 29% yield from 6-fluoronicotinic acid (2 steps). ^1H NMR (400 MHz, DMSO- d_6): δ 11.37 (br. s, 1 H), 9.08 (s, 1 H), 8.44 (s, 1 H), 8.18 (d, $J = 8.0$ Hz, 2 H), 7.94-7.93 (m, 2 H), 5.40 (br. s, 1 H), 4.58 (s, 2 H), 3.09-

3.00 (m, 1 H), 2.45 (s, 3 H), 1.32 (d, $J = 6.8$ Hz, 6 H). LCMS (Method C): RT = 0.760 min, m/z : 364.9 $[M+H]^+$.

Example 26:




6-isopropyl-5-methyl-3-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

A mixture of 6-isopropyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (257 mg, 1.00 mmol), 3-bromopyridine (316 mg, 2.00 mmol), CuI (10 mg, 0.05 mmol), L-proline (12 mg, 0.10 mmol) and K_2CO_3 (138 mg, 1.00 mmol) in DMSO (5 mL) was heated at 120 °C for 12 h under nitrogen atmosphere. After cooling, the mixture was filtered and the filtrate was evaporated. The residue was purified by preparative HPLC to give the title compound (130 mg, 37% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6): δ 11.40 (br. s, 1 H), 9.15 (s, 1 H), 8.90 (s, 1 H), 8.54 (d, $J = 4.0$ Hz, 1 H), 8.26-8.24 (m, 1 H), 8.17 (s, 1 H), 8.07 (s, 1 H), 7.61-7.58 (m, 1 H), 3.08-3.01 (m, 1 H), 2.45 (s, 3 H), 1.32 (d, $J = 6.8$ Hz, 6 H). LCMS (Method C): RT = 0.723 min, m/z : 334.9 $[M+H]^+$.


Example 27:

Step 1



Benzyl 2-cyclopropylacetate


K_2CO_3 (110.4 g, 0.80 mol) was added portionwise to a stirred solution of 2-cyclopropylacetic acid (40.0 g, 0.40 mol) in DMF (200 mL), followed by BnBr (75.2 g, 0.44 mol). After addition, the resulting mixture was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, and the residue was diluted with EtOAc (1000 mL). This solution was then washed with HCl (aq. 1 N, 100 mL $\times$ 3), dried and evaporated to give the crude title compound (65.0 g, 86% yield) as a colorless oil. This crude was used into next step without further purification.

Step 2**Benzyl 2-cyclopropyl-3-oxobutanoate**

5

LiHMDS (1 M in THF, 410.5 mL, 410.5 mmol) was added dropwise to a stirred and cooled (-78 °C) solution of benzyl 2-cyclopropylacetate (65.0 g, 342.1 mmol) in THF (600 mL). Stirring at -78 °C continued for 20 min before acetyl chloride (410.5 mmol) was added dropwise. The resulting mixture was stirred at -78 °C for additional 2 h, at which time TLC (PE/ EtOAc = 10:1) showed complete conversion. The mixture was quenched by addition of saturated aqueous NH₄Cl (200 mL), and then extracted with EtOAc (300 mL × 3). The combined organic layers were dried and evaporated. The residue was purified by flash chromatography (PE/EtOAc = 100:1) to give the title compound (30.0 g, 38% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 7.32-7.17 (m, 5 H), 5.12 (s, 2 H), 2.60 (d, *J* = 10.4 Hz, 1 H), 2.18 (s, 3 H), 1.30-1.22 (m, 1 H), 0.66-0.57 (m, 2 H), 0.28-0.18 (m, 2 H).


15

Step 3**6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one**


20

A mixture of 1H-pyrazol-5-amine (11.3 g, 136.0 mmol) and benzyl 2-cyclopropyl-3-oxobutanoate (30.0 g, 129.3 mmol) in AcOH (80 mL) was heated at 130 °C for 2 h. After evaporation of the solvent, the residue was washed with a mixture of PE and EtOAc (200 mL, 10:1) to give the crude title compound (24.0 g, 98% yield) as a gray solid. This crude was used in the next step without further purification.

25

Step 4**7-chloro-6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidine**


- 5 A suspension of 6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (20.5 g, 106 mmol) in POCl₃ (110.0 g, 720 mmol) was heated at 130 °C for 2 h. After completion of reaction, excess POCl₃ was removed under reduced pressure, and the residue was poured into ice-water. The solution was adjusted to pH = 9 by adding aqueous Na₂CO₃ and then extracted with EtOAc (200 mL × 3). The combined organic layers were dried (Na₂SO₄) and evaporated. The residue was
- 10 purified by flash chromatography (PE/EtOAc = 50:1-20:1) over silica gel to give the title compound (10.0 g, 44% yield) as a yellow oil.

Step 5

15 **3-bromo-7-chloro-6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidine**


- NBS (8.9 g, 50.0 mmol) in CH₃CN (50 mL) was added in portions to a stirred solution of 7-chloro-6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidine (10.0 g, 48.3 mmol) in DCM (80 mL) over a period of 30 min at room temperature. After addition, the mixture was stirred for another 1 h at
- 20 room temperature, at which time TLC showed the complete conversion. The solvent was evaporated; the residue was purified by silica gel chromatography eluted with PE/EtOAc (50:1-20:1) to give the title compound (12.5 g, 91% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 8.08 (s, 1 H), 2.78 (s, 3 H), 1.83 (m, 1 H), 1.26-1.19 (m, 2 H), 0.80-0.79 (m, 2 H).

25 **Step 6**

**3-bromo-6-cyclopropyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine**


NaOMe (7.6 g, 141.0 mmol) was added portionwise to a stirred solution of 3-bromo-7-chloro-6-cyclopropyl-5-methylpyrazolo[1,5-a]pyrimidine (10.0 g, 35.0 mmol) in methanol (80 mL). After addition, the reaction mixture was stirred at room temperature for 4 h, at which time LCMS showed completion of reaction. The solvent was evaporated under reduced pressure, and the residue was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (80 mL $\times$ 3). The combined organic layers were dried and concentrated to give the title compound (10.0 g, 100% yield) as an yellow oil. ^1H NMR (400 MHz, CDCl_3): δ 7.98 (s, 1 H), 4.33 (s, 3 H), 2.72 (s, 3 H), 1.72-1.66 (m, 1 H), 1.16-1.06 (m, 2 H), 0.78-0.69 (m, 2 H).

Step 7




6-cyclopropyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine

A mixture of 3-bromo-6-cyclopropyl-7-methoxy-5-methylpyrazolo[1,5-a]pyrimidine (6.6 g, 23.4 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (11.4 g, 35.2 mmol), $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (1.6 g, 2.4 mmol) and Na_2CO_3 (5.0 g, 46.8 mmol) in dioxane/ H_2O (125 mL/25 mL) was heated at 120 $^\circ\text{C}$ for 16 h under nitrogen protection. After cooling, the mixture was filtered through a short pad of Celite and then extracted with EtOAc (100 mL $\times$ 3). The combined organic layers were dried and evaporated. The residue was purified by flash column (PE/EtOAc = 10:1-3:1) over silica gel to give the title compound (3.8 g, 41% yield) as an yellow oil. ^1H NMR (400 MHz, CDCl_3): δ 8.19 (s, 1 H), 8.17 (s, 1 H), 7.99 (s, 1 H), 5.49 (s, 2 H), 4.36 (s, 3 H), 3.66-3.58 (m, 2 H), 2.74 (s, 3 H), 1.75-1.68 (m, 1 H), 1.15-1.09 (m, 2 H), 0.98-0.91 (m, 2 H), 0.79-0.73 (m, 2 H), -0.01--0.02 (s, 9 H).


Step 8**6-cyclopropyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

- 5 A mixture of 6-cyclopropyl-7-methoxy-5-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine (2.8 g, 7.0 mmol) in MeOH (40 mL) and HCl (6 N, 6 mL, 36.0 mmol) was heated at reflux for 2 h. The solvent was removed under reduced pressure, and the residue was diluted by addition of saturated aqueous Na₂CO₃. The resulting mixture was extracted with CH₂Cl₂ (80 mL x 3). The combined organic layers were dried and evaporated. The residue
10 was purified by flash column (DCM/MeOH = 9:1) to give the title compound (1.3 g, 73% yield) as a yellow solid. LCMS (ESI) m/z: 256.0 [M+H⁺].

Step 9

- 15 **6-cyclopropyl-5-methyl-3-(1-(5-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

- In a similar procedure as shown in Example 26, the title compound was prepared in 23% yield from 2-bromo-5-methylpyridine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.05 (s, 1 H), 8.34 (s, 1 H), 8.18-8.16 (m, 2 H), 7.86-7.82 (m, 2 H), 2.53 (s, 3 H), 2.35 (s, 3 H), 1.55-1.45 (m, 1 H), 0.90-0.86 (m, 2 H), 0.68-0.58 (m, 2 H). LCMS (Method C): RT = 0.803 min, m/z: 345.8 [M+H⁺].
20


Example 28:

6-cyclopropyl-5-methyl-3-(1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(6H)-one

5

In a similar procedure as shown in Example 26, the title compound was prepared in 13% yield from 2-bromo-4-methylpyridine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.56 (br. s, 1 H), 9.07 (br. s., 1 H), 8.36 (d, *J* = 4.0 Hz, 1 H), 8.19 (d, *J* = 0.4 Hz, 2 H), 7.82 (s, 1 H), 7.20 (d, *J* = 4.8 Hz, 1 H), 2.52 (s, 3 H), 2.43 (s, 3 H), 1.50-1.48 (m, 1 H), 0.88-0.86 (m, 2 H), 0.65-0.63 (m, 2 H). LCMS (Method C): RT = 0.797 min, *m/z*: 346.9 [M+H⁺].

10


Example 29:

6-cyclopropyl-5-methyl-3-(1-(pyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(6H)-one

15

In a similar procedure as shown in Example 1, the title compound was prepared in 34% yield from 2-chloropyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.53 (br. s, 1 H), 9.13 (s, 1 H), 8.89 (d, *J* = 4.8 Hz, 1 H), 8.27 (s, 1 H), 8.20 (s, 1 H), 7.50 (t, *J* = 4.8 Hz, 1 H), 2.53 (s, 3 H), 1.52-1.47 (m, 1 H), 0.90-0.85 (m, 2 H), 0.66-0.64 (m, 2 H). LCMS (Method C): RT = 0.724 min, *m/z*: 339.9 [M+H⁺].

20


Example 30:

6-cyclopropyl-5-methyl-3-(1-(4-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(6H)-one

5

In a similar procedure as shown in Example 1, the title compound was prepared in 29% yield from 2-chloro-4-methylpyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.05 (s, 1 H), 8.71 (d, *J* = 5.0 Hz, 1 H), 8.25 (d, *J* = 0.8 Hz, 1 H), 8.16 (s, 1 H), 7.35 (d, *J* = 4.8 Hz, 1 H), 2.56 (s, 3 H), 2.49 (s, 3 H), 1.53-1.46 (m, 1 H), 0.88-0.83 (m, 2 H), 0.66-0.65 (m, 2 H). LCMS (Method C): RT = 0.738 min, m/z: 347.9 [M+H⁺].

10


Example 31:

6-cyclopropyl-5-methyl-3-(1-(5-methylpyrimidin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(6H)-one

15

In a similar procedure as shown in Example 1, the title compound was prepared in 26% yield from 2-chloro-5-methylpyrimidine. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.52 (br. s, 1 H), 9.10 (s, 1 H), 8.74 (s, 2 H), 8.23 (s, 1 H), 8.19 (s, 1 H), 2.53 (s, 3 H), 2.33 (s, 3 H), 1.52-1.47 (m, 1 H), 0.90-0.85 (m, 2 H), 0.66-0.64 (m, 2 H). LCMS (Method C): RT = 0.743 min, m/z: 347.9 [M+H⁺].

20


Example 32:

6-cyclopropyl-3-(1-(5-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(6H)-one

5

In a similar procedure as shown in Example 11, the title compound was prepared in 11% yield from 6-fluoronicotinic acid (2 steps). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.51 (br. s, 1 H), 9.08-9.05 (m, 1 H), 8.41 (s, 1 H), 8.16-8.13 (m, 2 H), 7.91-7.90 (m, 2 H), 5.38-5.35 (m, 1 H), 4.55 (d, *J* = 5.6 Hz, 2 H), 2.50 (s, 3 H), 1.48-1.46 (m, 1 H), 0.88-0.82 (m, 2 H), 0.62-0.59 (m, 2 H). LCMS (Method C): RT = 0.724 min, *m/z*: 362.9 [M+H⁺].

10


Example 33:

3-(1-acetyl-1H-pyrazol-4-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one

15

Ac₂O (102 mg, 1.0 mmol) was added to a stirred and cooled (0 °C) solution of 6-ethyl-5-methyl-3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (120 mg, 0.49 mmol) in pyridine (5 ml). After addition, the mixture was stirred at 0 °C for 1 h then concentrated. The residue was purified by preparative HPLC to give the title compound (30 mg, 21% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.40 (s, 1H), 8.95 (d, *J* = 0.4 Hz, 1 H), 8.32 (s, 1 H), 8.24 (s, 1 H), 2.69 (s, 3 H), 2.51 (q, *J* = 1.6 Hz, 2 H), 2.44 (s, 3 H), 1.05 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.703 min, *m/z*: 285.8 [M+H⁺].

20


Example 34:

4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-N,N-dimethyl-1H-pyrazole-1-carboxamide

5

In a similar procedure as shown in Example 33, the title compound was prepared in 84% yield from dimethylcarbamic chloride. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.44 (s, 1 H), 8.69 (s, 1 H), 8.14 (s, 2 H), 3.13 (s, 6 H), 2.47-2.50 (m, 2 H), 2.40 (s, 3 H), 1.01 (t, $J = 7.2$ Hz, 3 H). LCMS (Method C): RT = 0.700 min, m/z : 314.9 $[\text{M}+\text{H}^+]$.

10


Example 35:

6-ethyl-5-methyl-3-(1-(pivaloyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

15

In a similar procedure as shown in Example 33, the title compound was prepared in 23.9% yield from pivaloyl chloride. ^1H NMR (400MHz, $\text{DMSO}-d_6$): δ 11.45 (s, 1 H), 8.85 (d, $J = 0.4$ Hz, 1 H), 8.28 (s, 1 H), 8.20 (s, 1 H), 2.50 (q, $J = 1.6$ Hz, 2 H), 2.43 (s, 3 H), 1.49 (s, 9 H), 1.05 (t, $J = 7.2$ Hz, 3 H). LCMS (Method C): RT = 0.848 min, m/z : 327.9 $[\text{M}+\text{H}^+]$.

20


Example 36:

Methyl 4-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazole-1-carboxylate

5

In a similar procedure as shown in Example 33, the title compound was prepared in 4.1% yield from methyl chloroformate. ¹H NMR (400MHz, DMSO-*d*₆): δ 11.40 (s, 1 H), 8.86 (s, 1 H), 8.30 (s, 1 H), 8.22 (s, 1 H), 4.03 (s, 3 H), 2.50 (q, *J* = 1.6 Hz, 2 H), 2.44 (s, 3 H), 1.05 (t, *J* = 7.6 Hz, 3 H). LCMS (Method C): RT = 0.687 min, *m/z*: 301.8 [M+H⁺].

10


Method B**Example 37:****Step 1**

15


Ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate

A solution of ethyl 1H-pyrazole-4-carboxylate (1.2 g, 8.6 mmol) in DMF (5 mL) was added dropwise to a stirred and cooled (0 °C) suspension of NaH (60%, 410 mg, 10.3 mmol) in DMF (5 mL). Stirring continued for 30 min at 0 °C before 2-fluoropyridine (915 mg, 9.4 mmol) was added. After addition, the ice bath was removed and the reaction mixture was heated at 80 °C for 3 h. After being cooled, the mixture was quenched by addition of saturated aqueous NH₄Cl and then extracted with EtOAc (40 mL × 3). The combined organic layers were dried and evaporated. The residue was purified by silica gel flash chromatography (PE/EtOAc = 5:1) to give the title compound (1.2 g, 65% yield) as a yellow oil.

25


Step 2**(1-(pyridin-2-yl)-1H-pyrazol-4-yl)methanol**

5 DIBAL-H (1 M in THF, 11.0 mL, 11.0 mmol) was added dropwise to a stirred and cooled (0 °C) solution of ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate (1.2 g, 5.5 mmol) in THF (20 mL). After addition, stirring at 0 °C continued for 3 h before the reaction mixture was quenched by addition of 1 M NH₄Cl (20 mL). The mixture was then extracted with EtOAc (40 mL × 3). The combined organic layers were dried and evaporated to afford the crude title compound (0.9 g, 93%
10 yield) as a colorless oil. This crude was used in the next step without further purification.


Step 3**2-(4-(chloromethyl)-1H-pyrazol-1-yl)pyridine**

15


To a solution of (1-(pyridin-2-yl)-1H-pyrazol-4-yl) methanol (0.9 g, 5.1 mmol) in DCM (10 mL) was added sulfurous dichloride (1.84 g, 15.3 mmol) at room temperature. After addition, the reaction mixture was stirred for 2 h and then concentrated. The residue was diluted with EtOAc (30 mL) and adjusted to pH = 9 by addition of 1 M aqueous K₂CO₃. The organic layer was
20 separated and the aqueous layer was extracted with EtOAc (30 mL × 3). The combined organic layers were dried and evaporated. The residue was purified by flash chromatography (PE/ EtOAc = 5: 1) to give the title compound (0.9 g, 90% yield) as yellow oil.

Step 4**2-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)acetonitrile**


- 5 KCN (1.0 g, 15.4 mmol) was added in portions to a stirred solution of 2-(4-(chloromethyl)-1H-pyrazol-1-yl)pyridine (0.9 g, 4.6 mmol) in DMSO/H₂O (10 mL/3 mL). The resulting mixture was heated at 50 °C for 5 h, at which time TLC showed complete conversion. The reaction mixture was cooled and diluted with EtOAc (50 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (30 mL × 3). The combined organic layers were dried, concentrated to
- 10 afford the crude title compound (0.8 g, 93% yield) as yellow oil. It was used in the next step without further purification.

Step 5**3-(dimethylamino)-2-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)acrylonitrile**


A mixture of 2-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)acetonitrile (0.8 g, 4.3 mmol) in DMF-DMA (2.0 mL) was heated at 140 °C for 30 min under microwave irradiation. The mixture was concentrated to afford the crude title compound, which was used in the next step without further purification.

Step 6**1'-(pyridin-2-yl)-1H,1'H-[4,4'-bipyrazol]-5-amine**

- 5 Concentrated HCl (15 mL) was added slowly to a stirred solution of hydrazine monohydrate (2.0 mL) in EtOH (20 mL), followed by 3-(dimethylamino)-2-(1-(pyridin-2-yl)-1H-pyrazol-4-yl) and acrylonitrile (11.1 g, 4.6 mmol). The resultant yellow solution was heated at reflux for 2 h. After cooling, the mixture was adjusted to pH = 9 by addition of 1 M aqueous K₂CO₃. The resulting mixture was then extracted with EtOAc (40 mL × 3). The combined organic layers were dried and
- 10 evaporated. The residue was purified by silica gel chromatography (DCM/MeOH = 10:1) to give the title compound (1.0 g, 96% yield) as a yellow oil. LCMS (Method C): RT = 0.427 min, m/z: 226.8 [M+H⁺].

Step 7**5-ethyl-6-methyl-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**


- 15 A mixture of 1'-(pyridin-2-yl)-1H,1'H-[4,4'-bipyrazol]-5-amine (150 mg, 0.66 mmol) and ethyl 2-methyl-3-oxopentanoate (209 mg, 1.32 mmol) in AcOH (10 mL) was heated at 160 °C for 1 h.
- 20 After evaporation of the solvent, the crude product was purified by preparative HPLC to give the title compound (10.6 mg, 5% yield) as a white solid. ¹H NMR (400MHz, DMSO-*d*₆): δ 11.49 (br. s, 1 H), 9.10 (s, 1 H), 8.51 (d, *J* = 4.8 Hz, 1 H), 8.22-8.19 (m, 2 H), 8.01-7.96 (m, 2 H), 7.37 (t, *J* = 5.6 Hz, 1 H), 2.75 (q, *J* = 7.6 Hz, 2 H), 2.03 (s, 1 H), 1.22 (t, *J* = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.754 min, m/z: 320.8 [M+H⁺].

Example 38:**5-isopropyl-6-methyl-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

5

In a similar procedure as shown in Example 37, the title compound was prepared in 7% yield from ethyl 2,4-dimethyl-3-oxopentanoate. ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 10.90 (br. s, 1 H), 8.97 (s, 1 H), 8.50 (d, $J = 4.4$ Hz, 1 H), 8.16-7.90 (m, 4 H), 7.35 (s, 1 H), 2.46-2.44 (m, 1 H), 2.07 (s, 3 H), 1.40-1.20 (m, 6 H). LCMS (Method C): RT = 0.782 min, m/z : 334.9 $[\text{M}+\text{H}^+]$.


10

Example 39:**5-cyclopropyl-6-methyl-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**


15

In a similar procedure as shown in Example 37, the title compound was prepared in 4% yield from ethyl 3-cyclopropyl-2-methyl-3-oxopropanoate. ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 11.16 (br. s, 1 H), 9.01 (s, 1 H), 8.51 (d, $J = 4.4$ Hz, 1 H), 8.18-8.15 (m, 2 H), 8.02-7.95 (m, 2 H), 7.36 (s, 1 H), 2.19-2.14 (m, 4 H), 1.04-0.99 (m, 4 H). LCMS (Method C): RT = 0.761 min, m/z : 332.9 $[\text{M}+\text{H}^+]$.

20

Example 40:**6-methoxy-5-methyl-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**


- 5 In a similar procedure as shown in Example 37, the title compound was prepared in 12% yield from ethyl 2-methoxy-3-oxobutanoate. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.58 (br. s, 1 H), 9.10 (d, *J* = 0.8 Hz, 1 H), 8.48-8.45 (m, 1 H), 8.23-8.20 (m, 2 H), 8.00-7.94 (m, 2 H), 7.37-7.34 (m, 1 H), 3.71 (s, 3 H), 2.39 (s, 3 H). LCMS (Method C): RT = 0.717 min, *m/z*: 322.8 [M+H⁺].

Example 41:**Step 1****6-ethyl-7-oxo-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-5-carboxylic acid**

15

A mixture of 1'-(pyridin-2-yl)-1H,1'H-[4,4'-bipyrazol]-5-amine (300 mg, 1.33 mmol), TsOH (228 mg, 1.33 mmol) and dimethyl 2-ethyl-3-oxosuccinate (299 mg, 1.59 mmol) in butan-1-ol (10 mL) was heated at reflux for 2 h. The solid was collected by filtration to give the crude title compound (200 mg, 43% yield), which was used in the next step without purification.


20

Step 2

6-ethyl-5-(hydroxymethyl)-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

5

Broane (1 M in THF, 5.4 mL, 5.4 mmol) was added dropwise to a stirred suspension of 6-ethyl-7-oxo-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-5-carboxylic acid (105 mg, 0.3 mmol) in THF (10 mL). The resulting mixture was heated at reflux for 16 h and then quenched by addition of MeOH (1 mL). The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (8.2 mg, 9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.35 (br. s, 1 H), 9.11 (s, 1 H), 8.51 (d, *J* = 4.4 Hz, 1 H), 8.25-8.22 (m, 2 H), 8.04-7.97 (m, 2 H), 7.38 (t, *J* = 5.2 Hz, 1 H), 5.68 (br. s, 1 H), 4.59 (s, 2 H), 2.54 (q, *J* = 7.2 Hz, 2 H), 1.08 (t, *J* = 7.2 Hz, 3 H). LCMS (Method A): RT = 1.121 min, *m/z*: 337.1 [M+H⁺].


15 **Example 42:**

3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-6,7-dihydro-4H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8(5H)-one

20 The mixture of 4-[1-(2-pyridyl)pyrazol-4-yl]-1H-pyrazol-5-amine (50 mg, 0.221 mmol) and ethyl 2-oxocyclopentanecarboxylate (41 mg, 0.265 mmol) in acetic acid (2 mL) was heated at 120 °C for 2 h. The reaction mixture was then cooled to room temperature. The precipitate was collected by filtration, washed with EtOH, then EtOAc, and dried to give the title compound (38 mg, 54% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.14 (s, 1H), 9.12 (d, *J* = 1.0 Hz, 1H),

8.52 (ddd, $J = 4.9, 1.8, 0.9$ Hz, 1H), 8.31 – 8.19 (m, 2H), 8.09 – 7.90 (m, 2H), 7.44 – 7.32 (m, 1H), 3.10 – 2.95 (m, 2H), 2.72 (t, $J = 7.3$ Hz, 2H), 2.12 (p, $J = 7.7$ Hz, 2H). LCMS (ESI) (Method D): RT = 4.47 min, m/z 319.1 $[M+H^+]$.

5 Example 43:




6-chloro-5-methyl-3-[1-(2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidin-7-one

In a similar procedure as shown in Example 42, this compound was prepared in 66% yield. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.18 (s, 1H), 9.12 (d, $J = 0.9$ Hz, 1H), 8.52 (ddd, $J = 4.8, 1.8, 0.9$ Hz, 1H), 8.30 (s, 1H), 8.22 (d, $J = 0.8$ Hz, 1H), 8.08 – 7.94 (m, 2H), 7.43 – 7.33 (m, 1H), 2.56 (s, 3H). LCMS (Method A): RT = 4.38 min, m/z : 327 $[M+H^+]$.

Example 44:

Step 1




2-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine

3,3-dibromo-1,1,1-trifluoropropan-2-one (59.0 g, 0.22 mol) was added in portions to a stirred solution of sodium acetate (36.8 g, 0.44 mol) in water (100 mL). The resulting mixture was heated at 100 °C for 30 min and cooled to room temperature, then a solution of picolinaldehyde (20.0 g, 0.20 mol) in ammonium hydroxide (35%, 200 mL) and MeOH (600 mL) was added dropwise. Stirring at room temperature continued for 12 h and the mixture was concentrated. The solid was collected by filtration and washed with water to give the crude title compound (23.0 g, 55%) as

brown solid. It was used directly in next step without further purification. LCMS (Method C): RT = 0.605 min, m/z: 213.7 [M+H⁺].


Step 2



2-(pyridin-2-yl)-1H-imidazole-4-carbonitrile


A solution of 2-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridine (21.0 g, 100 mmol) in MeOH (800 mL) and NH₄OH (5%, 1000 mL) was heated to 60 °C for 10 h. The solvent was evaporated. The solid was collected, washed with water and dried to give the crude title compound (8.7 g, 51% yield) as brown solid. It was used directly for next step without further purification. LCMS (Method C): RT = 0.390 min, m/z: 170.7 [M+H⁺].

Step 3




2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbonitrile

A solution of 2-(pyridin-2-yl)-1H-imidazole-4-carbonitrile (6.8 g, 40 mmol) in DMF (50 mL) was added dropwise to a stirred and cooled (0 °C) suspension of NaH (60%, 3.2 g, 80 mmol) in DMF (50 mL). Stirring continued for 30 min, then SEMCl (10.0 g, 60 mmol) was added. The reaction mixture was stirred at room temperature for 5 h, and quenched by addition of saturated aqueous NH₄Cl (20 mL). The resultant solution was extracted with EtOAc (200 mL × 3). The combined organic layers were dried, and evaporated. The residue was purified by silica gel chromatography (PE/EtOAc = 5:1) to give the title compound (7.7 g, 64% yield) as a yellow oil. LCMS (Method C): RT = 0.958 min, m/z: 300.8 [M+H⁺].


Step 4**2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde**

5 DIBAL-H (1 M, 15.0 mL, 15.0 mmol) was added dropwise to a stirred and cooled (-78 °C) solution of 2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbonitrile (3.0 g, 10 mmol) in THF (50 mL). After addition, the mixture was stirred for 30 min at -45 °C and 1 h at 0 °C. EtOH (5 mL) was added and the mixture was stirred for 1 h at 0 °C. The solvent was evaporated and the residue was purified by silica gel chromatography (PE/EtOAc = 2:1) to give the
 10 title compound (1.7 g, 57% yield) as a yellow solid. LCMS (Method C): RT = 0.896 min, m/z: 303.8 [M+H⁺].

Step 5**2-(2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)acetonitrile**

tBuOK (1 M in THF, 22.0 mL, 22.0 mmol), followed by a solution of 2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (3.0 g, 10 mmol) in THF (5 mL) was added in portions to a stirred and cooled (-78 °C) solution of TosMIC (2.2 g, 11.0 mmol) in THF
 20 (20 mL). After addition, the reaction mixture was stirred for 45 min at -55 °C, quenched by addition of MeOH (50 mL) and then heated at reflux for 2.5 h. The solvent was evaporated and the residue was diluted with AcOH (10 mL). The mixture was extracted with EtOAc (80 mL × 3). The combined organic layers were dried and evaporated. The residue was purified by silica gel chromatography (PE/EtOAc = 2:1) to give the title compound (1.3 g, 42% yield) as a yellow oil.
 25 LCMS (Method A): RT = 0.725 min, m/z: 314.9 [M+H⁺].

Step 6




3-(dimethylamino)-2-(2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)acrylonitrile

5

2-(2-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl) acetonitrile (625 mg, 2.0 mmol) in DMF-DMA (5 mL) was heated at reflux for 12 h and then concentrated to give the crude title compound (738 mg, 100% yield). This crude was used directly in the next step. LCMS (Method C): RT = 0.706 min, m/z: 369.9 [M+H⁺].

10


Step 7



4-(2-(pyridin-2-yl)-1H-imidazol-5-yl)-1H-pyrazol-5-amine

15 Concentrated HCl (0.2 mL) was added slowly to a stirred solution of hydrazine monohydrate (0.2 mL) in EtOH (10 mL), followed by 3-(dimethylamino)-2-(2-(pyridin-2-yl)-1-((2-trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)acrylonitrile (369 mg, 1 mmol). The resultant solution was heated at reflux for 2 h. After cooling, the mixture was adjusted to pH = 9 by addition of 1 M aqueous K₂CO₃. The resulting mixture was then extracted with EtOAc (10 mL × 3). The
 20 combined organic layers were dried and evaporated to give the crude title compound (110 mg, 49% yield) as a yellow oil. This crude was used in next step without further purification. LCMS (Method C): RT = 0.200 min, m/z: 226.7 [M+H⁺].

Step 8



6-ethyl-5-methyl-3-(2-(pyridin-2-yl)-1H-imidazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one


5

A mixture of 4-(2-(pyridin-2-yl)-1H-imidazol-5-yl)-1H-pyrazol-5-amine (150 mg, 0.66 mmol) and ethyl 2-ethyl-3-oxobutanoate (209 mg, 1.32 mmol) in AcOH (10 mL) was heated at 160 °C for 1 h. The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (10.6 mg, 5% yield) as a white solid. ¹H NMR (400MHz, DMSO-*d*₆): δ12.99 (br. s., 1 H), 8.61-8.59 (m, 1 H), 8.21-8.17 (m, 2 H), 8.11 (s, 0.3 H), 7.93-7.89 (m, 1 H), 7.62 (s, 1 H), 7.39-7.35 (m, 1 H), 2.48-2.47 (m, 2 H), 2.46 (s, 3 H), 1.03 (t, *J* = 7.2 Hz, 2 H). LCMS (Method A): RT = 0.932 min, *m/z*: 321.0 [M+H⁺].

10

Example 45:

Step 1




2-(4-(pyridin-3-yl)-1H-imidazol-1-yl)acetonitrile


A solution of 3-(1H-imidazol-4-yl)pyridine (8.0 g, 55.0 mmol) in tetrahydrofuran (100 mL) was added to a stirred and cooled (0 °C) suspension of NaH (60% dispersion in mineral oil, 3.0 g, 75.0 mmol) in THF (50 mL). Stirring continued for 30 min, and 2-bromoacetonitrile (6.5 g, 55.0 mmol) was added. After addition, the reaction mixture was stirred for 1 h at room temperature and then concentrated by evaporation. The residue was purified by silica gel chromatography (DCM/MeOH = 10:1) to give the title compound (7.5 g, 80% yield).

20


25

Step 2**3-(dimethylamino)-2-(4-(pyridin-3-yl)-1H-imidazol-1-yl)acrylonitrile**


- 5 A mixture of 2-(4-(pyridin-3-yl)-1H-imidazol-1-yl)acetonitrile (6.0 g, 35.2 mmol) in DMF-DMA (15 mL) was heated at 140 °C for 30 min under microwave irradiation and concentrated to give the crude title compound (6.0 g, 71% yield), which was used directly in the next step.

Step 3**4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine**


- 10 Concentrated HCl (20 mL) was added slowly to a stirred solution of hydrazine monohydrate (2.0 mL) in EtOH (100 mL), followed by 3-(dimethylamino)-2-(4-(pyridin-3-yl)-1H-imidazol-1-yl)acrylonitrile (6.0 g, 25.1 mmol). The resultant solution was heated at reflux for 2 h. After
15 cooling, the mixture was adjusted to pH = 9 by addition of 1 M aqueous K₂CO₃. The resulting mixture was then extracted with EtOAc (100 mL × 3). The combined organic layers were dried and concentrated by evaporation. The residue was purified by flash chromatography (DCM/MeOH = 5:1) to give the title compound (4.8 g, 85% yield) as a yellow oil.

Step 4**6-ethyl-5-methyl-3-(4-(pyridin-3-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

- 5 A mixture of 4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine (4.8 g, 28.5 mmol) and ethyl 2-ethyl-3-oxobutanoate (5.9 g, 34 mmol) in AcOH (100 mL) was heated at reflux for 2 h. The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (623 mg, 9.2% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.04-9.03 (m, 1 H), 8.43-8.41 (m, 1 H), 8.17-8.13 (m, 3 H), 8.01 (s, 1 H), 7.42-7.39 (m, 1 H), 2.50-2.48 (m, 2 H), 2.29 (s, 3 H), 1.02 (t, *J* = 7.2 Hz, 6 H). LCMS (Method A): RT = 0.933 min, *m/z*: 320.9 [M+H⁺].
- 10


Example 46:**Step1****4-(phenylsulfonyl)-5-(pyridin-2-yl)-4,5-dihydrooxazole**

- 15 KCN (2.7 g, 41.5 mmol) was added portionwise to a stirred solution of picolinaldehyde (10.0 g, 93.5 mmol) and 1-((isocyanomethyl)sulfonyl)-4-methylbenzene (18.0 g, 92.3 mmol) in ethanol (100 mL). The resulting mixture was stirred for 2 h at room temperature and then filtered. The solid was collected to give the crude title compound (20.0 g, 72% yield).
- 20

Step 2**2-(1H-imidazol-4-yl)pyridine**

A solution of 4-(phenylsulfonyl)-5-(pyridin-2-yl)-4,5-dihydrooxazole (20.0 g, 65.8 mmol) and ammonia (70 mL, 7 N in methanol) was heated at 100 °C for 20 h. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH = 10:1) to give the title compound (7.5 g, 79% yield) as a white solid.


Step 3



2-(4-(pyridin-2-yl)-1H-imidazol-1-yl)acetonitrile


A solution of 2-(1H-imidazol-4-yl)pyridine (7.5 g, 51.7 mmol) in tetrahydrofuran (80 mL) was added to a stirred and cooled (0 °C) suspension of NaH (60%, 2.5 g, 62.5 mmol) in THF (20 mL). Stirring continued for 30 min, and 2-bromoacetonitrile (6.2 g, 51.7 mmol) was added. After addition, the reaction mixture was stirred for 1 h at room temperature and then evaporated to dryness. The residue was purified by silica gel chromatography (DCM/MeOH = 10:1) to give the title compound (10.0 g, 105% yield) as a yellow oil.

Step 4




3-(dimethylamino)-2-(4-(pyridin-2-yl)-1H-imidazol-1-yl)acrylonitrile


A mixture of 2-(4-(pyridin-2-yl)-1H-imidazol-1-yl)acetonitrile (10.0 g, 54.3 mmol) in DMF-DMA (15 mL) was heated at 140 °C for 30 min under microwave conditions. The solvent was evaporated to give the crude title compound (11.0 g, 100%). It was used in the next step directly. LCMS (Method C): RT = 1.85 min, m/z: 240.1 [M+H⁺].

Step 5**4-(4-(pyridin-2-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine**

- 5 Concentrated HCl (15 mL) was added slowly to a stirred solution of hydrazine monohydrate (6.0 mL) in EtOH (100 mL), followed by 3-(dimethylamino)-2-(4-(pyridin-2-yl)-1H-imidazol-1-yl)acrylonitrile (11.0 g, 46.0 mmol). The resultant solution was heated at reflux for 2 h. After cooling, the mixture was adjusted to pH = 9 by addition of 1 M aqueous K₂CO₃. The resulting mixture was then extracted with EtOAc (200 mL × 3). The combined organic layers were dried and evaporated. The residue was purified by flash chromatography (DCM/MeOH = 10:1) to give the title compound (7.0 g, 67% yield) as a yellow oil. LCMS (Method C): RT = 0.479 min, m/z: 226.8 [M+H⁺].

Step 6**6-isopropyl-5-methyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**


- 15 A mixture of 4-(4-(pyridin-2-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine (600 mg, 2.6 mmol) and ethyl 2-acetyl-3-methylbutanoate (600 mg, 3.5 mmol) in AcOH (6 mL) was heated at reflux for 2 h. The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (100 mg, 11% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.04 (br. s., 1 H), 8.50 (d, *J* = 4.8 Hz, 1 H), 8.10 (s, 1 H), 7.94-7.81 (m, 4 H), 7.22 (s, 1 H), 3.04-2.97 (m, 1 H), 2.33 (s, 3 H), 1.28 (d, *J* = 6.8 Hz, 6 H). LCMS (Method C): RT = 0.657 min, m/z: 335.0 [M+H⁺].

Example 47:**6-ethyl-5-phenyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

5


In a similar procedure as shown in Example 46, the title compound was prepared in 7.5% yield from ethyl 2-benzoylbutanoate. ^1H NMR (400 MHz, DMSO- d_6): δ 12.66 (br. s., 1 H), 8.05 (d, J = 4.0 Hz, 1 H), 8.22 (s, 1 H), 7.94-7.82 (m, 3 H), 7.82-7.78 (m, 1 H), 7.55-7.50 (m, 5 H), 7.22-7.19 (m, 1 H), 2.31 (q, J = 6.8 Hz, 2 H), 1.00 (t, J = 7.2 Hz, 3 H). LCMS (Method C): RT = 0.710 min, m/z: 382.9 $[\text{M}+\text{H}^+]$.

10


Example 48:**6-Ethyl-5-methyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

15


In a similar procedure as shown in Example 46, the title compound was prepared in 16% yield from ethyl 2-ethyl-3-oxobutanoate. ^1H NMR (300 MHz, CD_3OD): δ 8.54-8.52 (m, 1H), 8.35 (d, J = 7.8 Hz, 1H), 8.11 (s, 1H), 8.06 (s, 2H), 8.00-7.98 (m, 1H), 7.92-7.89 (m, 1H), 7.33-7.29 (m, 1H), 6.18 (d, J = 7.8 Hz, 1H). MS m/z: 279 $[\text{M}+\text{H}^+]$.

Example 49:**5-Methyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**


In a similar procedure as shown in Example 46, the title compound was prepared in 46% yield from ethyl 3-oxobutanoate. ¹H NMR (300 MHz, CD₃OD): δ 8.59-8.57 (d, *J* = 5.1 Hz, 1H), 8.23 (s, 1H), 8.11 (s, 1H), 8.04-8.02 (m, 2H), 7.96-7.94 (m, 1H), 7.39-7.37 (m, 1H), 5.91 (s, 1H), 2.44 (s, 3H). MS *m/z*: 293 [M+H⁺].

Example 50**Step 1****(Z)-3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile**


A mixture of 2-(4-pyridyl)acetonitrile (1.0 g, 8.46 mmol) in DMF-DMA (11.3 mL) and DMF was heated at 125 °C for 18 h. The reaction mixture was diluted with ice-water, extracted with EtOAc (6x). The combined organics were dried (Na₂SO₄), filtered and concentrated. The crude product was purified by silica flash chromatography (0-5% MeOH/DCM) to give the title compound (1.236 g, 84.3% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.38 – 8.27 (m, 2H), 7.80 (s, 1H), 7.32 – 7.22 (m, 2H), 3.26 (s, 6H). LCMS (ESI) *m/z* 174 [M+H⁺].

Step 2**4-(4-pyridyl)-1H-pyrazol-5-amine**


To a solution of (Z)-3-(dimethylamino)-2-(4-pyridyl)prop-2-enitrile (1.235 g, 7.130 mmol) in EtOH (30 mL) was added hydrazine hydrate (80 mass% in water) (2.856 g, 71.30 mmol), followed by concentrated HCl solution until pH reached 3.0 (about 3.5 mL). The mixture was heated at 90 °C for 30 min. The reaction mixture was cooled to room temperature, neutralized with 1 M Na₂CO₃, extracted with EtOAc (3x). The combined organics were dried (Na₂SO₄), filtered and concentrated to give the title compound (1.0 g, 87.6% yield) as a yellow solid which was used in the next step without purification. LCMS (ESI) m/z 161 [M+H⁺].

Step 3**6-methyl-5-phenyl-3-(4-pyridyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one**


A mixture of 4-(4-pyridyl)-1H-pyrazol-5-amine (100 mg, 0.624 mmol), ethyl 2-methyl-3-oxo-3-phenyl-propanoate (193 mg, 0.936 mmol) and H₂SO₄ (191 mg, 1.87 mmol) in EtOH (2 mL) was heated at 80 °C for 24 h. The mixture was cooled to room temperature. A precipitate formed and was collected by filtration. The filter cake was washed with ether, dried under vacuum to give the title compound (112 mg, 59.4% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.50 (s, 1H), 8.40 (d, J = 6.35 Hz, 2H), 8.20 (s, 2H), 7.62 – 7.54 (m, 2H), 7.53 – 7.39 (m, 3H), 6.54 (s, 1H), 1.99 (s, 3H). LCMS (ESI) m/z 303 [M+H⁺].

Example 51:**Step 1****Ethyl 2-ethyl-3-oxopentanoate**

- 5 A solution of ethyl 3-oxopentanoate (2.0 g, 14 mmol) in THF (20 mL) was cooled to 0 °C before addition of sodium hydride (60% dispersion in mineral oil, 0.64g, 16.0mmol). The resulting mixture was stirred at room temperature for 0.5 h before slow addition of bromoethane (1.7 g, 16 mmol). The mixture was stirred at room temperature for 1 h before being diluted with water (100 mL). The reaction mixture was extracted with ethyl acetate (100 mL) and the combined organics
- 10 layer was dried over Na₂SO₄, filtered, and concentrated to afford crude ethyl 2-ethyl-3-oxopentanoate (1.2 g) as yellow oil.


Step 2**5,6-Diethyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

- 15 In a similar procedure as shown in Example 46, the title compound was prepared in 4% yield from ethyl 2-ethyl-3-oxopentanoate. ¹H NMR (300 MHz, CD₃OD): δ 8.50 (d, *J* = 3.9 Hz, 1H), 8.09 (s, 1H), 7.95-7.83 (m, 4H), 7.30 (s, 1H), 4.92 (s, 1H), 3.32-2.61 (m, 4H), 1.18 (t, *J* = 7.2 Hz, 3H), 1.28 (t, *J* = 7.5 Hz, 1H). MS *m/z*: 335 [M+H⁺].

Example 52:


6-Methyl-5-phenyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

- 5 In a similar procedure as shown in Example 46, the title compound was prepared in 6% yield from ethyl 2-methyl-3-oxo-3-phenylpropanoate. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.52 (s, 1H), 8.25 (s, 1H), 7.82-7.99 (m, 4H), 7.55 (s, 5H), 7.23 (s, 1H), 1.94 (s, 3H). MS *m/z*: 369 [M+H⁺].


Example 53:**Step 1**

5-(Thiazol-4-yl)-4-tosyl-4,5-dihydrooxazole


- 10 To a solution of thiazole-4-carbaldehyde (3.2 g, 28.0 mmol) and 1-(isocyanomethylsulfonyl)-4-methylbenzene (5.0 g, 25.6 mmol) in ethanol (75 mL), was added finely powdered potassium cyanide (0.17 g, 2.6 mmol). The resulting mixture was stirred at room temperature for 2 h before
- 15 the solids were collected by filtration. The solids were washed with ether (100 mL) and dried to afford 5-(thiazol-4-yl)-4-tosyl-4,5-dihydrooxazole as a yellow solid (5.5 g, 65% yield).

Step 2**4-(1H-Imidazol-5-yl)thiazole**


To a pressure tube was added 5-(thiazol-4-yl)-4-tosyl-4,5-dihydrooxazole (5.0 g, 16 mmol), aqueous ammonia (150 mL), and methanol (150 mmol). The resulting mixture was stirred at 120 °C for 20 h. After cooling to room temperature the mixture was concentrated and the residue was purified on silica gel (dichloromethane : methanol = 10:1) to afford 4-(1H-imidazol-5-yl)thiazole as a solid (2.0 g, 86% yield). MS m/z: 152 [M+H⁺].

Step 3**2-(4-(Thiazol-4-yl)-1H-imidazol-1-yl)acetonitrile**

To a solution of 4-(1H-imidazol-5-yl)thiazole (1.5 g, 10.3 mmol) dissolved in THF (150 mL) was added sodium hydride (250 mg, 10.3 mmol) at 0 °C. The mixture was stirred for 30 min before dropwise addition of 2-bromoacetonitrile (1.24 g, 10.3 mmol). The resulting mixture was stirred at room temperature for 3 h before being diluted with water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude residue was purified on silica gel (dichloromethane : methanol = 10:1) to afford 2-(4-(thiazol-4-yl)-1H-imidazol-1-yl)acetonitrile (1.0 g, 53% yield) as yellow solid. MS m/z: 191 [M+H⁺].

Step 4**(E)-3-(Dimethylamino)-2-(4-(thiazol-4-yl)-1H-imidazol-1-yl)acrylonitrile**


A solution of 2-(4-(thiazol-4-yl)-1H-imidazol-1-yl)acetonitrile (200 mg, 1.1 mmol) and
5 dimethylformamide dimethylacetal (260 mg, 2.2 mmol) in acetonitrile (10 mL) was heated to reflux for 2 h. The solvent was evaporated *in vacuo* and ethyl acetate was added to the mixture. The solids were collected via filtration to afford (*E*)-3-(dimethylamino)-2-(4-(thiazol-4-yl)-1H-imidazol-1-yl)acrylonitrile as a yellow solid (110 mg, 65% yield). MS *m/z*: 246 [*M*+*H*⁺].

Step 5**4-(4-(Thiazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine**

To a solution of (*E*)-3-(dimethylamino)-2-(4-(thiazol-4-yl)-1H-imidazol-1-yl)acrylonitrile (100
mg, 0.41 mmol) and hydrazine hydrate (0.2 mL, 1 mmol) in ethanol (10 mL) at 0 °C was added
aqueous hydrochloric acid until the pH = 1-2. The reaction mixture was then heated to reflux for
15 2 h before cooling to room temperature and diluting with water. The mixture was extracted with ethyl acetate and the combined organics layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude residue was then purified on silica gel (dichloromethane :

methanol = 10:1) to afford 4-(4-(thiazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine as off-white solid (60 mg, 58% yield). MS m/z: 233 [M+H⁺].


Step 6



5 6-Ethyl-5-methyl-3-(4-(thiazol-4-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one


A mixture of 4-(4-(thiazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazol-5-amine (60 mg, 0.26 mmol) and ethyl 2-ethyl-3-oxobutanoate (61 mg, 0.38 mmol) in acetic acid (10 mL) was stirred at 150 °C for 2 h under microwave heating. The solution was then cooled to room temperature and concentrated. The crude residue was dissolved in water and extracted with ethyl acetate. The combined organics layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude residue was purified on silica gel (dichloromethane : methanol = 10:1) to afford desired product as an off-white solid (30 mg, 30% yield). ¹H NMR (300 MHz, CD₃OD): δ 9.05 (s, 1H), 8.10 (s, 1H), 7.94 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 2.63 (q, *J* = 7.2 Hz, 2H), 2.41 (s, 3H), 1.15 (t, *J* = 7.2 Hz, 3H). MS m/z: 327 [M+H⁺].

Example 54:




6-ethyl-5-methyl-3-(4-(pyrimidin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

This compound was prepared following a similar procedure as that shown in Example 53. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.82-8.80 (m, 3H), 8.19-8.15 (m, 2H), 7.46 (s, 1H), 2.52-2.50 (q, *J* = 7.5 Hz, 2H), 2.36 (s, 3H), 1.04-0.99 (t, *J* = 7.5 Hz, 3H). MS *m/z*: 322 [M+H⁺].


Example 55:**5 Step 1****methyl 1-(cyanomethyl)-1H-imidazole-4-carboxylate**

To a solution of methyl 1*H*-imidazole-4-carboxylate (3.78 g, 30 mmol) in anhydrous THF (60 mL) was added sodium hydride (0.72 g, 30 mmol). The solution was then stirred at room temperature for 1 h before addition of 2-bromoacetonitrile (4.2 g, 35 mmol). The reaction was stirred at room temperature for 2 h before being concentrated *in vacuo*. The crude residue was purified on silica gel (petroleum ether : ethyl acetate = 3:1) to afford the desired product (2.48 g, 50% yield). MS *m/z*: 166 [M+H⁺].

Step 2**(E)-Methyl 1-(1-cyano-2-(dimethylamino)vinyl)-1H-imidazole-4-carboxylate**

To a solution of methyl 1-(cyanomethyl)-1*H*-imidazole-4-carboxylate (2.48 g, 15 mmol) in anhydrous DMF (30 mL) was added dimethoxy-*N,N*-dimethylmethanamine (7.2 g, 60 mmol). The solution was then heated to 100 °C and stirred for 3 h. The reaction mixture was then cooled to room temperature and concentrated to afford the crude desired product (3.3 g, 100% yield).


5 Step 3



Methyl 1-(5-amino-1*H*-pyrazol-4-yl)-1*H*-imidazole-4-carboxylate

To a solution of (*E*)-methyl 1-(1-cyano-2-(dimethylamino)vinyl)-1*H*-imidazole-4-carboxylate (3.3 g, 15 mmol) in ethanol (50 mL) was added hydrazine monohydrate (10 mL). The reaction was then stirred at reflux for 2 h before concentration to dryness. The crude residue was purified on silica gel (dichloromethane : methanol = 20:1) to afford the desired product (1.86 g, 60% yield). MS *m/z*: 208 [*M*+*H*⁺].


Step 4



15 **Methyl 1-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1*H*-imidazole-4-carboxylate**

To a solution of methyl 1-(5-amino-1*H*-pyrazol-4-yl)-1*H*-imidazole-4-carboxylate (1.86 g, 9 mmol) in acetic acid (20 mL) was added ethyl 2-ethyl-3-oxobutanoate (2.37 g, 15 mmol). The reaction was then heated to reflux and stirred for 4 h. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The crude residue was purified on silica gel (dichloromethane : methanol = 15:1) to afford the desired product (1.35 g, 50% yield). MS *m/z*: 302 [M+H⁺].

Step 5




1-(6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1*H*-imidazole-4-carboxamide

A solution of methyl 1-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-*a*]pyrimidin-3-yl)-1*H*-imidazole-4-carboxylate (301 mg, 1 mmol) dissolved in methanolic ammonia (7 M, 20 mL) was stirred at 150 °C for 12 h. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The crude residue was purified on silica gel (dichloromethane : methanol = 10:1) to give the desired product (143 mg, 50% yield). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.20 (s, 1H), 8.10 (s, 1H), 7.90 (s, 1H), 7.84 (s, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 2.48 (q, *J* = 7.2 Hz, 2H), 2.32 (s, 3H), 1.02 (t, *J* = 7.2 Hz, 3 H). MS *m/z*: 287 [M+H⁺].

Example 56


Step 1



Ethyl 5-amino-1*H*-pyrazole-4-carboxylate

To a mixture of 2-cyano-3-ethoxy-acrylic acid ethyl ester (10 g, 59 mmol) in ethanol (100 mL) was added hydrazine hydrate (3.6 g, 71 mmol). The mixture was stirred at reflux for 3 h before being concentrated *in vacuo* to afford the crude product. This material was used in subsequent reactions without further purification. MS m/z: 156 [M+H⁺].


5 Step 2



Ethyl 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate


To a mixture of ethyl 5-amino-1H-pyrazole-4-carboxylate (100 mg, 0.65 mmol) in acetic acid (5 mL) was added 2-ethyl-3-oxo-butyric acid ethyl ester (102 mg, 0.65 mmol). The mixture was stirred at reflux for 12 h under nitrogen before cooling to room temperature. The solvent was removed *in vacuo* to afford a crude residue. The crude product was purified on silica gel (petroleum ether : ethyl acetate = 8:5) to afford the desired product (110 mg, 70% yield). MS m/z: 250 [M+H⁺].

Step 3




6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbohydrazide

To a mixture of 6-ethyl-5-methyl-7-oxo-4,7-dihydro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (100 mg, 0.4 mmol) in ethanol (10 mL) was added hydrazine hydrate (401 mg, 20 mmol). The mixture was stirred at reflux for 12 h before cooling the reaction to room temperature and concentrating. The crude residue was purified by HPLC to afford 6-ethyl-5-the desired product (30 mg, 32% yield). MS m/z: 236 [M+H⁺].

Step 4

Ethyl 2-(2-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonyl)hydrazinyl)-2-oxoacetate

- 5 To a mixture of 6-ethyl-5-methyl-7-oxo-4,7-dihydro-pyrazolo[1,5-a]pyrimidine-3-carbohydrazide (500 mg, 2.13 mmol) in dichloromethane : DMF (10 mL : 10 mL) was added triethylamine (430 mg, 4.26 mmol). Then chloro-oxo-acetic acid ethyl ester (579 mg, 4.26 mmol) was added and the mixture was stirred at room temperature for 4 h. The solvent was evaporated and the crude residue was purified on silica gel (dichloromethane: methanol = 15:1) to afford the desired product (700 mg, 82% yield) as a white solid. MS m/z: 336 [M+H⁺].
- 10


Step 5

Ethyl 5-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1,3,4-oxadiazole-2-carboxylate

- 15 To a solution of 2-(2-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonyl)hydrazinyl)-2-oxoacetate (100 mg, 0.3 mmol) in dichloromethane : DMF (5 mL : 5 mL) was added 4-methylbenzene-1-sulfonyl chloride (171 mg, 0.9 mmol) and triethylamine (91 mg, 0.9 mmol). The mixture was stirred at room temperature for 5 h before the solution was

concentrated. The crude residue was purified on silica gel (dichloromethane : methanol = 25:1) to afford the desired product (50 mg, 52% yield) as a white solid. MS m/z : 318 $[M+H]^+$.

Step 6




5 5-(6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1,3,4-oxadiazole-2-carboxamide

Ethyl 5-(6-ethyl-5-methyl-7-oxo-4,7-dihydro-pyrazolo[1,5-a]pyrimidin-3-yl)-1,3,4-oxadiazole-2-carboxylate (50 mg, 0.16 mmol) was dissolved in ammonium hydroxide (7 mL). The mixture was stirred at room temperature for 12 h before being concentrated. The crude residue was purified *via*
 10 HPLC to afford the desired product (15 mg, 33% yield) as a white solid. ^1H NMR (300 MHz, DMSO- d_6): δ 12.03 (s, 1H), 8.63 (s, 1H), 8.40 (s, 1H), 8.29 (s, 1H), 4.05 (s, 1H), 2.53 (t, J = 7.8 Hz, 2H), 2.44 (s, 3H), 1.05 (t, J = 7.2 Hz, 3H). MS m/z : 289 $[M+H]^+$.

Example 57

Step 1




15

6-ethyl-5-methyl-7-oxo-N'-picolinoyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbohydrazide

To a mixture of pyridine-2-carboxylic acid (170 mg, 1.4 mmol) in DMF (10 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (480 mg, 2.5 mmol) and N-

hydroxybenzotriazole (420 mg, 2.5 mmol). The mixture was stirred at room temperature for 1 h before addition of 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbohydrazide (300 mg, 1.3 mmol). The mixture was stirred at 40 °C for 12 h before being concentrated. The crude residue was purified *via* prep-TLC to give the desired product (85 mg, 18% yield). MS *m/z*: 341 [M+H⁺].

Step 2




6-Ethyl-5-methyl-3-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

To a solution of 6-ethyl-5-methyl-7-oxo-N'-picolinoyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbohydrazide (78 mg, 0.23 mmol) in dichloromethane : DMF (5 mL : 5 mL) was added 4-methylbenzene-1-sulfonyl chloride (130 mg, 0.69 mmol) and triethylamine (70 mg, 0.69 mmol). The mixture was stirred at room temperature for 5 h before being concentrated. The crude residue was purified by HPLC to afford the desired product (5 mg, 6% yield). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.81 (d, *J* = 5.6 Hz, 1H), 8.39 (s, 1H), 8.24 (d, *J* = 7.9 Hz, 1H), 8.08 (t, *J* = 9.0 Hz, 1H), 7.64 (dd, *J* = 7.4, 4.8 Hz, 1H), 2.55 (t, *J* = 7.5 Hz, 2H), 2.48 (s, 3H), 1.06 (t, *J* = 7.3 Hz, 3H). MS *m/z*: 323 [M+H⁺].

Example 58


Step 1



6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile

A mixture of 5-amino-1H-pyrazole-4-carbonitrile (4.0 g, 37 mmol) and ethyl 2-ethyl-3-oxobutanoate (5.8 g, 27 mmol) in acetic acid (40 mL) was stirred at 120 °C for 3 h. The mixture was concentrated, dissolved in water, and then 1N sodium hydroxide was added to the solution until a precipitate formed. The precipitate was collected *via* filtration and dried to afford the
5 desired product (5.0 g, 67% yield). MS m/z: 203 [M+H⁺].


Step 2



Ethyl 5-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1,2,4-oxadiazole-3-carboxylate

10 To a mixture of 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo [1,5-a]pyrimidine-3-carbonitrile (0.5 g, 2.47 mmol) and (Z)-ethyl 2-chloro-2-(hydroxyimino)acetate (0.37g, 2.47 mmol) in acetone (50 mL) was added triethylamine (0.5 g, 4.94 mmol). The mixture was stirred at 60 °C for 16 h, and then concentrated. The crude product was purified on silica gel (dichloromethane : methanol = 3:1) to afford the desired product (230 mg, 30% yield) as a white solid. MS m/z: 318 [M+H⁺].

15 Step 3




5-(6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1,2,4-oxadiazole-3-carboxamide

A mixture of 5-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-1,2,4-oxadiazole-3-carboxylate (60 mg, 0.19 mmol) in ammonium hydroxide (5 mL) was stirred at 40
20

°C for 48 h before the mixture was concentrated. The crude residue was purified on silica gel (dichloromethane : methanol = 3:1) to afford the desired product (8 mg, 14% yield) as a white solid. ¹H NMR (300 MHz, CD₃OD) δ 8.21 (s, 1H), 2.73~2.66 (m, 2H), 2.27 (s, 3H), 1.15 (t, *J* = 7.5 Hz, 3H). MS *m/z*: 289 [M+H⁺].

5 Example 59


Step 1



(Z)-N'-hydroxypicolinimidamide


To a solution of ammonium hydroxide (840 mg, 12 mmol) in methanol (50 mL) was added
10 sodium bicarbonate (1.1 g, 13 mmol) and pyridine-2-carbonitrile (1 g, 9.6 mmol). The mixture
heated to 60 °C for 2 h. The solvent was then evaporated and the crude residue was washed with
water to afford the desired product (1g, 77 % yield). MS *m/z*: 138 [M+H⁺].

Step 2




(Z)-N-hydroxypicolinimidoyl chloride

(Z)-N'-hydroxypicolinimidine (170 mg, 1.24 mmol) was dissolved in a mixture of concentrated
HCl (1 mL) and water (5 mL) at 0 °C. To this solution was added sodium nitrite (85 mg, 1.24
mmol) dissolved in water (2 mL) and the mixture was stirred at 0 °C for 1 h. The pH of the
20 reaction was adjusted with a saturated solution of sodium hydrogen carbonate until pH= 3 was
reached. The precipitate was filtered and washed with ice-cold water to afford the desired product
(120 mg, 62% yield). MS *m/z*: 157 [M+H⁺].

Step 3

6-Ethyl-5-methyl-3-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

5 To a mixture of 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile (26 mg, 0.13 mmol) and (*Z*)-*N*-hydroxypicolinimidoyl chloride (20 mg, 0.13 mmol) in acetone (5 mL) was added triethylamine (2 mL). The mixture was heated to 70 °C and stirred for 2 h. The reaction was cooled to room temperature before concentration to dryness. The crude residue was purified *via* HPLC to afford the desired product (5 mg, 12% yield). ¹H NMR (300 MHz, CD₃OD):
 10 δ 8.48 (d, *J* = 4.5 Hz, 1H), 8.23 (d, *J* = 8.1 Hz, 1H), 8.17 (s, 1H), 7.96 (t, *J* = 8.6 Hz, 1H), 7.48 (dd, *J* = 7.1, 4.5 Hz, 1H), 2.73 (q, *J* = 7.4 Hz, 2H), 2.26 (s, 3H), 1.19 (t, *J* = 7.4 Hz, 3H). MS *m/z*: 323 [M+H⁺].


Example 60**Step 1**

6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbaldehyde

15 To a round bottomed flask was added 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile (3.7 g, 18.3 mmol), water (8 mL), and formic acid (8 mL). This mixture was placed under an inert atmosphere before addition of Raney nickel (1.074 g, 18.3 mmol).
 20 The reaction was heated to 70 °C overnight before additional Raney nickel (1.074 g, 18.3 mmol) was added. The solution was heated to 70 °C for an additional 4 h before cooling to room temperature and filtering off the solids. The solids were washed with water and the filtrate was extracted with DCM. The combined organics layer was dried over Na₂SO₄, filtered, and

concentrated. The crude residue was purified on silica gel (ethyl acetate : methanol) to afford the desired product (1.125 g, 30% yield) as a yellow solid. MS m/z: 206 [M+H⁺].


Step 2



(E)-6-Ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbaldehyde oxime

To a vial was added 6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbaldehyde (400 mg, 1.95 mmol), hydroxylamine hydrochloride (271 mg, 3.90 mmol), and ethanol. To this solution was added 1 drop of concentrated HCl and the reaction was stirred overnight at room temperature. The precipitate was collected via filtration to afford the desired product (400 mg, 93% yield). MS m/z: 221 [M+H⁺].


Step 3



(Z)-6-Ethyl-N-hydroxy-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbimidoyl chloride

To a vial was added (E)-6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbaldehyde oxime (140 mg, 0.63 mmol), dichloroethane, and N-chloro succinimide (102 mg, 0.76 mmol). The mixture was stirred at room temperature for 6 h before heating to 60 °C for 2 h. The solution was then cooled to room temperature and DMF was added. The reaction was stirred overnight at room temperature before diluting the reaction with water and extracting with DCM. The combined organics layer was dried over Na₂SO₄, filtered, and concentrated to crude product. This material was used in the subsequent reaction without further purification. MS m/z: 255 [M+H⁺].

Step 4

**6-Ethyl-5-methyl-3-(5-(pyridin-2-yl)isoxazol-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one**

To a round bottomed flask was added (Z)-6-ethyl-N-hydroxy-5-methyl-7-oxo-4,7-

5 dihydropyrazolo[1,5-a]pyrimidine-3-carbimidoyl chloride (162 mg, 0.64 mmol), ethyl acetate (20 mL), K₂CO₃ (176 mg, 1.27 mmol), and ethynylpyridine (193 μ L, 1.91 mmol). The reaction was fitted with a reflux condenser and heated to reflux overnight. The reaction was cooled to room temperature and filtered. The solid was collected and purified *via* HPLC to afford the desired product (8 mg, 4% yield). ¹H NMR (400MHz, DMSO-*d*₆): δ 8.80 - 8.73 (m, 1 H), 8.36 (s, 1 H), 8.07 - 7.96 (m, 2 H), 7.69 (s, 1 H), 7.54 (ddd, *J* = 1.4, 4.8, 7.3 Hz, 1 H), 2.56 - 2.51 (m, 2 H), 2.46 (s, 3 H), 1.05 (t, *J* = 7.3 Hz, 3 H). MS *m/z*: 322 [M+H⁺].

LCMS Method A

Experiments performed on an Agilent 1200 HPLC (with a PDA detector and a ELSD detector) with Agilent 6100 MSD mass spectrometer using ESI as ionization source using an Xtimate TM-C18 30*2.1mm column and a 0.8ml/minute flow rate. Acquire Time: 2 min, Wavelength: UV220, Oven Temp.: 50 °C. The solvent system was a gradient starting with 100% water containing 0.038%TFA (solvent A) and acetonitrile containing 0.02%TFA (solvent B), followed by a gradient up to 40% solvent A and 60% solvent B over the next 0.9 minutes . This was maintained for 0.6minutes before returning to 100% solvent A and solvent B over the next 0.5 minute. Total run time was 2 min.

LCMS Method B

Experiments performed on an SHIMADZU 20A HPLC (with a PDA detector) with SHIMADZU 2010EV MSD mass spectrometer using ESI as ionization source using an Xtimate TM-C18 30*2.1mm column and a 1.2ml/minute flow rate. The solvent system was a gradient starting with 90% water containing 0.038%TFA (solvent A) and 10% acetonitrile containing 0.02%TFA (solvent B), followed by a gradient up to 20% solvent A and 80% solvent B over the next 0.9 minutes . This was maintained for 0.6minutes before returning to 90% solvent A and 10% solvent B over the next 0.5 minute. Total run time was 2 min.


LCMS Method C





Experiments performed on an SHIMADZU 20A HPLC (with a PDA detector) with SHIMADZU 2010EV MSD mass spectrometer using ESI as ionization source using an Merk RP-18e 2*25mm column and a 1.5ml/minute flow rate. The solvent system was a gradient starting with 95% water containing 0.038%TFA (solvent A) and 5% acetonitrile containing 0.02%TFA (solvent B), followed by a gradient up to 5% solvent A and 95% solvent B over the next 0.7 minutes . This was maintained for 0.4minutes before returning to 95% solvent A and 5% solvent B over the next 0.4 minute. Total run time was 1.5 min.

LCMS Method D

Experiments performed on a Agilent 6140 quadrupole LC/MS system linked to a HPLC Agilent 1200 system with a UV detector monitoring at 254 nm, and mass spectrometry scanning 90-1300 amu in ESI+ ionization mode. This system uses an Agilent SB C18 (1.8um 30 x 2.1mm) column, maintained at 25 °C and a 0.4 ml / minute flow rate. The initial solvent system was 95% water containing 0.05% TFA (solvent A) and 5% acetonitrile containing 0.05% TFA (solvent B) for the first 0.3 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 6.5 minutes. This was maintained for 1.5 minute before returning to 95% solvent A and 5% solvent B over the next 0.1minutes. Total run time was 10 minutes.


Table 1



Example	Structure	Name	Synth. Method	LCMS (ESI) <i>m/z</i>	NMR
61		5,6-dimethyl-3-[1-(2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidin-7-one	B	307	¹ H NMR (400 MHz, DMSO) δ 11.49 (s, 1H), 9.18 – 9.06 (d, <i>J</i> = 1.1 Hz, 1H), 8.60 – 8.47 (ddd, <i>J</i> = 4.6, 1.8, 0.9 Hz, 1H), 8.27 – 8.12 (m, 2H), 8.08 – 7.92 (m, 2H), 7.44 – 7.33 (m, 1H), 2.42 (s, 3H), 2.01 (s, 3H)

62		6-fluoro-5-methyl-3-[1-(2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidin-7-one	B	311	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.83 (s, 1H), 9.11 (d, <i>J</i> = 0.9 Hz, 1H), 8.52 (ddd, <i>J</i> = 4.8, 1.8, 0.9 Hz, 1H), 8.30 (s, 1H), 8.23 (d, <i>J</i> = 1.0 Hz, 1H), 8.07 – 7.95 (m, 2H), 7.43 – 7.33 (m, 1H), 2.45 (d, <i>J</i> = 3.4 Hz, 3H)
63		5,6-diethyl-3-[1-(2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidin-7-one	B	335	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.39 (s, 1H), 9.09 (d, <i>J</i> = 1.0 Hz, 1H), 8.52 (ddd, <i>J</i> = 4.9, 1.8, 0.9 Hz, 1H), 8.23 – 8.17 (m, 2H), 8.07 – 7.94 (m, 2H), 7.43 – 7.34 (m, 1H), 2.76 (q, <i>J</i> = 7.5 Hz, 2H), 2.53 (q, <i>J</i> = 7.4 Hz, 2H), 1.27 (t, <i>J</i> = 7.5 Hz, 3H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H)
64		5-methyl-7-oxo-3-[1-(2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidine-6-carbonitrile	B	318	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.81, (s, 1H), 9.22 (d, <i>J</i> = 0.8 Hz, 1H), 8.57 – 8.46 (m, 2H), 8.28 (d, <i>J</i> = 0.9 Hz, 1H), 8.06 – 7.92 (m, 2H), 7.37 (ddd, <i>J</i> = 7.2, 4.9, 1.3 Hz, 1H), 2.78 (s, 3H)
65		6-ethyl-5-methyl-3-[1-(5-methyl-2-pyridyl)pyrazol-4-yl]-4H-pyrazolo[1,5-a]pyrimidin-7-one	B	335	¹ H NMR (400 MHz, DMSO) δ 11.49 – 11.40 (s, 1H), 9.09 – 9.03 (d, <i>J</i> = 0.7 Hz, 1H), 8.37 – 8.32 (m, 1H), 8.21 – 8.15 (m, 2H), 7.91 – 7.80 (m, 2H), 2.51 – 2.49 (q, <i>J</i> = 7.4 Hz, 2H), 2.44 (s, 3H), 2.36 (s, 3H), 1.10 – 1.01 (t, <i>J</i> = 7.4 Hz, 3H)


66		6-ethyl-3-(1-(isoquinolin-1-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	A	371	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.52 (m, 1 H), 9.05 (s, 1 H), 8.97 (d, <i>J</i> = 8.7 Hz, 1 H), 8.43 (d, <i>J</i> = 5.5 Hz, 1 H), 8.32 (s, 1 H), 8.21 (d, <i>J</i> = 0.7 Hz, 1 H), 8.09 (d, <i>J</i> = 8.0 Hz, 1 H), 7.92 (d, <i>J</i> = 5.7 Hz, 1 H), 7.86 (m, 1 H), 7.79 - 7.65 (m, 1 H), 2.41 (s, 3 H), 1.03 (t, <i>J</i> = 7.3 Hz, 3 H).
67		6-ethyl-5-methyl-3-(1-(3-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	A	335	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.38 (br. s., 1 H), 8.80 (s, 1 H), 8.38 (d, <i>J</i> = 3.0 Hz, 1 H), 8.14 (d, <i>J</i> = 1.1 Hz, 2 H), 7.87 (d, <i>J</i> = 6.9 Hz, 1 H), 7.37 (dd, <i>J</i> = 4.6, 7.6 Hz, 1 H), 2.50 (m, 2 H), 2.40 (s, 3 H), 1.02 (t, <i>J</i> = 7.4 Hz, 3 H).
68		6-ethyl-3-(1-(isoquinolin-3-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	A	371	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.72 - 11.23 (bs, 1 H), 9.39 - 9.28 (m, 1 H), 9.20 - 9.01 (m, 1 H), 8.39 - 8.31 (m, 1 H), 8.28 - 8.22 (m, 1 H), 8.21 - 8.13 (m, 2 H), 8.12 - 8.03 (m, 1 H), 7.85 - 7.73 (m, 1 H), 7.67 - 7.54 (m, 1 H), 2.50 (m, 2 H), 2.42 (s, 3 H), 1.10 - 0.98 (m, 3 H).
69		6-ethyl-5-methyl-3-(1-(pyridazin-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	A	322	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.45 (bs, 1 H), 9.41 (s, 1 H), 9.20 (dd, <i>J</i> = 1.5, 4.7 Hz, 1 H), 8.34 (s, 1 H), 8.28 - 8.20 (m, 2 H), 7.90 (dd, <i>J</i> = 4.5, 8.8 Hz, 1 H), 2.50 (m, 2 H), 2.43 (s, 3 H), 1.03 (t, <i>J</i> = 7.3 Hz, 3 H).

70		6-ethyl-3-(1-(6-methoxypyridin-2-yl)-1H-pyrazol-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	A	351	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.53 (bs, 1 H), 8.90 (d, <i>J</i> = 0.7 Hz, 1 H), 8.17 - 8.04 (m, 1 H), 7.87 (t, <i>J</i> = 8.0 Hz, 2 H), 7.48 (d, <i>J</i> = 7.8 Hz, 1 H), 6.75 (d, <i>J</i> = 8.0 Hz, 1 H), 3.97 (s, 3 H), 2.50 (m, 2 H), 2.39 (s, 3 H), 1.08 - 0.93 (m, 3 H).
71		6-ethyl-5-methyl-3-(1-(4-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	A	335	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.45 (s, 1 H), 9.06 (s, 1 H), 8.34 (d, <i>J</i> = 5.0 Hz, 1 H), 8.18 (d, <i>J</i> = 1.8 Hz, 2 H), 7.80 (s, 1 H), 7.19 (d, <i>J</i> = 5.0 Hz, 1 H), 2.50 (m, 2 H), 2.41 (2 s, 6 H), 1.02 (t, <i>J</i> = 7.3 Hz, 3 H).
72		6-ethyl-5-methyl-3-(1-(pyrazin-2-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	A	322	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 11.50 (m, 1 H), 9.25 (d, <i>J</i> = 1.6 Hz, 1 H), 9.11 (s, 1 H), 8.69 - 8.50 (m, 2 H), 8.31 (s, 1 H), 8.21 (s, 1 H), 2.50 (m, 2 H), 2.42 (s, 3 H), 1.02 (t, <i>J</i> = 7.4 Hz, 3 H).
73		5,6-dimethyl-3-(4-(pyridin-2-yl)-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	D	307	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆): δ 12.19 (s, 1H), 8.51 (s, 1H), 8.1 (s, 1H), 7.93 (d, <i>J</i> = 6 Hz, 3H), 7.85 (d, <i>J</i> = 22.8 Hz, 1H), 7.22 (s, 1H), 2.31 (s, 3H), 1.99 (s, 3H).
74		1-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-N-methyl-1H-imidazole-4-carboxamide	D	301	¹ H NMR (300 MHz, DMSO): δ 8.13 (s, 1H), 8.04 (s, 1H), 7.63 (s, 1H), 2.83 (d, <i>J</i> = 4.8 Hz, 2H), 2.56 (m, 2H), 2.31 (s, 3H), 1.11 (m, 3H).


75		1-(6-ethyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-N,N-dimethyl-1H-imidazole-4-carboxamide	D	315	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆): δ 12.03 (s, 1H), 8.14-7.78 (m, 3H), 3.25 (s, 6H), 7.31-7.26 (m, 1H), 2.57-2.51 (m, 2H), 2.38 (s, 3H), 1.11 (s, <i>J</i> = 7.2 Hz, 3H).
----	---	---	---	-----	--

Example 76**6-ethyl-3-(1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one****Step 1:****2-(1H-imidazol-1-yl)acetonitrile**


To a solution of 1H-Imidazole (5 g, 73.5 mmol) in THF was added sodium hydride (1.8 g, 45 mmol) and stirred at room temperature for 0.5 hour before addition of then bromo-acetonitrile (8.8 g, 73.9 mmol) and stirring at room temperature for 2 hours. The reaction was quenched via the addition of water (50 mL) and saturated ammonium chloride (50 mL) solution and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organics layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude residue was purified on silica gel (petroleum ether : ethyl acetate = 10: 1) to afford 2-(1H-imidazol-1-yl)acetonitrile (4.6 g, 59%) as a yellow oil. LRMS *m/z*: 108 [*M*+*H*⁺].

Step 2:**(E)-3-(dimethylamino)-2-(1H-imidazol-1-yl)acrylonitrile**

A mixture of 2-(1H-imidazol-1-yl) acetonitrile (200 mg, 1.87 mmol) and N,N-dimethylformamide diethyl acetal (550 mg, 3.7 mmol) was heated to 90 ° C in a microwave reactor for 15 minutes. The reaction was cooled to room temperature and the crude mixture was filtered through silica gel eluting with ethyl acetate (30 mL). The solvent was evaporated and the product was distilled to afford (E)-3-(dimethylamino)-2-(1H-imidazol-1-yl)acrylonitrile (150 mg, 49.5%).

Step 3:**4-(1H-imidazol-1-yl)-1H-pyrazol-5-amine**



To a solution of (E)-3-(dimethylamino)-2-(1H-imidazol-1-yl)acrylonitrile (100 mg, 0.6 mmol) in ethanol (20 mL) was added hydrazine hydrate (0.66 mmol) at room temperature. The reaction solution was cooled to 0 °C and the PH was adjusted to 4-5 by addition of HCl. The mixture was refluxed for 2 hours before cooling to room temperature and concentrating. The crude residue was purified on silica gel (petroleum ether : ethyl acetate = 1:1) to afford 4-(1H-imidazol-1-yl)-1H-pyrazol-5-amine (50 mg, 54.4%).




Step 4:**6-ethyl-3-(1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one**


To a solution of 4-(1H-imidazol-1-yl)-1H-pyrazol-5-amine (50 mg, 0.34 mmol) in acetic acid (10 mL) was added ethyl 2-ethyl-3-oxobutanoate (54 mg, 0.34 mmol) at room temperature before heating the solution to reflux for 2 h. The reaction was cooled to room temperature and concentrated. The crude residue was washed with methanol (5 mL) to afford 6-ethyl-3-(1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (10 mg, 12%). ¹H NMR (300 MHz, CD₃OD): δ 8.25 (s, 1H), 8.12 (s, 1H), 7.50 (s, 1H), 7.34 (s, 1H), 2.67 (q, *J* = 7.8 Hz, 2H), 2.45 (s, 3H), 2.17 (t, *J* = 7.5 Hz, 3H). LRMS *m/z*: 244 [M+H⁺].

Using procedures similar to those described in Example 76, the following compounds were prepared.

10

Example	Structure	Name	LCMS (ESI) <i>m/z</i>	NMR
77		6-ethyl-5-methyl-3-(2-methyl-1H-imidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one	258	¹ H NMR (300 MHz, CD ₃ OD): δ 7.90 (s, 1H), 7.05 (d, <i>J</i> = 1.8 Hz, 1H), 6.91 (d, <i>J</i> = 1.5 Hz, 1H), 2.54 (q, <i>J</i> = 7.5 Hz, 2H), 2.30 (s, 3H), 2.16 (s, 3H), 1.05 (t, <i>J</i> = 7.2 Hz, 3H).
78		3-(1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	216	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆): δ 12.80 (br, 1H), 9.38 (s, 1H), 8.25 (s, 1H), 7.93 (d, <i>J</i> = 3.6 Hz, 1H), 7.87 (d, <i>J</i> = 3.6 Hz, 1H), 5.79 (s, 1H), 2.33 (s, 3H).

79		6-ethyl-3-(1H-imidazol-1-yl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one	306	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆): δ 12.80 (s, 1H), 7.93 (s, 2H), 7.51 (d, 5H), 7.41 (s, 1H), 7.10 (s, 1H), 2.22 (d, 2H), 0.98 (s, 3H).
80		6-ethyl-3-(4-iodo-1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	370	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 12.10 (br. s., 1H), 8.04 (s, 1H), 7.79 (d, J = 1.37 Hz, 1H), 7.57 (d, J = 1.37 Hz, 1H), 2.50 (m, 2H), 2.17 - 2.36 (m, 3H), 1.02 (t, J = 7.21, 3H).
81		6-ethyl-3-(5-iodo-1H-imidazol-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	370	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 12.00 - 12.33 (m, 1H), 7.93 (br. s., 2H), 7.17 (s, 1H), 2.50 (m, 2H), 2.27 (s, 3H), 1.02 (t, J = 7.32 Hz, 3H).

82		3-(1H-benzo[d]imidazol-1-yl)-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one	294	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆): δ 12.13 (s, 1H), 8.32 (s, 1H), 8.15 (s, 1H), 7.64 - 7.82 (m, 1H), 7.15 - 7.34 (m, 3H), 2.50 (M+1), 2.27 (s, 3H), 1.05 (t, J = 7.32 Hz, 3H).
----	---	---	-----	---

EXAMPLE 83

Assessment of Inhibitory Effect of Test Compounds on KDM5A demethylase activity

KDM5A demethylase assay (MassSpec assay - A)

Full length recombinant Flag tagged KDM5A protein was purified from Sf9 insect cells. The demethylation reaction buffer contained 50 mM TrisCl pH 7.4, 0.01% Triton X-100, 0.025 mg/mL BSA, 1 mM ascorbate (Cat# A4034, Sigma Aldrich), 2 mM TCEP (Cat# D9779, Sigma Aldrich), 2.0 μM α-ketoglutarate (# K2010, Sigma Aldrich) and 50 μM Fe₂(NH₄)₂(SO₄)₂ (Cat# F1543, Sigma Aldrich). In a 25 μL demethylation reaction system, 20 nM recombinant KDM5A and was incubated with compounds for 10 minutes in the above buffer, and then 2.0 α-ketoglutarate (# K2010, Sigma Aldrich), 4.0 μM biotinylated H3K9me1 peptide (1-21 aa), and Fe₂(NH₄)₂(SO₄)₂ were added to initiate the reaction. (All reagent concentrations are final reagent concentrations.)

Reactions were incubated for 30 minutes at room temperature, and then quenched by addition of an equal volume of 1% formic acid. After termination, plates were sealed and frozen at -80 °C for analysis.

KDM5A demethylase assays (TR-FRET assay- B)


Full length recombinant Flag tagged KDM5A protein was purified from Sf9 insect cells. The demethylation reaction buffer contained 50 mM TrisCl pH 7.4, 0.01% Triton X-100, 0.025 mg/mL BSA, 1 mM ascorbate, 2 mM TCEP, 3.0 μM α-ketoglutarate, and 50 μM Fe₂(NH₄)₂(SO₄)₂. In a 10 μL demethylation reaction system, 2 nM recombinant KDM5A and was incubated with compounds for 15 minutes in the above buffer (V_t 5 uL) in a 384 well Proxi Plate (Perkin Elmer Corp.), and then 0.1 μM biotinylated H3K9me1 peptide (1-21 aa, New England Peptide, V_t 5 uL) was added to initiate the reaction (V_t 10 uL). (All protein/reagent concentrations are final concentrations.)





Reactions were incubated for 25 minutes at room temperature, and then quenched by addition of 5 uL of detection reagents (buffer as above with addition of 0.3 mM EDTA, 150 mM NaCl, 150 nM SA-SurelightAPC and 1.5 nM Eu(W1024)-K3K4Me1/2 antibody (TR-FRET reagents both Perkin-Elmer)). After a one hour incubation assays were read on a Perkin-Elmer Envision equipped with a laser source and appropriate filters. IC₅₀s were calculated using standard dose-response equations and relative to a Max (no inhibition) and Min (no enzyme or quenched enzyme) controls.





KDM5A demethylase assays (TR-FRET assay- C)





Full length recombinant Flag tagged KDM5A protein was purified from Sf9 insect cells. The demethylation reaction buffer contained 50 mM HEPES pH 7.0, 0.01% Triton X-100, 0.5 mM ascorbate, 2 mM DTT, 1 μM α-ketoglutarate, and 100 μM Fe₂(NH₄)₂(SO₄)₂. In a 10 μL demethylation reaction system, 2 nM recombinant KDM5A was added to compounds in the above buffer (V_t 5 uL) in a 384 well Proxi Plate (Perkin Elmer Corp.) and then 0.1 μM biotinylated H3K9me1 peptide (1-21 aa, New England Peptide, V_t 5 uL) was added to initiate the reaction (V_t 10 uL). (All protein/reagent concentrations are final concentrations.) Reactions were incubated for 30 minutes at room temperature, and then quenched by addition of 5uL stop buffer (3mM EDTA, 50 mM TrisCl pH 7.5, 0.01% Triton X-100, 0.01 mg/mL BSA) followed by addition of 5 uL of detection reagents (buffer as above without EDTA but with addition of 200 nM SA-XL665 (CisBio) and 2 nM Eu(W1024)-anti-H3K4Me1-2 antibody (PerkinElmer)). After a 30 minute incubation assays were read on a Perkin-Elmer Envision equipped with appropriate filters. IC₅₀s were calculated using standard dose-response equations and relative to a Max (no inhibition) and Min (no enzyme or quenched enzyme) controls.





Data for representative compounds from Example 83 is provided in the following table (in μM).





Example	Structure	A KDM5A MS (IC ₅₀)	B KDM5A HTRF (IC ₅₀)	C KDM5A HTRF (IC ₅₀)
1		0.0263		





2			0.0161	
3			0.158	
4			0.047	
5			0.0603	





6			0.0529	
7			0.0086	
8			0.136	
9			0.0166	






10			0.201	
11			0.0023	
12			0.0313	
13			0.0661	






14			0.0165	
15			0.0661	
16			0.0406	
17			0.0141	






18			0.0098	
19			0.0057	
20			0.0083	
21			0.0091	






22			0.0236	
23			0.0543	
24			0.0166	
25			0.0066	






27				0.0332
28			0.0134	
29			0.0185	
30			0.0048	






31			0.0487	
32			0.0079	
33			0.196	
34			4.18	
35			0.543	






36			1.0	
37			0.0335	
38			1.0	
39			0.624	
40			0.101	






41			0.0041	
42				0.0322
43			0.0605	
45		6.32		
46				0.0234







47		0.574		
48		0.0705		
49			0.0437	
51		0.0708		
52		0.47		



53		0.453		
54		0.538		
55		0.0945		
56		0.276		
57		0.268		

58		0.332		
59		0.518		
60		4.0		
61		0.0661		
62		0.212		

63			0.169	
64			0.83	
65			0.0051	
66		0.861		
67		0.363		

68		0.0369		
69		0.233		
70		3.73		
71		0.0263		
72		0.076		

73		0.0537		
74		0.996		
75		0.178		
77		3.38		
79		43.2		
80		29.4		


81		3.05		
82		80.0		

While a number of embodiments have been described, these examples may be altered to provide other embodiments that utilize the compounds and methods described herein. Therefore, the scope of this invention is to be defined by the appended claims rather than by the specific
5 embodiments that have been represented by way of example.

CLAIMS

We claim:

1. The use of a compound of formula (I):



I

or a pharmaceutically acceptable salt thereof, wherein:

R¹ and R² are each independently H, C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂, -C(O)SR^a,
 10 -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂,
 -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂,
 -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein
 each C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is
 15 independently optionally substituted with one or more groups R^x; and wherein R¹ and R² are
 not each H; or R¹ and R² taken together with the atoms to which they are attached form a 4, 5,
 6, 7, or 8 membered carbocyclyl, which carbocyclyl is optionally substituted with one or more
 groups R^x;

R³ is H, C₁₋₆alkyl, trifluoromethyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, halo,
 -OR^f, -SR^f, -N(R^f)₂, -CN, or -NO₂, wherein said alkyl, carbocyclyl and heterocyclyl are
 20 optionally substituted with one or more groups independently selected from oxo, halo, C₁₋₃
 alkoxy and C₁₋₃alkyl;

R⁴ is H, C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, heterocyclyl, halo, -OR^g, -SR^g, -N(R^g)₂,
 -CN, -NO₂, -C(O)R^g, -CO₂R^g, -C(O)N(R^g)₂, -C(O)SR^g, -C(O)C(O)R^g, -C(O)CH₂C(O)R^g,
 -C(S)N(R^g)₂, -C(S)OR^g, -S(O)R^g, -SO₂R^g, -SO₂N(R^g)₂, -N(R^g)C(O)R^g, -N(R^g)C(O)N(R^g)₂,
 25 -N(R^g)SO₂R^g, -N(R^g)SO₂N(R^g)₂, -N(R^g)N(R^h)₂, -N(R^g)C(=N(R^g))N(R^g)₂, -C=NOR^g,
 -C(=N(R^g))N(R^g)₂, -OC(O)R^g, or -OC(O)N(R^g)₂, wherein each C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂
 alkynyl, carbocyclyl, and heterocyclyl of R⁴ is optionally substituted with one or more groups
 R^x;

R⁵ is H, C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₁₂
 30 alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with

one or more groups independently selected from oxo, C₁₋₁₂ alkyl, C₁₋₁₂haloalkyl, carbocyclyl, heterocyclyl, halo, -CN, -NO₂, -NR^mR^m, -OR^m, -C(=O)OR^m, and -OC(=O)R^m; or R⁵ and R² taken together with the atoms to which they are attached form a heterocyclyl;

each R^a is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x;

each R^f is independently selected from H, C₁₋₃ alkyl, trifluoromethyl, 3-6 membered carbocyclyl, and 3-6 membered heterocyclyl; or two R^f groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^g is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^g groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^m is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, and benzyl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, carbocyclyl, C₁₋₆alkanoyl, phenyl, or benzyl is optionally substituted with one or more groups independently selected from halo, -CN, -NO₂, -NR^yR^z, and -OR^w; or two R^m groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

A is a monocyclic or bicyclic heteroaryl ring that is substituted with R⁴ and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl;

each R^t is independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈carbocyclyl, and heterocyclyl is optionally substituted with one or more groups R^x; or two R^t groups together with the nitrogen to which they are attached form a 3-6 membered heterocycle;

each R^v is independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl, wherein each C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, and heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halo, amino, hydroxyl, and C_{1-C6} alkyl that is optionally substituted with one or more groups independently selected from oxo and halo; or two R^v are taken together with the nitrogen to which they are attached to form a heterocyclyl that is optionally substituted with one or more groups

independently selected from oxo, halo and C₁₋₃alkyl that is optionally substituted with one or more groups independently selected from oxo and halo;

each R^w is independently selected from H, C₁₋₄alkyl, C₁₋₄alkanoyl, phenyl, benzyl, and phenethyl;

each R^x is independently selected from oxo, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl,

5 carbocyclyl, -F, -Cl, -Br, -I, -NO₂, -N(R^v)₂, -CN, -C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂,
-O-R^v, -S-R^v, -O-C(O)-R^v, -O-C(O)-O-R^v, -C(O)-R^v, -C(O)-O-R^v, -S(O)-R^v, -S(O)₂-R^v,
-O-C(O)-N(R^v)₂, -N(R^v)-C(O)-OR^v, -N(R^v)-C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v,
-N(R^v)-S(O)-R^v, -N(R^v)-S(O)₂-R^v, -N(R^v)-S(O)-N(R^v)₂, and -N(R^v)-S(O)₂-N(R^v)₂, wherein any
C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl and carbocyclyl is optionally substituted with
10 one or more groups independently selected from oxo, halo, -NO₂, -N(R^v)₂, -CN,
-C(O)-N(R^v)₂, -S(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -O-R^v, -S-R^v, -O-C(O)-R^v, -C(O)-R^v, -C(O)-O-R^v,
-S(O)-R^v, -S(O)₂-R^v, -C(O)-N(R^v)₂, -S(O)₂-N(R^v)₂, -N(R^v)-C(O)-R^v, -N(R^v)-S(O)-R^v-N(R^v)-
S(O)₂-R^v and C₁₋₆alkyl that is optionally substituted with one or more groups independently
selected from oxo and halo; and

15 each R^y and R^z is independently selected from H, C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl,
phenyl, benzyl, and phenethyl, or R^y and R^z together with the nitrogen to which they are
attached form a heterocyclyl;
for the prophylactic or therapeutic treatment of a proliferative disorder.

20 2. The use of claim 1 wherein the treatment further comprises the administration of a cytotoxic
agent or radiation.

3. The use of claim 2 wherein the cytotoxic agent is a radioactive isotope or a
chemotherapeutic agent.

25

4. The use of claim 2 wherein the cytotoxic agent is a chemotherapeutic agent.

5. The use of claim 4 wherein the chemotherapeutic agent is a taxane.

30 6. The use of claim 5 wherein the taxane is paclitaxel or docetaxel.

7. The use of claim 3 wherein the chemotherapeutic agent is a platinum agent.

8. The use of claim 2 wherein the cytotoxic agent is selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism.
9. The use of claim 4 wherein the chemotherapeutic agent is an antagonist of EGFR.
10. The use of claim 9 wherein the antagonist of EGFR is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine or a pharmaceutically acceptable salt thereof (*e.g.*, erlotinib).
11. The use of claim 4 wherein chemotherapeutic agent is a RAF inhibitor.
12. The use of claim 11 wherein the RAF inhibitor is a BRAF and/or CRAF inhibitor.
13. The use of claim 11 wherein the RAF inhibitor is vemurafenib.
14. The use of claim 4 wherein the chemotherapeutic agent is a PI3K inhibitor.
15. The use of any one of claims 1-14 wherein the proliferative disorder is lung cancer, melanoma, colorectal cancer, pancreatic cancer, or breast cancer.
16. The use of any one of claims 1-15 wherein R^1 is H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$, $-N(R^a)C(O)R^a$, $-N(R^a)C(O)N(R^a)_2$, $-N(R^a)SO_2R^a$, $-N(R^a)SO_2N(R^a)_2$, $-N(R^a)N(R^a)_2$, $-N(R^a)C(=N(R^a))N(R^a)_2$, $-C=NOR^a$, $-C(=N(R^a))N(R^a)_2$, $-OC(O)R^a$, or $-OC(O)N(R^a)_2$, wherein each C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, and heterocyclyl of R^1 and R^2 is independently optionally substituted with one or more groups R^x .
17. The use of any one of claims 1-15 wherein R^1 is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, carbocyclyl, heterocyclyl, halo, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-CN$, $-NO_2$, $-C(O)R^a$, $-CO_2R^a$, $-C(O)N(R^a)_2$, $-C(O)SR^a$, $-C(O)C(O)R^a$, $-C(O)CH_2C(O)R^a$, $-C(S)N(R^a)_2$, $-C(S)OR^a$, $-S(O)R^a$, $-SO_2R^a$, $-SO_2N(R^a)_2$,

-N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂,
 -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each
 C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is independently
 optionally substituted with one or more groups R^x.

5

18. The use of any one of claims 1-15 wherein R¹ and R² taken together with the atoms to
 which they are attached form a 4, 5, 6, 7, or 8 membered carbocyclyl.

19. The use of any one of claims 1-15 wherein, R¹ is H, C₁₋₆alkyl, carbocyclyl, halo, -CN,
 10 wherein any C₁₋₆alkyl or carbocyclyl is optionally substituted with one or more groups
 independently selected from carbocyclyl, halo, -CN, and -O-R^v.

20. The use of any one of claims 1-15 wherein R¹ is H, methyl, ethyl, isopropyl, cyclopropyl,
 methoxy, fluoro, chloro, or cyano; or wherein R¹ and R² taken together with the atoms to which
 15 they are attached form a 5 membered carbocyclyl.

21. The use of any one of claims 1-20 wherein R² is H, C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl,
 carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂,
 -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂,
 20 -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂,
 -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each
 C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is independently
 optionally substituted with one or more groups R^x.

22. The use of any one of claims 1-20 wherein, R² is C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl,
 carbocyclyl, heterocyclyl, halo, -OR^a, -SR^a, -N(R^a)₂, -CN, -NO₂, -C(O)R^a, -CO₂R^a, -C(O)N(R^a)₂,
 -C(O)SR^a, -C(O)C(O)R^a, -C(O)CH₂C(O)R^a, -C(S)N(R^a)₂, -C(S)OR^a, -S(O)R^a, -SO₂R^a, -SO₂N(R^a)₂,
 -N(R^a)C(O)R^a, -N(R^a)C(O)N(R^a)₂, -N(R^a)SO₂R^a, -N(R^a)SO₂N(R^a)₂, -N(R^a)N(R^a)₂,
 -N(R^a)C(=N(R^a))N(R^a)₂, -C=NOR^a, -C(=N(R^a))N(R^a)₂, -OC(O)R^a, or -OC(O)N(R^a)₂, wherein each
 30 C₁₋₁₂alkyl, C₂₋₁₂alkenyl, C₂₋₁₂alkynyl, carbocyclyl, and heterocyclyl of R¹ and R² is independently
 optionally substituted with one or more groups R^x.

23. The use of any one of claims 1-20 wherein, R² is H, C₁₋₆alkyl, or aryl, wherein each C₁₋₆
 alkyl is optionally substituted with one or more groups independently selected from -O-R^v.

24. The use of any one of claims 1-20 wherein R^2 is H, methyl, ethyl, isopropyl, hydroxymethyl, or phenyl; or wherein R^1 and R^2 taken together with the atoms to which they are attached form a 5 membered carbocyclyl.

25. The use of any one of claims 1-24 wherein R^3 is H.

26. The use of any one of claims 1-24 wherein R^3 is C_{1-3} alkyl, trifluoromethyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, halo, hydroxyl, $-OR^f$, $-SH$, $-SR^f$, $-N(R^f)_2$, $-CN$, or $-NO_2$.

27. The use of any one of claims 1-26 wherein A is a 5 or 6 membered monocyclic heteroaryl ring that is substituted with R^4 and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

28. The use of any one of claims 1-26 wherein A is a 9 or 10 membered bicyclic heteroaryl ring that is substituted with R^4 and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

29. The use of any one of claims 1-26 wherein A is a 5-membered heteroaryl ring comprising 1, 2, 3, or 4 heteroatoms that is substituted with R^4 and that is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

30. The use of any one of claims 1-26 wherein A is a 5-membered heteroaryl ring comprising 1, 2, 3, or 4 nitrogen atoms, which ring is substituted with R^4 and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

31. The use of any one of claims 1-26 wherein A is a 5-membered heteroaryl ring comprising 1 heteroatom, which ring is substituted with R^4 and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-OR^t$, $-C(O)R^t$, $-CO_2R^t$, $-OC(O)R^t$, $-N(R^t)_2$, and carbocyclyl.

32. The use of any one of claims 1-26 wherein A is a 5-membered heteroaryl ring comprising 2 heteroatoms, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.
33. The use of any one of claims 1-26 wherein A is a 5-membered heteroaryl ring comprising 3 heteroatoms, which ring is substituted with R⁴ and which ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -OR^t, -C(O)R^t, -CO₂R^t, -OC(O)R^t, -N(R^t)₂, and carbocyclyl.
34. The use of any one of claims 1-26 wherein A is a pyrazole, imidazole, oxadiazole, or isoxazole ring, which pyrazole, imidazole, oxadiazole, or isoxazole ring is substituted with R⁴ and which pyrazole, imidazole, oxadiazole, or isoxazole ring is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, carbocyclyl, and -N(R^t)₂.
35. The use of any one of claims 1-26 wherein A is a pyrazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.
36. The use of any one of claims 1-26 wherein A is an imidazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.
37. The use of any one of claims 1-26 wherein A is an oxadiazole ring which is substituted with R⁴ and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, C₁₋₆alkoxycarbonyl, C₃₋₈carbocyclyl, and -N(R^t)₂.

38. The use of any one of claims 1-26 wherein A is an isoxazole ring which is substituted with R^4 and which is also optionally substituted with one or more groups independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, C_{1-6} alkoxycarbonyl, C_{3-8} carbocyclyl and $-N(R^1)_2$.

5

39. The use of any one of claims 1-38 wherein R^4 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl, heterocyclyl, $-C(O)R^g$, $-CO_2R^g$, or $-C(O)N(R^g)_2$, wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl, and heterocyclyl of R^4 is optionally substituted with one or more groups R^x .

10

40. The use of any one of claims 1-39 wherein R^4 is heteroaryl that is optionally substituted with one or more groups R^x .


15

41. The use of any one of claims 1-39 wherein R^4 is heteroaryl that is optionally substituted with one or more groups independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, carbocyclyl, -F, -Cl, -Br, -I, $-NO_2$, $-N(R^v)_2$, -CN, $-C(O)-N(R^v)_2$, $-O-R^v$, $-O-C(O)-R^v$, $-C(O)-R^v$, $-C(O)-O-R^v$, $-C(O)-N(R^v)_2$, and $-N(R^v)-C(O)-R^v$.


20


42. The use of any one of claims 1-39 wherein R^4 is a pyrimidine, thiazole, pyridine, isoquinoline, or pyridazine ring, which ring is optionally substituted with one or more groups independently selected from C_{1-6} alkyl, carbocyclyl, -F, -Cl, -Br, -I, $-N(R^v)_2$, $-O-R^v$, and $-C(O)-O-R^v$.

43. The use of any one of claims 1-26 wherein -A- R^4 taken together is selected from:





25








44. The use of claim 1 wherein the compound is selected from:











and pharmaceutically acceptable salts thereof.

45. A compound of formula (I) as described in any one of claims 1-44, or a salt thereof, provided that:

when $-A-R^4$ is 2-pyridyl, 3-pyridyl, 4-piperidino-3-pyridyl, 4-hydroxy-3-pyridyl, 4-methoxy-3-pyridyl, 4-morpholino-3-pyridyl, 4-pyrrolidino-3-pyridyl, 6-fluoro-2-pyridyl, and R^3 is hydrogen, methyl, ethyl, or methoxy, then R^1 is not H; and

when $-A-R^4$ is 2-thienyl and R^3 is trifluoromethyl, then R^1 is not H; and

when R^1 and R^2 taken together with the atoms to which they are attached form a 5 membered carbocyclyl and $-A-R^4$ is 1-naphthyl, then R^3 is not methyl;

when R^1 is 2-hydroxyethyl, R^2 is methyl, and R^3 is methyl, then $-A-R^4$ is not 6-(N,N-dimethylamino)-4-methyl-3-pyridyl; and

when R^1 is 3-thienyl, R^2 is hydrogen, R^3 is hydrogen, then $-A-R^4$ is not 2-pyridyl or 3-pyridyl; and

when R^1 is hydrogen, R^2 is 3-nitrophenyl or 2, 3, 4, 5-tetrafluorophenyl, and R^3 is trifluoromethyl, then $-A-R^4$ is not 2-thienyl; and

when R^3 is methylthio then $-A-R^4$ is not 1,2,4-oxadiazol-5-yl substituted with 4-methylphenyl, 4-chlorophenyl, phenyl, 3,4-methylenedioxyphenyl, or 2-thienyl; and

when R^2 is H, R^3 is H, and $-A-R^4$ is 3-thienyl, then R^1 is not phenyl, 3-thienyl, 2-thienyl, 1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-5-yl, 1-ethyl-1H-pyrazol-3-yl, or 1-ethyl-1H-pyrazol-5-yl.

46. A composition comprising a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

47. The composition according to claim 46, in combination with an additional therapeutic agent.

48. The composition according to claim 47, wherein the additional therapeutic agent is a chemotherapeutic agent.

49. A method of increasing efficacy of a cancer treatment comprising a cytotoxic agent in an individual comprising administering to the individual (a) an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof, and (b) an effective amount of the cytotoxic agent.

50. A method of treating an individual with cancer who has an increased likelihood of developing resistance to a cytotoxic agent comprising administering to the individual (a) an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof, and (b) an effective amount of the cytotoxic agent.

51. A method of treating cancer in an individual comprising administering to the individual (a) a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof, and (b) cytotoxic agent.

52. The method of claim 51, wherein the respective amounts of the a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof and the cytotoxic agent are effective to increase the period of cancer sensitivity and/or delay the development of cell resistance to the cytotoxic agent.

53. A method of increasing efficacy of a cancer treatment comprising a cytotoxic agent in an individual comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.

54. A method of treating cancer in an individual wherein cancer treatment comprises administering to the individual (a) an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof and (b) a cytotoxic agent, wherein the cancer treatment has increased efficacy compared to a standard treatment comprising administering an effective amount of the cytotoxic agent without (in the absence of) the compound of formula (I) as described in any one of claims 1-45 or the pharmaceutically acceptable salt thereof.

55. A method of delaying and/or preventing development of cancer resistant to a cytotoxic agent in an individual, comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.

56. A method of increasing sensitivity to a cytotoxic agent in an individual with cancer comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.

57. A method of extending the period of a cancer therapy agent sensitivity in an individual with cancer comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.
- 5 58. A method of extending the duration of response to a cancer therapy in an individual with cancer comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.
59. The method of any one of claims 52, 53, 55, and 56 wherein the method further comprises (b)
10 administering to the individual an effective amount of the cytotoxic agent.
60. The method of any one of claims 49-56 or 59, wherein the cytotoxic agent is a chemotherapeutic agent.
- 15 61. The method of claim 60 wherein the chemotherapeutic agent is a taxane.
62. The method of claim 61, wherein the taxane is paclitaxel or docetaxel.
63. The method of claim 60 wherein the chemotherapeutic agent is a platinum agent.
20
64. The method of any one of claims 49-56 or 59, wherein the cytotoxic agent is selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors,
25 immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A; inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism.
65. The method of claim 60 wherein the chemotherapeutic agent is an antagonist of EGFR.
30
66. The method of claim 65, wherein the antagonist of EGFR is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine or a pharmaceutically acceptable salt thereof (*e.g.*, erlotinib).
67. The method of claim 60, wherein the chemotherapeutic agent is a RAF inhibitor.
35
68. The method of claim 67, wherein the RAF inhibitor is a BRAF and/or CRAF inhibitor.

69. The method of claim 67, wherein the RAF inhibitor is vemurafenib.

70. The method of claim 60 wherein the chemotherapeutic agent is a PI3K inhibitor.

5

71. A method of treating a proliferative disorder in an individual comprising administering to the individual an effective amount of a compound of formula (I) as described in any one of claims 1-45 or a pharmaceutically acceptable salt thereof.

10 72. The method of any one of claims 49-70, wherein the cancer is lung cancer, melanoma, colorectal cancer, pancreatic cancer, and/or breast cancer.

73. The method of claim 71 wherein the proliferative disorder is lung cancer, melanoma, colorectal cancer, pancreatic cancer, and/or breast cancer.

15

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/054114

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/519 A61P35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2012/277224 A1 (MCCALL JOHN M [US] ET AL) 1 November 2012 (2012-11-01) abstract page 5, paragraph 117 page 69 - page 70 page 92 - page 145 ----- -/--	1-4,8, 15-17, 19-22, 25,27, 39,51



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 December 2014

Date of mailing of the international search report

20/01/2015

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Damiani, Federica

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/054114

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S Selleril ET AL: "Synthesis, benzodiazepine receptor affinity and in vivo testing of 3-aryl-4,7-dihydro-6-(Nr-alkylpyrazol-3'-o r 5'-yl)pyrazolo[1,5-a]pyrimidin-7-ones", Eur J Med Chem, 1 January 1997 (1997-01-01), pages 941-953, XP055158110, Retrieved from the Internet: URL:http://ac.els-cdn.com/S0223523497896389/1-s2.0-S0223523497896389-main.pdf?_tid=67a2218c-813b-11e4-b3e5-00000aacb35d&acdnt=1418305467_a84620dc34b658989be0f719d7f5c27e [retrieved on 2014-12-11] page 943; compounds 2f, 3f -----	45,46
X	SILVIA SELLERI ET AL: "Synthesis and Benzodiazepine Receptor Affinity of Pyrazolo[1,5- a]pyrimidine Derivatives. 3. New 6-(3-Thienyl) Series as [alpha]1 Selective Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 2, 1 January 2003 (2003-01-01), pages 310-313, XP055158395, ISSN: 0022-2623, DOI: 10.1021/jm020999w page 310 - page 311; table 1 -----	45-47
X	EP 0 531 901 A2 (FUJISAWA PHARMACEUTICAL CO [JP]) 17 March 1993 (1993-03-17) abstract page 17 page 50 - page 60 -----	45,46
X	US 2012/088775 A1 (ZHANG HAILIN [CN] ET AL) 12 April 2012 (2012-04-12) abstract page 17 - page 23 -----	45,46
X	EP 1 238 979 A1 (EISAI CO LTD [JP]) 11 September 2002 (2002-09-11) compounds RN344293-21-6, RN344293-25-0 -----	45
X	IBRAHIM, S. S. ET AL: "Synthesis and biological activities of some new fully fused quinazoline derivatives", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY , 37B(1), 62-67 CODEN: IJSBDB; ISSN: 0376-4699, 1998, XP009181683, page 65; table I ----- -/--	45

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2014/054114

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/072881 A1 (GUZI TIMOTHY J [US] ET AL) 29 March 2007 (2007-03-29) page 55 -----	45
X	BORISOV, ALEXANDER V. ET AL: "Parallel Liquid-Phase Synthesis of 5-(1H-4-Pyrazolyl)-[1,2,4]oxadiazole Libraries", JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 11, no. 6, 27 August 2009 (2009-08-27), pages 1023-1029, XP002733713, ISSN: 1520-4766, DOI: 10.1021/CC900070M page 1028 -----	45
X	WANG, XIAOLUN ET AL: "Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 21, 20 October 2010 (2010-10-20), pages 7874-7878, XP002733714, ISSN: 0022-2623, DOI: 10.1021/JM1007566 page 7876; compound 12 -----	45
X	QI, JINLONG ET AL: "Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 3, 22 January 2011 (2011-01-22), pages 934-943, XP002733715, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2011.01.010 abstract page 937; compound 14 -----	45,46
X,P	WO 2014/066795 A1 (BIOENERGENIX [US]; MCCALL JOHN [US]; KELLY ROBERT C [US]; ROMERO DONNA) 1 May 2014 (2014-05-01) page 14, paragraph 48 Examples; page 35 -----	1-4,8, 15-17, 19-22, 25, 27-33, 35,37, 39,45-48

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/054114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2012277224 A1	01-11-2012	US 2012277224 A1	01-11-2012
		WO 2012149157 A2	01-11-2012
EP 0531901 A2	17-03-1993	AU 2280592 A	11-03-1993
		CA 2077732 A1	10-03-1993
		CN 1070404 A	31-03-1993
		EP 0531901 A2	17-03-1993
		JP H0788386 B2	27-09-1995
		JP H06287188 A	11-10-1994
		JP H07252256 A	03-10-1995
		TW 257763 B	21-09-1995
		US 5356897 A	18-10-1994
		US 5478827 A	26-12-1995
		US 5624931 A	29-04-1997
US 2012088775 A1	12-04-2012	CN 101906105 A	08-12-2010
		US 2012088775 A1	12-04-2012
		WO 2010142216 A1	16-12-2010
EP 1238979 A1	11-09-2002	AT 290006 T	15-03-2005
		AT 300546 T	15-08-2005
		AU 773258 B2	20-05-2004
		AU 2023501 A	18-06-2001
		CA 2394120 A1	14-06-2001
		CN 1409713 A	09-04-2003
		DE 60018462 D1	07-04-2005
		DE 60018462 T2	16-02-2006
		DE 60021630 D1	01-09-2005
		DE 60021630 T2	08-06-2006
		EP 1238979 A1	11-09-2002
		EP 1408040 A1	14-04-2004
		ES 2234704 T3	01-07-2005
		NZ 519241 A	24-12-2004
		PT 1238979 E	29-07-2005
		TW I271406 B	21-01-2007
		US 2003078277 A1	24-04-2003
		US 2005004147 A1	06-01-2005
		US 2005004159 A1	06-01-2005
		WO 0142247 A1	14-06-2001
US 2007072881 A1	29-03-2007	AR 063096 A1	30-12-2008
		CA 2665127 A1	17-04-2008
		CL 2007002856 A1	18-01-2008
		CN 101573363 A	04-11-2009
		EP 2069349 A2	17-06-2009
		JP 2010505839 A	25-02-2010
		PE 09742008 A1	19-07-2008
		TW 200821313 A	16-05-2008
		US 2007072881 A1	29-03-2007
		WO 2008045267 A2	17-04-2008
WO 2014066795 A1	01-05-2014	NONE	